Substituted oxazolidinones and their use

ABSTRACT

The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.

The invention relates to novel substituted oxazolidinones, to processesfor their preparation, to their use for the treatment and/or prophylaxisof diseases and their use for preparing medicaments for the treatmentand/or prophylaxis of diseases, in particular of thromboembolicdisorders.

Blood coagulation is a protective mechanism of the organism which helpsto “seal” defects in the wall of the blood vessels quickly and reliably.Thus, loss of blood can be avoided or kept to a minimum. Haemostasisafter injury of the blood vessels is effected mainly by the coagulationsystem in which an enzymatic cascade of complex reactions of plasmaproteins is triggered. Numerous blood coagulation factors are involvedin this process, each of which factors converts, on activation, therespectively next inactive precursor into its active form. At the end ofthe cascade comes the conversion of soluble fibrinogen into insolublefibrin, resulting in the formation of a blood clot. In bloodcoagulation, traditionally the intrinsic and the extrinsic system, whichend in a joint reaction path, are distinguished. Here, factors Xa andIIa (thrombin) play key roles.

Factor Xa bundles the signals of the two coagulation paths since it isformed both via factor VIIa/tissue factor (extrinsic path) and via thetenase complex (intrinsic path) by conversion of factor X. The activatedserine protease Xa cleaves prothrombin to thrombin.

Via a bunch of reactions, thrombin transfers the signals from thecascade to the coagulation state of the blood. Thrombin cleavesfibrinogen directly to fibrin. It activates factor XIII, which isrequired for stabilizing the fibrin clot, to factor XIIIa. In addition,thrombin is a potent trigger of platelet aggregation (via PAR-1activation), which also contributes considerably to haemostasis. Byactivating TAFI (thrombin-activatable fibrinolysis inhibitor) to TAFIa,thrombin in a complex with thrombomodulin inhibits the dissolution ofthe clot. Activation of factors V and VIII potentiates the production ofthrombin and thus in turn amplifies the coagulation reaction; theactivated protein C, produced in a complex with thrombomodulin,antagonizes this increased thrombin production, thus preventingexcessive haemostasis (thrombosis).

In addition to unbound factor X and thrombin in the blood, bound formsare also known. During the formation of a fibrin clot, thrombin andprothrombinase (factor Xa in a complex) are bound to the fibrinskeleton. These enzyme molecules are still active and cannot beinhibited by endogenous antithrombin III. Thus, in this manner, clotsstill have a general coagulative potential.

During the course of many cardiovascular and metabolic disorders, as aresult of systemic factors, such as, for example, hyperlipidaemia,diabetes or smoking, owing to changes in the blood with stasis, such as,for example, atrial fibrillation, or owing to pathologic changes of thevascular walls, for example endothelial dysfunctions or atherosclerosis,there is an increased tendency of coagulation and platelet activation.This unwanted and excessive haemostasis can, by forming fibrin- andplatelet-rich thrombi, cause thromboembolic disorders and thromboticcomplications with life-threatening states.

Haemostasis is subject to a complex regulatory mechanism. Uncontrolledactivation of the coagulation system or defect inhibition of theactivation processes may lead to the formation of local thromboses orembolisms in vessels (arteries, veins, lymph vessels) or cardiaccavities. This may lead to serious thrombotic or thromboembolicdisorders. In addition, systemic hypercoagulability may lead toconsumption coagulopathy in the context of a disseminated intravasalcoagulation. Thromboembolic complications are furthermore encountered inmicroangiopathic haemolytic anaemias, extracorporeal circulatorysystems, such as haemodialysis, and also prosthetic heart valves andstents.

Thromboembolic disorders are the most frequent cause of morbidity andmortality in most industrialized countries [Heart Disease: A Textbook ofCardiovascular Medicine, Eugene Braunwald, 5th edition, 1997, W.B.Saunders Company, Philadelphia].

In the therapy and prophylaxis of thromboembolic and thromboticdisorders, anticoagulants, i.e. substances for inhibiting or preventingblood coagulation, play an essential role. For the treatment of acutethromboembolic or thrombotic disorders—in particular those where rapidand simple reduction or adjustment of anticoagulation is required (forexample actue coronary syndrome, sepsis)—or disorders requiring ashort-term prophylactic inhibition of the coagulation system as required(for example haemodialysis, cardioconversion), anticoagulants areadministered parenterally.

The anticoagulants known from the prior art, for example substances forinhibiting or preventing blood coagulation, have various, frequentlygrave disadvantages. Accordingly, in practice, efficient and safetreatment methods or the prophylaxis of acute thrombotic/thromboembolicdisorders is frequently found to be difficult and unsatisfactory.

In the acute therapy and prophylaxis of thromboembolic disorders, use ismade, firstly, of heparin and low-molecular-weight heparins (NMH) whichare administered intravenously or subcutaneously. Heparin is a mixtureof highly sulphated glucosaminoglucans of animal origin (molar mass 3-40kDa, with the highest frequency at 15 kDa; for example extracted frombovine lungs), of which, depending on the preparation, about 30% actanticoagulatively. Accordingly, the dosage is in units and has to becontrolled accurately in the patient. Uncontrolled administrationwithout monitoring results in a high risk of underdosage or overdosageand thus haemorrhages. Low-molecular-weight heparins (NMH) are preparedfrom unfractionated heparin (UFH). With respect to their size, they arebetter defined, and owing to their lower size, they have a modifiedside-effect profile.

The heparins do not act directly at the enzyme, but, by binding toantithrombin III (AT(III)), accelerate binding of AT(III) to coagulationfactors having an AT(III) binding site. These include in particularfactor Xa and thrombin (factor IIa). Whereas the potency of UFHs isapproximately the same for both enzymes, the NMHs exhibit an activityspectrum which is shifted in favour of factor Xa, ultimately culminatingin the pure factor Xa inhibition of the pentasaccharide fondaparinux.Under certain aspects, this indirect mechanism is disadvantageous:

In the case of diseases associated with consumption coagulopathy, thedepletion of AT(III) results in heparins no longer being effective. Incontrast: by administering heparins, the last reserve of free AT(III) isremoved from the organism.

During the formation of a thrombus, prothrombinase (factor Xa) andthrombin are bound to the thrombus. These coagulation enzymes are activeand contribute to the further development of the thrombus. Accordingly,in the risk reduction in arterial disorders, particular attention ispaid to the inhibition of thrombus-bound thrombin or factor Xa. AT(III)is, as a protein, owing to its size, not able to inhibit thrombus-boundcoagulation factors. Accordingly, it is not possible for heparins tocontribute to this risk reduction.

In the context of the use for treating diseases such as, for example,acute coronary syndrome or sepsis, it is a particular advantage if thetherapy can be discontinued short-term. UFHs have a relatively shorthalf-life of 30-150 minutes. Moreover, their action can be antagonizedby protamine sulphate. The long half-life of the different NMHs, inparticular of fondaparinux, which make it virtually impossible to simplyadjust the therapy to acute situations, is disadvantageous here. Inaddition, the action of these substances can be antagonized onlypartially by protamine sulphate.

In general, when UFH is administered, there is a high risk of bleeding,where in particular cerebral bleeding and bleeding in thegastrointestinal tract may occur, and there may be thrombopenia,alopecia medicomentosa or osteoporosis [Pschyrembel, KlinischesWörterbuch [Clinical Dictionary], 257th edition, 1994, Walter de GruyterVerlag, page 610, key word “Heparin”; Römpp Lexikon Chemie [RömppChemical Encyclopaedia], Version 1.5, 1998, Georg Thieme VerlagStuttgart, key word “Heparin”]. Low-molecular-weight heparinshave—albeit with lower incidence—a similar side-effect spectrum—inparticular with regard to the occurrence of HIT-II.

Associated with cardiac diseases or else septic disorders, there may besimultaneous—occasionally acute—kidney dysfunction. In these situations,substances which are eliminated via the kidneys may accumulate in thebody, leading to a significantly increased risk of bleeding. Whereas inthe case of UFHs, it is not necessary to adjust the dosage, the dosageof NMHs has to be adjusted. Fondaparinux is not recommended for patientswith serious kidney dysfunction.

Additionally used—albeit much less frequently—are hirudin and thesynthetically produced peptide bivalirudin derived therefrom, and alsothe low-molecular-weight substance argatroban. These are direct thrombininhibitors exhibiting a high risk of bleeding. In cases of kidneydysfunction, the dosage of hirudin and bivalirudin has to be adjusted.Argatroban has a comparably weak antithrombotic action and is poorlywater-soluble. As a result of the lacking inhibition of factor Xa, it isnot possible to inhibit thrombin production within and outside of athrombus, i.e. in the case of a highly excessive coagulation reaction,there is the risk that these substances are “titred out”.

Further substances which can be administered parenterally are indevelopment. These are substances which inhibit either factor Xa orthrombin, thus inhibiting either thrombin production or thrombinactivity.

In addition, there are substances which are used or developed for oraltherapy. Owing to their activity profile and physicochemical profile(poor solubility, slow onset of action, long half-life) they are oflittle, if any, use for treatment in acute situations. Such a class ofanticoagulants are the vitamin K antagonists. These include, forexample, 1,3-indanediones, but especially compounds such as warfarin,phenprocoumone, dicumarole and other coumarine derivatives whichunselectively inhibit the synthesis of various products of certainvitamin-K-dependent coagulation factors in the liver. Owing to themechanism of action, the onset of the activity is very slow (latencytime to onset of action 36 to 48 hours). The compounds can beadministered orally; however, owing to the high risk of bleeding and thenarrow therapeutic index, complicated individual adjustment andobservation of the patient is required. In addition, furtherside-effects such as gastrointestinal dysfunctions, hair loss and skinnecroses, have been described.

Other anti-thrombin or anti-factor-Xa substances which are indevelopment for oral therapy have a solubility which is too low forparenteral therapy or have—which is desirable for oral therapy—a longhalf-life, which does not allow a quick reaction to changes.

Recently, approaches have been described where low-molecular-weightthrombin and factor Xa inhibitors were tested in vitro and in vivo invarious mixing ratios. Here, a strong synergistic potential was found.Tanogitran is a low-molecular-weight substance which has been describedto inhibit, in vitro, both thrombin and factor Xa, but which has astrong preference for thrombin inhibition. A substantial fraction oftanogitran is excreted unchanged via the kidneys, which makes it likelythat the dosage has to be adjusted in case of kidney insufficiency.

For antithrombotic medicaments, the therapeutic width is of centralimportance: The distance between the therapeutically active dose forcoagulation inhibition and the dose where bleeding may occur should beas big as possible so that maximum therapeutic activity is achieved at aminimum risk profile.

As shown by the experiments with mixtures of low-molecular-weightthrombin and factor Xa inhibitors, compounds which inhibit both thrombinand factor Xa would, by virtue of their dual character, have aparticularly strong synergism, thus being particularly effective incontrolling the formation of thrombi. In this manner, the compoundsinhibit the two key enzymes of the coagulation cascade, withoutcompletely blocking the individual enzymes. The remaining rest of factorXa and thrombin results in an intact haemostasis and thus a particularlyadvantageous therapeutic width. In an arteriovenous shunt model inrabbits, it was possible to demonstrate that coadministration of onlyweakly antithrombotically active dosages of the selective factor Xainhibitor PD0313052 and the selective thrombin inhibitor argatrobanresults in a strong superadditive antithrombotic effect. In addition,when the individual doses with the maximum synergistic effect werecombined, no increased bleeding was observed. These observations allowthe conclusion to be drawn that simultaneous inhibition of thrombin andfactor Xa increases the therapeutic width with respect to the distancebetween antithrombotic action and bleeding risk (Journal of Thrombosisand Haemostasis, 4: 834-841).

This synergism is particularly pronounced when the prothrombin time as afunction of the substance concentration is studied by direct comparisonwith pure factor Xa and thrombin inhibitors. This strong effect on thetwo key enzymes of the coagulation cascade is considered to beparticularly advantageous when a high risk of thrombi formation ispresent, or when the formation of thrombi may result in a fatal disease.Both are relevant, for example, in the case of atherothromboticdisorders of the acute coronary syndrome type or the situation after anacute myocardial infarction.

Furthermore, in contrast to heparins, hirudin and vitamin K antagonists,compounds inhibiting both thrombin and factor Xa would also be activeagainst coagulation factors bound to fibrin clots. The limitation of thethrombotic potential of an already existing clot is a critical point inthe prevention of arterial occlusion. This is achieved particularlyeffectively by inhibiting both the present thrombin activity and theformation of new thrombin in the clot. Whereas a pure thrombin inhibitorcannot prevent the avalanche-like thrombin production by the clot-boundfactor Xa-containing prothrombinase complex and the inhibitory effectcan thus be overcompensated in a highly stimulated coagulation by thelarge amount of thrombin produced, pure factor Xa inhibitors are notcapable of inhibiting the thrombin activity already present. Sinceinhibition is likewise not possible by physiological mechanisms, thisclot-bound thrombin poses a particularly large risk. In contrast, dualcompounds, i.e. compounds inhibiting both thrombin and factor Xa, arecapable of inhibiting both the thrombin production and the thrombinactivity on clots, thus also preventing a potential clot growth.

Oxazolidinones as non-peptidic low-molecular-weight factor Xa inhibitorsare described in WO 01/47919.

Accordingly, it is an object of the present invention to provide dualcompounds, i.e. compounds which inhibit both thrombin and factor Xa andwhich, by inhibiting thrombin production and thrombin activity on clots,prevent their potential growth, which have a broad therapeutic windowand good solubility in water and physiological media, for controllingdiseases, in particular thromboembolic disorders, in humans and animals.

The invention provides compounds of the formula

in which

-   R¹ represents chlorine, trifluoromethoxy, methyl, ethyl, n-propyl,    methoxy, methoxymethyl or ethoxymethyl,-   R² represents hydrogen or methyl,-   and-   R³ represents a group of the formula

where

-   * is the point of attachment to the oxopyridine ring,-   n represents the number 1, 2, 3 or 4,-   m represents the number 1 or 2,-   R⁴ represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl,    2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl,    3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl,    tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,-   R⁵ represents hydrogen, methyl or ethyl,-   or-   R⁴ and R⁵ together with the nitrogen atom to which they are attached    form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring,    a morpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a    1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a    4-hydroxypiperidin-1-yl ring,-   R⁶ represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl,    2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl,    3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl,    tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,-   R⁷ represents hydrogen, methyl or ethyl,-   R⁶ and R⁷ together with the nitrogen atom to which they are attached    form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring,    a morpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a    1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a    4-hydroxypiperidin-1-yl ring,-   and their salts, their solvates and the solvates of their salts.

Compounds according to the invention are the compounds of the formula(I) and their salts, solvates and solvates of the salts, the compounds,comprised by formula (I), of the formulae mentioned below and theirsalts, solvates and solvates of the salts and the compounds, comprisedby formula (I), mentioned below as exemplary embodiments and theirsalts, solvates and solvates of the salts if the compounds, comprised byformula (I), mentioned below are not already salts, solvates andsolvates of the salts.

Depending on their structure, the compounds according to the inventioncan exist in stereoisomeric forms (enantiomers, diastereomers).Accordingly, the invention comprises the enantiomers or diastereomersand their respective mixtures. From such mixtures of enantiomers and/ordiastereomers, it is possible to isolate the stereoisomerically uniformcomponents in a known manner.

If the compounds according to the invention can be present in tautomericforms, the present invention comprises all tautomeric forms.

In the context of the present invention, preferred salts arephysiologically acceptable salts of the compounds according to theinvention. The invention also comprises salts which for their part arenot suitable for pharmaceutical applications, but which can be used, forexample, for isolating or purifying the compounds according to theinvention.

Physiologically acceptable salts of the compounds according to theinvention include acid addition salts of mineral acids, carboxylic acidsand sulphonic acids, for example salts of hydrochloric acid, hydrobromicacid, sulphuric acid, phosphoric acid, methanesulphonic acid,ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid,naphthalene disulphonic acid, acetic acid, trifluoroacetic acid,propionic acid, lactic acid, tartaric acid, malic acid, citric acid,fumaric acid, maleic acid and benzoic acid.

Physiologically acceptable salts of the compounds according to theinvention also include salts of customary bases, such as, by way ofexample and by way of preference, alkali metal salts (for example sodiumsalts and potassium salts), alkaline earth metal salts (for examplecalcium salts and magnesium salts) and ammonium salts, derived fromammonia or organic amines having 1 to 16 carbon atoms, such as, by wayof example and by way of preference, ethylamine, diethylamine,triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine,triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine,dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine andN-methylpiperidine.

In the context of the invention, solvates are those forms of thecompounds according to the invention which, in solid or liquid state,form a complex by coordination with solvent molecules. Hydrates are aspecific form of the solvates where the coordination is with water. Inthe context of the present invention, preferred solvates are hydrates.

Moreover, the present invention also comprises prodrugs of the compoundsaccording to the invention. The term “prodrugs” includes compounds whichfor their part may be biologically active or inactive but which, duringthe time they spend in the body, are converted into compounds accordingto the invention (for example metabolically or hydrolytically).

In the formulae of the group which may represent R³, the end point ofthe line which is marked by an * is not a carbon atom or a CH₂ group,but is part of the bond to the atom to which R³ is attached.

Preference is given to compounds of the formula (I) in which

-   R¹ represents chlorine, trifluoromethoxy, methyl, ethyl, n-propyl,    methoxy or methoxymethyl,-   R² represents hydrogen or methyl,-   and-   R³ represents a group of the formula

where

-   * is the point of attachment to the oxopyridine ring,-   n is the number 1, 2 or 3,-   m represents the number 1 or 2,-   R⁴ represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl,    2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl,    3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl,    tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,-   R⁵ represents hydrogen, methyl or ethyl,-   or-   R⁴ and R⁵ together with the nitrogen atom to which they are attached    form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring,    a morpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a    1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a    4-hydroxypiperidin-1-yl ring,-   R⁶ represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl,    2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl,    3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl,    tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,-   R⁷ represents hydrogen, methyl or ethyl,-   R⁶ and R⁷ together with the nitrogen atom to which they are attached    form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring,    a morpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a    1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a    4-hydroxypiperidin-1-yl ring,-   and their salts, their solvates and the solvates of their salts.

Preference is also given to compounds of the formula (I) in which

-   R¹ represents methyl, ethyl, n-propyl, methoxy or methoxymethyl,-   R² represents hydrogen or methyl,-   and-   R³ represents a group of the formula

where

-   * is the point of attachment to the oxopyridine ring,-   n is the number 1, 2 or 3,-   m represents the number 1 or 2,-   R⁴ represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl,    2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl,    3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl,    tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,-   R⁵ represents hydrogen, methyl or ethyl,-   R⁶ represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl,    2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl,    3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl,    tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,-   R⁷ represents hydrogen, methyl or ethyl,-   and their salts, their solvates and the solvates of their salts.-   Preference is also given to compounds of the formula (I) in which-   R¹ represents methyl, ethyl, n-propyl, methoxy or methoxymethyl,

R² represents hydrogen,

-   or-   R¹ represents methyl,-   R² represents methyl,    and-   R³ represents a group of the formula

where

-   * is the point of attachment to the oxopyridine ring,-   n represents the number 1, 2 or 3,-   m represents the number 1 or 2,-   R⁴ represents hydrogen, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl,    3-hydroxyprop-1-yl or 4-hydroxycyclohex-1-yl,-   R⁵ represents hydrogen,-   R⁶ represents hydrogen, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl,    3-hydroxyprop-1-yl or 4-hydroxycyclohex-1-yl,-   R⁷ represents hydrogen,-   and their salts, their solvates and the solvates of their salts.

Preference is also given to compounds of the formula (I) in which

-   R¹ represents methyl, methoxy or methoxymethyl,-   R² represents hydrogen,-   or-   R¹ represents methyl,-   R² represents methyl,-   and-   R³ represents a group of the formula

where

-   * is the point of attachment to the oxopyridine ring,-   n represents the number 2,-   m represents the number 1,-   R⁴ represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,-   R⁵ represents hydrogen,-   R⁶ represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,-   R⁷ represents hydrogen,-   and their salts, their solvates and the solvates of their salts.

Preference is also given to compounds of the formula (I) in which

-   R¹ represents methyl or methoxy,-   R² represents hydrogen,-   or-   R¹ represents methyl,-   R² represents methyl,-   and-   R³ represents a group of the formula

where

-   * is the point of attachment to the oxopyridine ring,-   n represents the number 2,-   m represents the number 1,-   R⁴ represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,-   R⁵ represents hydrogen,-   R⁶ represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,-   R⁷ represents hydrogen,    and their salts, their solvates and the solvates of their salts.-   Preference is also given to compounds of the formula (I) in which-   R¹ represents methyl, methoxy or methoxymethyl,-   R² represents hydrogen,-   or-   R¹ represents methyl,-   R² represents methyl,-   and-   R³ represents a group of the formula

where

* is the point of attachment to the oxopyridine ring,

-   n is the number 2,-   R⁴ is 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,-   R⁵ is hydrogen,-   and their salts, their solvates and the solvates of their salts.

Preference is also given to compounds of the formula (I) in which

-   R¹ represents methoxymethyl,-   R² represents hydrogen,-   or-   R¹ represents methyl,-   R² represents methyl,-   and-   R³ represents a group of the formula

where

-   * is the point of attachment to the oxopyridine ring,-   n represents the number 2,-   R⁴ represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,-   R⁵ represents hydrogen,-   and their salts, their solvates and the solvates of their salts.

Preference is also given to compounds of the formula (I) in which

-   R¹ represents methyl,-   R² represents hydrogen,-   or-   R¹ represents methyl,-   R² represents methyl,-   and-   R³ represents a group of the formula

where

-   * is the point of attachment to the oxopyridine ring,-   m represents the number 1,-   R⁶ represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,-   R⁷ represents hydrogen,-   and their salts, their solvates and the solvates of their salts.

Preference is also given to compounds of the formula (I) in which nrepresents the number 2.

Preference is also given to compounds of the formula (I) in which mrepresents the number 1.

Preference is also given to compounds of the formula (I) in which R¹represents methyl, methoxy or methoxymethyl.

Preference is also given to compounds of the formula (I) in which R²represents hydrogen.

Preference is also given to compounds of the formula (I) in which R¹represents methyl and R² represents hydrogen.

Preference is also given to compounds of the formula (I) in which R¹represents methyl and R² represents methyl.

Preference is also given to compounds of the formula (I) in which R⁴represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl.

Preference is also given to compounds of the formula (I) in which R⁵represents hydrogen.

Preference is also given to compounds of the formula (I) in which R⁶represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl.

Preference is also given to compounds of the formula (I) in which R⁷represents hydrogen.

Preference is also given to compounds of the formula (I) in which

-   R¹ represents methyl, ethyl, n-propyl, methoxy or methoxymethyl,-   R² represents hydrogen or methyl,-   and-   R³ represents a group of the formula

where

-   * is the point of attachment to the oxopyridine ring,-   n represents the number 1, 2 or 3,-   m represents the number 1 or 2,-   R⁴ represents methyl, ethyl, cyclopropyl, cyclobutyl,    2-methoxyeth-1-yl, 3-methoxyprop-1-yl, tetrahydrofuran-2-ylmethyl or    1,4-dioxan-2-ylmethyl,-   R⁵ represents hydrogen, methyl or ethyl,-   or-   R⁴ and R⁵ together with the nitrogen atom to which they are attached    form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring,    a morpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a    1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a    4-hydroxypiperidin-1-yl ring,-   R⁶ represents methyl, ethyl, cyclopropyl, cyclobutyl,    2-methoxyeth-1-yl, 3-methoxyprop-1-yl, tetrahydrofuran-2-ylmethyl or    1,4-dioxan-2-ylmethyl,-   R⁷ represents hydrogen, methyl or ethyl,-   R⁶ and R⁷ together with the nitrogen atom to which they are attached    form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring,    a morpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a    1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a    4-hydroxypiperidin-1-yl ring,-   and their salts, their solvates and the solvates of their salts.

Preference is also given to compounds of the formula (I) in which

-   R¹ represents methyl, ethyl, n-propyl, methoxy or methoxymethyl,-   R² represents hydrogen,-   or-   R¹ represents methyl,-   R² represents methyl,-   and-   R³ represents a group of the formula

where

-   * is the point of attachment to the oxopyridine ring,-   n represents the number 1, 2 or 3,-   m represents the number 1 or 2,-   R⁴ represents methyl, ethyl or cyclopropyl,-   R⁵ represents hydrogen, methyl or ethyl,-   or-   R⁴ and R⁵ together with the nitrogen atom to which they are attached    form a morpholin-4-yl ring, a 4-methylpiperazin-1-yl or a    4-hydroxypiperidin-1-yl ring,-   R⁶ represents cyclopropyl, cyclobutyl, 2-methoxyeth-1-yl,    tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,-   R⁷ represents hydrogen, methyl or ethyl,-   R⁶ and R⁷ together with the nitrogen atom to which they are attached    form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring,    a 1,1-dioxothiomorpholin-4-yl ring, a 1,4-oxazepan-4-yl ring or a    4-methylpiperazin-1-yl ring,-   and their salts, their solvates and the solvates of their salts.

Preference is also given to compounds of the formula (I) in which

-   R¹ represents methyl, methoxy or methoxymethyl,-   R² represents hydrogen,-   or-   R¹ represents methyl,-   R² represents methyl,-   and-   R³ represents a group of the formula

where

-   * is the point of attachment to the oxopyridine ring,-   n represents the number 1, 2 or 3,-   m represents the number 1 or 2,-   R⁴ represents methyl or cyclopropyl,-   R⁵ represents hydrogen or methyl,-   or-   R⁴ and R⁵ together with the nitrogen atom to which they are attached    form a 4-methylpiperazin-1-yl or a 4-hydroxypiperidin-1-yl ring,-   R⁶ represents cyclopropyl, cyclobutyl or 2-methoxyeth-1-yl,-   R⁷ represents hydrogen or methyl,-   R⁶ and R⁷ together with the nitrogen atom to which they are attached    form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring    or a 4-methylpiperazin-1-yl ring,-   and their salts, their solvates and the solvates of their salts.

Particular preference is also given to the compound5-chloro-N-{[(5S)-3-{4-[3-{2-[(trans-4-hydroxycyclohexyl)amino]ethyl}-2-oxopyridin-1(2H)-yl]-3-methoxyphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamideof the formula

and its salts, its solvates and the solvates of its salts. The compoundis described in Example 6.

Particular preference is also given to the compound5-chloro-N-{[(5S)-3-{4-[3-{2-[(2-hydroxyethyl)amino]ethyl}-2-oxopyridin-1(2H)-yl]-3-(methoxymethyl)phenyl}-2-oxo-1,3-oxazolidin-5-yl]ethyl}thiophene-2-carboxamideof the formula

and its salts, its solvates and the solvates of its salts. The compoundis described in Example 9.

Particular preference is also given to the compound5-chloro-N-{[(5S)-3-{4-[3-{2-[(trans-4-hydroxycyclohexyl)amino]ethyl}-2-oxopyridin-1(2H)-yl]-3-(methoxymethyl)phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamideof the formula

and its salts, its solvates and the solvates of its salts. The compoundis described in Example 10.

Particular preference is also given to the compound5-chloro-N-{[(5S)-3-{4-[3-{2-[(trans-4-hydroxycyclohexyl)amino]ethoxy}-2-oxopyridin-1(2H)-yl]-3-methylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamideof the formula

and its salts, its solvates and the solvates of its salts. The compoundis described in Example 21.

Particular preference is also given to the compound5-chloro-N-{[(5S)-3-{4-[3-{2-[(2-hydroxyethyl)amino]ethyl}-2-oxopyridin-1(2H)-yl]-3,5-dimethylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamideof the formula

and its salts, its solvates and the solvates of its salts. The compoundis described in Example 37.

Particular preference is also given to the compound5-chloro-N-{[(5S)-3-{4-[3-{2-[(trans-4-hydroxycyclohexyl)amino]ethyl}-2-oxopyridin-1(2H)-yl]-3,5-dimethylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamideof the formula

and its salts, its solvates and the solvates of its salts. The compoundis described in Example 38.

The specific radical definitions given in the respective combinations orpreferred combinations of radicals are, independently of the respectivegiven combination of radicals, also replaced by any of the radicaldefinitions of other combinations.

Very particular preference is given to combinations of two or more ofthe preferred ranges mentioned above.

The invention furthermore provides a process for preparing the compoundsof the formula (I), or the salts, solvates or solvates of the saltsthereof, wherein

[A] a compound of the formula

in which n, R¹ and R² have the meaning given above, and

-   X represents hydroxyl or bromine,-   is reacted with a compound of the formula

in which R⁴ and R⁵ have the meaning given above,

to give a compound of the formula

in which n, R¹, R², R⁴ and R⁵ have the meaning given above,

or

[B] a compound of the formula

in which m, R¹ and R² have the meaning given above, and

Y represents hydroxyl or chlorine,

is reacted with a compound of the formula

in which R⁶ and R⁷ have the meaning given above,

to give a compound of the formula

in which m, R¹, R², R⁶ and R⁷ have the meaning given above.

The compounds of the formulae (Ia) and (Ib) form the compounds of theformula (I).

The free base of the salts can be obtained, for example, bychromatograpy on a reversed phase column using an acetonitrile/watergradient with addition of a base, in particular by using an RP18Phenomenex Luna C18(2) column and diethylamine as base, or by dissolvingthe salts in an organic solvent and extracting with aqueous solutions ofbasic salts such as sodium bicarbonate.

The invention furthermore provides a process for preparing the compoundsof the formula (I) or solvates thereof wherein salts of the compounds orsolvates of the salts of the compounds are converted by chromatographywith addition of a base into the compounds.

If X is hydroxyl, the reaction according to process [A] is generallycarried out in inert solvents in the presence oftrifluoromethanesulphonic anhydride, if appropriate in the presence of abase, preferably in a temperature range of from −78° C. to roomtemperature at atmospheric pressure.

Inert solvents are, for example, dichloromethane, diethyl ether,nitromethane, 1,2-dichloroethane or acetonitrile; preference is given todichloromethane.

Bases are, for example, 2,6-dimethylpyridine, pyridine,2,6-di-tert-butyl-4-methylpyridine, diisopropylethylamine, 2,6-lutidine,trimethylamine, preference is given to 2,6-dimethylpyridine.

If X is bromine, the reaction according to process [A] is generallycarried out in inert solvents, preferably in a temperature range of from−78° C. to room temperature at atmospheric pressure.

Inert solvents are, for example, dimethylformamide.

If Y is hydroxyl, the reaction according to process [B] is generallycarried out in inert solvents, in the presence oftrifluoromethanesulphonic anhydride, if appropriate in the presence of abase, preferably in a temperature range of from −78° C. to roomtemperature at atmospheric pressure.

Inert solvents are, for example, dichloromethane, diethyl ether,nitromethane, 1,2-dichloroethane or acetonitrile; preference is given todichloromethane.

Bases are, for example, 2,6-dimethylpyridine, pyridine,2,6-di-tert-butyl-4-methylpyridine, diisopropylethylamine, 2,6-lutidine,trimethylamine, preference is given to 2,6-dimethylpyridine.

If Y is chlorine, the reaction according to process [B] is generallycarried out in inert solvents, if appropriate in the presence of ahalogen salt, preferably in a temperature range of from room temperatureto reflux of the solvent at atmospheric pressure.

Inert solvents are, for example, 1,2-dimethoxyethane.

A halogen salt is, for example, sodium iodide.

The compounds of the formulae (III) and (V) are known or can besynthesized according to known processes from the corresponding startingmaterials.

The compounds of the formula (II) in which X represents hydroxyl areknown or can be prepared by reacting the compound of the formula

in the first step with compounds of the formula

in which n, R¹ and R² have the meaning given above,

to give compounds of the formula

in which n, R¹ and R² have the meaning given above,

-   cyclizing, in the second step, in the presence of phosgene or    phosgene equivalents such as, for example, carbonyldiimidazole (CU),-   and, in the third step, removing the silyl group, giving the    compounds of the formula

The reaction of the first step is generally carried out in inertsolvents, in the presence of a Lewis acid, preferably in a temperaturerange of from room temperature to reflux of the solvent at atmosphericpressure.

Inert solvents are, for example, polar aprotic solvents, such as, forexample, acetonitrile, butyronitrile, dichloromethane or chloroform;preference is given to acetonitrile.

Lewis acids are, for example, magnesium perchlorate, ytterbium(III)trifluoromethanesulphonate, lithium bromide, magnesium triflate oraluminium trichloride; preference is given to magnesium perchlorate.

The reaction of the second step is generally carried out in inertsolvents, in the presence of a base, preferably in a temperature rangeof from room temperature to reflux of the solvent at atmosphericpressure.

Inert solvents are, for example, polar aprotic solvents, such as, forexample, acetonitrile or butyronitrile.

Bases are, for example, strong tertiary amine bases, such as, forexample, 4-N,N-dimethylaminopyridine.

Preference is given to the reaction with N,N′-carbonyldiimidazole ascarbonic acid equivalent with addition of 4-N,N-dimethylaminopyridine asbase.

The reaction of the third step is carried out by methods known to theperson skilled in the art, for example by reaction withtetrabutylammonium fluoride in a solvent, such as, for example,tetrahydrofuran, or by reaction with hydrogen chloride in methanol,preferably in a temperature range of from room temperature to reflux ofthe solvent at atmospheric pressure.

The compound of the formula (VI) is known or can be synthesized by knownprocesses from the corresponding starting materials.

In an alternative process, compounds of the formula (II) in which Xrepresents hydroxy can be prepared by reacting the compounds of theformula

in which n, R¹ and R² have the meaning given above

with compounds of the formula

in which

Q represents halogen, preferably bromine or chlorine, or hydroxyl,

followed by removal of the silyl group.

If Q is halogen, the reaction is generally carried out in inertsolvents, if appropriate in the presence of a base, preferably in atemperature range of from −30° C. to 50° C. at atmospheric pressure.

Inert solvents are, for example, tetrahydrofuran, methylene chloride,pyridine, dioxane or dimethylformamide, preference is given totetrahydrofuran or methylene chloride.

Bases are, for example, triethylamine, diisopropylethylamine orN-methylmorpholine; preference is given to diisopropylethylamine.

If Q is hydroxyl, the reaction is generally carried out in inertsolvents, in the presence of a dehydrating agent, if appropriate in thepresence of a base, preferably in a temperature range of from −30° C. to50° C. at atmospheric pressure.

Inert solvents are, for example, halogenated hydrocarbons, such asdichloromethane or trichloromethane, hydrocarbons, such as benzene,nitromethane, dioxane, dimethylformamide or acetonitrile. It is alsopossible to use mixtures of the solvents. Particular preference is givento dichloromethane or dimethylformamide.

Here, suitable dehydrating agents are, for example, carbodiimides, suchas, for example, N,N′-diethyl-, N,N′-dipropyl-, N,N′-diisopropyl-,N,N′-dicyclohexylcarbodiimide,N-(3-dimethylaminoisopropyl)-N′-ethylcarbodiimide hydrochloride (EDC),N-cyclohexylcarbodiimide-N′-propyloxymethyl-polystyrene(PS-carbodiimide) or carbonyl compounds, such as carbonyldiimidazole, or1,2-oxazolium compounds, such as 2-ethyl-5-phenyl-1,2-oxazolium3-sulphate or 2-tert-butyl-5-methylisoxazolium perchlorate, or acylaminocompounds, such as 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, orpropanephosphonic anhydride, or isobutyl chloroformate, orbis(2-oxo-3-oxazolidinyl)phosphoryl chloride orbenzotriazolyloxy-tri(dimethylamino)phosphonium hexafluorophosphate, orO-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate(HBTU), 2-(2-oxo-1-(2H)-pyridyl)-1,1,3,3-tetramethyluroniumtetrafluoroborate (TPTU) orO-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HATU), or 1-hydroxybenzotriazole (HOBt), orbenzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate(BOP), or N-hydroxysuccinimide, or mixtures of these, with bases.

Bases are, for example, alkali metal carbonates, such as, for example,sodium carbonate or potassium carbonate, or sodium bicarbonate orpotassium bicarbonate, or organic bases, such as trialkylamines, forexample triethylamine, N-methyl-morpholine, N-methylpiperidine,4-dimethylaminopyridine or diisopropylethylamine.

The condensation with HATU or with EDC is preferably carried out in thepresence of HOBt.

A silyl group is removed by methods known to the person skilled in theart, for example by reaction with tetrabutylammonium fluoride in asolvent, such as, for example, tetrahydrofuran, or by reaction withhydrogen chloride in methanol, preferably in a temperature range of fromroom temperature to reflux of the solvent at atmospheric pressure.

The compounds of the formula (XVII) are known or can be synthesized byknown processes from the corresponding starting materials.

The compounds of the formula (II) in which X represents bromine areknown or can be prepared by reacting the compounds of the formula (II)in which X represents hydroxyl with thionyl bromide, as described inExample 11A.

The compounds of the formula (VII) are known or can be prepared byreducing the nitro group in compounds of the formula

in which n, R¹ and R² have the meaning given above.

The reaction is generally carried out using a reducing agent in inertsolvents, preferably in a temperature range of from room temperature toreflux of the solvents at from atmospheric pressure to 3 bar.

Reducing agents are, for example, palladium on carbon, hydrogen, tindichloride, titanium trichloride or ammonium formate and palladium oncarbon in a mixture of ethanol and ethyl acetate; preference is given topalladium on carbon and hydrogen or tin dichloride.

Inert solvents are, for example, ethers, such as diethyl ether, methyltert-butyl ether, 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycoldimethyl ether or diethylene glycol dimethyl ether, alcohols, such asmethanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol,hydrocarbons, such as benzene, xylene, toluene, hexane, cyclohexan ormineral oil fractions, or other solvents, such as dimethylformamide,dimethylacetamide, acetonitrile or pyridine; preferred solvents aretetrahydrofuran, methanol, ethanol, isopropanol or, in the case of tindichloride, dimethylformamide.

The compounds of the formula (IX) are known, can be synthesized by knownprocesses from the corresponding starting materials or can be preparedanalogously to the process described in the examples section.

The compounds of the formula (IV), in which Y represents chlorine areknown or can be prepared by reacting compounds of the formula

in which R¹ and R² have the meaning given above, and

A represents methyl or (2-methoxyethoxy)methyl, in a first step byremoving the methoxy- or (2-methoxyethoxy)methoxy group, to givecompounds of the formula

in which R¹ and R² have the meaning given above,

and, in the second step, with compounds of the formula

in which m has the meaning given above, and

E represents bromine or iodine.

If A represents methyl, the reaction of the first step is generallycarried out in inert solvents, in the present of bromine tribromide,preferably in a temperature range of from −78° C. to room temperature atatmospheric pressure.

Inert solvents are, for example, dichloromethane or 1,2-dichloroethane;preference is given to dichloromethane.

If A is (2-methoxyethoxy)methyl, the reaction of the first step isgenerally carried out in inert solvents, in the presence oftrifluoroacetic acid, preferably in a temperature range of from roomtemperature to reflux of the solvent at atmospheric pressure.

Inert solvents are, for example, dichloromethane or 1,2-dichlorethane;preference is given to dichloromethane.

The reaction of the second step is generally carried out in inertsolvents in the presence of a base, preferably in a temperature range offrom room temperature to reflux of the solvent at atmospheric pressure.If appropriate, this reaction is carried out in a microwave oven.

Inert solvents are, for example, N,N-dimethylformamide or1-methyl-2-pyrrolidine; preference is given to N,N-dimethylformamide.

Bases are, for example, alkali metal carbonates, such as caesiumcarbonate, sodium carbonate or potassium carbonate.

Compounds of the formula (XII) are known or can be synthesized by knownprocesses from the corresponding starting materials.

The compounds of the formula (IV) in which Y represents hydroxyl areknown or can be prepared by reacting, in the second step of thesynthesis given above, the compounds of the formula (XI) with(2-bromoethoxy)(tert-butyl)dimethylsilane, followed by removal of thesilyl group.

The compounds of the formula (X) are known or can be prepared byreacting the compounds of the formula (VI) in a first step withcompounds of the formula

in which R¹ and R² have the meaning given above, and

A represents methyl or represents (2-methoxyethoxy)methyl,

to give compounds of the formula

in which R¹ and R² have the meaning given above, and

A represents methyl or represents (2-methoxyethoxy)methyl,

and, in the second step, cyclizing in the presence of phosgene orphosgene equivalents, such as, for example, carbonyldiimidazole (CU), togive the compounds of the formula (X).

The reaction of the first step is carried out according to the processdescribed for the reaction of the compound of the formula (VI) withcompounds of the formula (VII) to give compounds of the formula (VIII).

The reaction of the second step is carried out according to the processdescribed for the reaction of compounds of the formula (VIII) to givecompounds of the formula (II).

The compounds of the formula (XIII) are known or can be prepared byreducing the nitro group in compounds of the formula

in which R¹ and R² have the meaning given above, and

A represents methyl or represents (2-methoxyethoxy)methyl.

The reactions are carried out according to the process described for thereaction of compounds of the formula (IX) to give compounds of theformula (VII).

The compounds of the formula (XV) are known or can be synthesized byknown processes from the corresponding starting materials.

The compounds of the formula (XVI) are known or can be prepared byremoving the phthalimide protective group from compounds of the formula

in which n, R¹ and R² have the meaning given above.

The reaction is generally carried out using an aqueous methylaminesolution or a solution of hydrazine hydrate in ethanol, preferably usingan aqueous methylamine solution at reflux of the solvents underatmospheric pressure.

The compounds of the formula (XVIII) are known or can be prepared byreacting, in a first step, compounds of the formula (VII) with acompound of the formula

to give compounds of the formula

in which n, R¹ and R² have the meaning given above,

and, in a second step, cyclizing in the presence of phosgene or phosgeneequivalents, such as, for example, carbonyldiimidazole (CU), to give thecompounds of the formula (XVIII).

The reaction of the first step is carried out according to the processdescribed for the reaction of the compound of the formula (VI) withcompounds of the formula (VII) to give compounds of the formula (VIII).

The reaction of the second step is carried out according to the processdescribed for the reaction of compounds of the formula (VIII) to givecompounds of the formula (II).

The compound of the formula (XIX) is known or can be synthesized byknown processes from the corresponding starting materials.

The preparation of the compounds according to the invention can beillustrated by the synthesis schemes below:

The compounds according to the invention have an unforeseeable usefulspectrum of pharmacological activity.

Accordingly they are suitable for use as medicaments for the treatmentand/or prophylaxis of diseases in humans and animals.

The compounds according to the invention are dual inhibitors of theblood coagulation factors Xa and thrombin (factor IIa) acting, inparticular, as anticoagulants. The compounds inhibit both thrombin andfactor Xa, prevent, by inhibiting thrombin production and activity onclots, their potential growth and have a wide therapeutic window.

In addition, the compounds according to the invention have favourablephysicochemical properties such as, for example, good solubility inwater and physiological media, which is advantageous for theirtherapeutic application.

The present invention furthermore provides the use of the compoundsaccording to the invention for the treatment and/or prophylaxis ofdisorders, preferably thromboembolic disorders and/or thromboemboliccomplications.

“Thromboembolic disorders” in the sense of the present invention are inparticular disorders such as myocardial infarction with ST segmentelevation (STEMI) and without ST segment elevation (non-STEMI), stableangina pectoris, unstable angina pectoris, reocclusions and restenosesafter coronary interventions such as angioplasty or aortocoronarybypass, peripheral arterial occlusion diseases, pulmonary embolisms,deep venous thromboses and kidney venous thromboses, transitoryischaemic attacks and also thrombotic and thromboembolic stroke.

Accordingly, the compounds according to the invention are also suitablefor the prevention and treatment of cardiogenic thromboembolisms, suchas, for example, cerebral ischaemias, stroke and systemicthromboembolisms and ischaemias, in patients having actue, intermittentor persistant cardial arrhythmias, such as, for example, atrialfibrillation, and those undergoing cardioversion, furthermore inpatients having cardiac valve disorders or having artificial cardiacvalves.

Thromboembolic complications are furthermore encountered inmicroangiopathic haemolytic anaemias, extracorporeal circulatorysystems, such as haemodialysis, and prosthetic heart valves.

Moreover, the compounds according to the invention are also suitable forthe prophylaxis and/or treatment of atherosclerotic vascular disordersand inflammatory disorders such as rheumatic disorders of the locomotorapparatus, and in addition also for the prophylaxis and/or treatment ofAlzheimer's disease. Moreover, the compounds according to the inventioncan be used for inhibiting tumour growth and formation of metastases,for microangiopathies, age-related macula degeneration, diabeticretinopathy, diabetic nephropathy and other microvascular disorders, andalso for the prevention and treatment of thromboembolic complications,such as, for example, venous thromboembolisms, for tumour patients, inparticular those undergoing major surgical interventions or chemo- orradiotherapy.

Moreover, the compounds according to the invention are also suitable forthe prophylaxis and/or treatment of pulmonary hypertension.

The term “pulmonary hypertension” includes certain forms of pulmonaryhypertension, as determined, for example, by the World HealthOrganization (WHO) (Clinical Classification of Pulmonary Hypertension,Venice 2003). Examples which may be mentioned are pulmonary arterialhypertension, pulmonary hypertension associated with disorders of theleft heart, pulmonary hypertension associated with pulmonary disordersand/or hypoxia and pulmonary hypertension owing to chronicthromboembolisms (CTEPH).

“Pulmonary arterial hypertension” comprises idiopathic pulmonaryarterial hypertension (IPAH, formally also referred to as primarypulmonary hypertension), familiar pulmonary arterial hypertension (FPAH)and associated pulmonary-arterial hypertension (APAH), which isassociated with collagenoses, congenital systemic-pulmonary shunt vitia,portal hypertension, HIV infections, the ingestion of certain drugs andmedicaments, with other disorders (thyroid disorders, glycogen storagedisorders, Morbus Gaucher, hereditary teleangiectasy,haemoglobinopathies, myeloproliferative disorders, splenectomy), withdisorders having a significant venous/capillary contribution, such aspulmonary-venoocclusive disorder and pulmonary-capillaryhaemangiomatosis, and also persisting pulmonary hypertension ofneonates.

Pulmonary hypertension associated with disorders of the left heartcomprises a diseased left atrium or ventricle and mitral or aorta valvedefects.

Pulmonary hyptertension associated with pulmonary disorders and/orhypoxia comprises chronic obstructive pulmonary disorders, interstitialpulmonary disorder, sleep apnoea syndrome, alveolar hypoventilation,chronic high-altitude sickness and inherent defects.

Pulmonary hypertension owing to chronic thromboembolisms (CTEPH)comprises the thromboembolic occlusion of proximal pulmonary arteries,the thromboembolic occlusion of distal pulmonary arteries andnon-thrombotic pulmonary embolisms (tumour, parasites, foreign bodies).

The present invention furthermore provides the use of the compoundsaccording to the invention for preparing medicaments for the treatmentand/or prophylaxis of pulmonary hypertension associated withsarcoidosis, histiocytosis X and lymphangiomatosis.

Moreover, the substances according to the invention may also be suitablefor treating pulmonary and hepatic fibroses.

Moreover, the compounds according to the invention may also be suitablefor the treatment and/or prophylaxis of sepsis (or septicaemia),systemic inflammatory syndrome (SIRS), septic organ dysfunction, septicorgan failure and multiorgan failure, acute respiratory distresssyndrome (ARDS), acute lung injury (ALI), septic shock, DIC(disseminated intravascular coagulation or consumption coagulopathy)and/or septic organ failure.

“Sepsis” is defined as the presence of an infection and a systemicinflammatory response syndrome (hereinbelow referred to as “SIRS”). SIRSoccurs associated with infections, but also other states such asinjuries, burns, shock, operations, ischaemia, pancreatitis, reanimationor tumours. The definition of the ACCP/SCCM Consensus ConferenceCommittee from 1992 (Crit Care Med 1992; 20:864-874) describes thediagnosis symptoms and measuring parameters required for the diagnosis“SIRS” (inter alia body temperature change, increased pulse, breathingdifficulties and changed blood picture). The later (2001)SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conferenceessentially kept the criteria, but fine-tuned details (Levy et al., CritCare Med 2003; 31:1250-1256).

In the course of sepsis, there may be a generalized activation of thecoagulation system (disseminated intravascular coagulation orconsumption coagulopathy, hereinbelow referred to as “DIC”) withmicrothromboses in various organs and secondary haemorrhagiccomplications. Moreover, there may be endothelial damage with increasedpermeability of the vessels and seeping of fluids and proteins into theextravasal lumen. As the sepsis progresses, there may be failure of anorgan (for example kidney failure, liver failure, respiratory failure,central-nervous deficits and/or cardiovascular failure) or multiorganfailure. “Septic shock” refers to the onset of hypotension requiringtreatment, which hypotension promotes further organ damage and isassociated with a worsening of the prognosis.

Pathogens may be bacteria (Gram-negative and Gram-positive), fungi,viruses and/or eukaryotes. Entrance point or primary infection may be,for example, pneumonia, an infection of the urinary tract orperitonitis. Infection can be, but is not necessarily, associated withbacteremia.

DIC and/or SIRS may occur during sepsis, but also as a result ofoperations, tumour diseases, burns or other injuries. In DIC, there is amassive activation of the coagulatory system at the surface of damagedendothelial cells, the surfaces of foreign bodies or injuredextravascular tissue. As a result, there is coagulation in small vesselsof various organs with associated hypoxia and subsequent organdysfunction. Secondary, there is a consumption of coagulation factors(for example factor X, prothrombin and fibrinogen) and platelets, whichreduces the ability of the blood to coagulate and may result in seriousbleeding.

Therapy of sepsis consists, firstly, of consequent elimination of theinfectious cause, for example by operative focal reconstruction andantibiosis. Secondly, it consists in temporary intensive medical supportof the affected organ systems. Therapies of various stages of thisdisease have been described, for example, in the following publication(Dellinger et al., Crit Care Med 2004; 32:858-873). For DIC, there areno proven effective therapies.

The invention furthermore provides medicaments comprising a compoundaccording to the invention and one or more further active compounds, inparticular for the treatment and/or prophylaxis of the disordersmentioned above. Exemplary and preferred active compound combinationsare:

Antibiotic Therapy

Various antibiotics or antifungal medicament combinations are suitable,either as calculated therapy (prior to the presence of the microbialdiagnosis) or as specific therapy.

Fluid Therapy

for example crystalloids or colloidal fluids.

Vasopressors

for example norepinephrins, dopamines or vasopressin

Inotropic Therapy

for example dobutamine

Corticosteroids

for example hydrocortisone, or fludrocortisone

Recombinant Human Activated Protein C

Xigris

Blood Products

for example erythrocyte concentrates, platelet concentrates,erythropoietin or fresh frozen plasma

Artificial ventilation in the case of sepsis-induced acute lung injury(ALI)

or acute respiratory distress syndrome (ARDS)

for example permissive hypercapnia, reduced tidal volumes

Sedation, analgesia and neuromuscular blockade

Sedation: for example diazepam, lorazepam, midazolam or propofol.Opioids: for example fentanyl, hydromorphone, morphine, meperidine orremifentanil. NSAIDs: for example ketorolac, ibuprofen or acetaminophen.Neuromuscular blockade: for example pancuronium

Glucose Control

for example insulin, glucose

Renal Replacement Methods

for example continuous veno-venous haemofiltration or intermittenthaemodialysis. Low doses of dopamine for renal protection.

Anticoagulants

for example for thrombosis prophylaxis or renal replacement methods, forexample unfractionated heparins, low-molecular-weight heparins,heparinoids, hirudin, bivalirudin or argatroban.

Bicarbonate Therapy

Stress Ulcer Prophylaxis

for example H2-receptor inhibitors, antacids

In addition, the compounds according to the invention can also be usedfor preventing coagulation ex vivo, for example for preserving blood andplasma products, for cleaning/pretreatment of catheters and othermedical aids and instruments, for coating synthetic surfaces of medicalaids and instruments used in vivo or ex vivo or for biological samplescomprising factor Xa and/or factor IIa.

The present invention furthermore provides the use of the compoundsaccording to the invention for the treatment and/or prophylaxis ofdisorders, in particular the disorders mentioned above.

The present invention furthermore provides the use of the compoundsaccording to the invention for preparing a medicament for the treatmentand/or prophylaxis of disorders, in particular the disorders mentionedabove.

The present invention furthermore provides a method for the treatmentand/or prophylaxis of disorders, in particular the disorders mentionedabove, using an anticoagulatory effective amount of the compoundaccording to the invention.

The present invention furthermore provides a method for preventing thecoagulation of blood in vitro, in particular in banked blood orbiological samples containing factor Xa and/or factor IIa, which methodis characterized in that an anticoagulatory effective amount of thecompound according to the invention is added.

The present invention furthermore provides medicaments comprising acompound according to the invention and one or more further activecompounds, in particular for the treatment and/or prophylaxis of thedisorders mentioned above. By way of example and by way of preference,the following active compounds or combinations may be mentioned:

-   lipid-lowering substances, in particular    HMG-CoA-(3-hydroxy-3-methylglutaryl-coenzyme A) reductase    inhibitors, such as, for example, lovastatin (Mevacor; U.S. Pat. No.    4,231,938), simvastatin (Zocor; U.S. Pat. No. 4,444,784),    pravastatin (Pravachol; U.S. Pat. No. 4,346,227), fluvastatin    (Lescol; U.S. Pat. No. 5,354,772) and atorvastatin (Lipitor; U.S.    Pat. No. 5,273,995);-   coronary therapeutics/vasodilatators, in particular ACE (angiotensin    converting enzyme) inhibitors, such as, for example, captopril,    lisinopril, enalapril, ramipril, cilazapril, benazepril, fosinopril,    quinapril and perindopril, or All (angiotensin II) receptor    antagonists, such as, for example, embusartan (U.S. Pat. No.    5,863,930), losartan, valsartan, irbesartan, candesartan, eprosartan    and ternisartan, or β-adrenoceptor antagonists, such as, for    example, carvedilol, alprenolol, bisoprolol, acebutolol, atenolol,    betaxolol, carteolol, metoprolol, nadolol, penbutolol, pindolol,    propanolol and timolol, or alpha-1-adrenoceptor antagonists, such    as, for example, prazosine, bunazosine, doxazosine and terazosine,    or diuretics, such as, for example, hydrochlorothiazide, furosemide,    bumetanide, piretanide, torasemide, amiloride and dihydralazine, or    calcium channel blockers, such as, for example, verapamil and    diltiazem, or dihydropyridine derivatives, such as, for example,    nifedipin (Adalat) and nitrendipine (Bayotensin), or nitro    preparations, such as, for example, isosorbide 5-mononitrate,    isosorbide dinitrate and glycerol trinitrate, or substances causing    an increase in cyclic guanosine monophosphate (cGMP), such as, for    example, stimulators of soluble guanylate cyclase (WO 98/16223, WO    98/16507, WO 98/23619, WO 00/06567, WO 00/06568, WO 00/06569, WO    00/21954, WO 00/66582, WO 01/17998, WO 01/19776, WO 01/19355, WO    01/19780, WO 01/19778, WO 07/045,366, WO 07/045,367, WO 07/045,369,    WO 07/045,370, WO 07/045,433);-   plasminogen activators (thrombolytics/fibrinolytics) and compounds    which promote thrombolysis/fibrinolysis, such as inhibitors of the    plasminogen activator inhibitor (PAI inhibitors) or inhibitors of    the thrombin-activated fibrinolysis inhibitor (TAFI inhibitors) such    as, for example, tissue plasminogen activator (t-PA), streptokinase,    reteplase and urokinase;-   anticoagulatory substances (anticoagulants), such as, for example,    heparin (UFH), low-molecular-weight heparins (NMH), such as, for    example, tinzaparin, certoparin, parnaparin, nadroparin, ardeparin,    enoxaparin, reviparin, dalteparin, danaparoid,-   AVE 5026 (Sanofi-Aventis, Company Presentation 2008, Feb. 12),-   M118 (Momenta Pharmaceuticals Inc, Press Release 2008, Feb. 14),-   ORG42675 (Organon International Inc, Company World Wide Website    2007, April),-   and direct thrombin inhibitors (DTI), such as, for example,    Exanta (ximelagatran)

Rendix (dabigatran)

AZD-0837 [AstraZeneca Annual Report 2006, Mar. 19, 2007]

SSR-182289A [J. Lorrain et al. Journal of Pharmacology and ExperimentalTherapeutics 2003, 304, 567-574; J-M Altenburger et al. Bioorg. Med.Chem. 2004, 12, 1713-1730]

TGN-167 [S. Combe et al. Blood 2005, 106, abstract 1863 (ASH 2005)],

N-[(benzyloxy)carbonyl]-L-phenylalanyl-N-[(1S)-1-(dihydroxyboryl)-4-methoxybutyl]-D-prolinamide[WO 2005/084685]

Sofigatran [WHO Drug Information 2007, 21, 77]

MCC-977 [Mitsubishi Pharma website pipeline 2006, Jul. 25, 2006],

MPC-0920 [Press Release: Myriad Genetics Begins Phase 1 Trial ofAnti-Thrombin Drug MPC-0920″, Myriad Genetics Inc, 02. Mai 2006] and

TGN-255 (flovagatran)

and direct factor Xa inhibitors, such as, for example,

rivaroxaban (BAY 59-7939):5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide[WO 2001/47919]

AX-1826 [S. Takehana et al. Japanese Journal of Pharmacology 2000, 82(Suppl. 1), 213P; T. Kayahara et al. Japanese Journal of Pharmacology2000, 82 (Suppl. 1), 213P],

tanogitran (BIBT-986, prodrug: BIBT-1011):N-[(1R)-1-{2-[({4-[amino(imino)methyl]-phenyl}amino)methyl]-1-methyl-1H-benzimidazol-5-yl}-1-methyl-2-oxo-2-pyrrolidin-1-ylethyl]glycine[American Chemical Society—226th National Meeting, New York City, N.Y.,USA, 2003]

compounds disclosed in WO 2004/056784,

YM-150 [Y. Iwatsuki et al. Blood 2006, 108, abstract 911 (ASH 2006)],

N-{4-bromo-2-[(5-chloropyridin-2-yl)carbamoyl]-6-hydroxyphenyl}-1-isopropylpiperidine-4-carboxamide[JP 2005/179272]

compounds disclosed in WO 2000/242270,

AZ 12300547:6-[4-({(2S)-4-[(3-chloro-1H-indol-6-yl)sulphonyl]-2-methyl-6-oxopiperazin-1-yl}methyl)phenyl]-2-methylpyridazin-3(2H)-one[K. L Granberg et al. American Chemical Society—232th National Meeting,San Francisco, USA, 2006, MEDI 391]

compounds disclosed in WO 2007/008142,

razaxaban (DPC-906):1-(3-amino-1,2-benzisoxazol-5-yl)-N-(4-{2-[(dimethylamino)-methyl]-1H-imidazol-1-yl}-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide[J. Med. Chem. 2005, 48, 1729-1744]

apixaban (BMS-562247):1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide[WO 2003/026652, WO 2003/049681]

BMS-691648:3-chloro-N-[(3S,4R)-1-(methylsulphonyl)-4-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}piperidin-3-yl]-1H-indole-6-carboxamide[T. Güngör et al. Drugs Fut. 2006, 31(Suppl A): abstract P118; WO2004/082687]

DX-9065a:(2S)-3-{7-[amino(imino)methyl]-2-naphthyl}-2-(4-{[(3S)-1-ethanimidoyl-pyrrolidin-3-yl]oxy}phenyl)propanoicacid [T. Nagahara et al. J. Med. Chem. 1994, 37, 1200-1207]

DU-176b [Y. Morishima et al. Blood 2004, 104, abstract 1862 (ASH 2004);T. Fukuda et al. Blood 2004, 104, abstract 1852 (ASH 2004); T. Furugohriet al. Blood 2004, 104, abstract 1851 (ASH 2004)],

N-(5-chloropyridin-2-yl)-N′-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-{[(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl]ethanediamide[US 2005/0020645, WO 2005/47296]

compounds disclosed in US 2005/0020645,

LY517717:N-{(1R)-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-1-phenylethyl}-1H-indole-6-carboxamide[WO 2000/76971, WO 2002/100847]

813893 [Proteinase Inhibitor Design—Fourth SCI-RSC Symposium, Proteinase2004: Strategies for New Medicines (Part I), London],

6-chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulphonamide[N. S. Watson et al. Bioorg. Med. Chem. Lett. 2006, 16, 3784; WO2002/100830; WO 2002/100886]

KFA-1982 (prodrug of KFA-1829) [T. Koizumi et al. Journal of Thrombosisand Hemostasis 2003, 1 Suppl 1, P2022],

EMD-503982 [Merck KGaA Annual Report 2006, 48-49],

EM D-495235:5-chloro-N-[(1R)-1-(methoxymethyl)-2-{[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]amino}-2-oxoethyl]thiophene-2-carboxamide[Bioorg. Med. Chem. Lett. 2004, 14, 5817-5822]

M-55113:4-[(6-chloro-2-naphthyl)sulphonyl]-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]piperazin-2-one[H. Nishida et al. Chem. Pharm. Bull. 2001, 49, 1237-1244]

M-55551/M-55555:(2R)-4-[(6-chloro-2-naphthyl)sulphonyl]-6-oxo-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]piperazine-2-carboxylicacid [H. Nishida et al. Chem. Pharm. Bull. 2002, 50, 1187-1194]

M-55190: ethyl(2R)-4-[(6-chloro-2-naphthyl)sulphonyl]-6-oxo-1-[(1-pyridin-4-ylpiperidin-4-yl)methyl]piperazine-2-carboxylate[H. Nishida et al. 16th Int Symp Med Chem, Bologna, 18-22 Sep. 2000,Abst PA-125]

M-55532:7-[(6-chloro-2-naphthyl)sulphonyl]-8a-(methoxymethyl)-1′-pyridin-4-yltetrahydro-5H-spiro[1,3-oxazolo[3,2-a]pyrazine-2,4′-piperidin]-5-one[H. Nishida et al. 228th ACS National Meeting, Philadelphia, Aug. 22-26,2004, MEDI-251; H. Nishida et al. Chem. Pharm. Bull. 2004, 52, 406-412;dito 459-462]

N-({7-[(5-chloro-1H-indol-2-yl)sulphonyl]-5-oxo-1′-propionyltetrahydro-8aH-spiro[1,3-oxazolo-[3,2-a]pyrazine-2,4′-piperidin]-8a-yl}methyl)-N-methylglycine[WO 2006/106804]

PRT54021 [U. Sinha et al. Blood 2006, 108, abstract 907 (ASH 2006); K.Abe et al. Blood 2006, 108, abstract 901 (ASH 2006)],

compounds disclosed in WO 2006/002099,

otamixaban (FXV-673, RPR-130673): methyl(2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate[V. Chu et al. Thrombosis Research 2001, 103, 309-324; K. R. Guertin etal. Bioorg Med. Chem. Lett. 2002, 12, 1671-1674]

AVE3247 [Sanofi Aventis Company Presentation, Paris 2007, Feb. 13],

SAR377142 (SSR-7142) [Sanofi Aventis Company Presentation, Paris 2007,Feb. 13],

HMR-2906 [XVIIth Congress of the International Society for Thrombosisand Haemostasis, Washington D.C., USA, 14-21 Aug. 1999; Generatinggreater value from our products and pipeline. Aventis SA CompanyPresentation, 5 Feb. 2004],

idraparinux [Harry R. Büller et al. Blood, 2006, 108, abstract 571 (ASH2006)] and

fondaparinux;

substances which inhibit the aggregation of platelets (plateletaggregation inhibitors, thrombocyte aggregation inhibitors), such as,for example, acetylsalicylic acid (such as, for example, aspirin),ticlopidine (ticlid), clopidogrel (plavix) and prasugrel;

fibrinogen receptor antagonists (glycoprotein-IIb/IIIa antagonists),such as, for example, abciximab, eptifibatide, tirofiban, lamifiban,lefradafiban and fradafiban;

and also antiarrhythmics.

The present invention further relates to medicaments which comprise atleast one compound according to the invention, normally together withone or more inert, non-toxic, pharmaceutically suitable excipients, andto the use thereof for the aforementioned purposes.

The compounds according to the invention can act systemically and/orlocally. For this purpose, they can be administered in a suitable waysuch as, for example, by the oral, parenteral, pulmonal, nasal,sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival,otic route or as implant or stent.

The compounds according to the invention can be administered inadministration forms suitable for these administration routes.

Suitable for oral administration are administration forms which functionaccording to the prior art and deliver the compounds according to theinvention rapidly and/or in modified fashion, and which contain thecompounds according to the invention in crystalline and/or amorphizedand/or dissolved form, such as, for example, tablets (uncoated or coatedtablets, for example having enteric coatings or coatings which areinsoluble or dissolve with a delay and control the release of thecompound according to the invention), tablets which disintegrate rapidlyin the mouth, or films/wafers, films/lyophilizates, capsules (forexample hard or soft gelatin capsules), sugar-coated tablets, granules,pellets, powders, emulsions, suspensions, aerosols or solutions.

Parenteral administration can take place with avoidance of an absorptionstep (e.g. intravenous, intraarterial, intracardiac, intraspinal orintralumbar) or with inclusion of an absorption (e.g. intramuscular,subcutaneous, intracutaneous, percutaneous or intraperitoneal).Administration forms suitable for parenteral administration are, interalia, preparations for injection and infusion in the form of solutions,suspensions, emulsions, lyophilizates or sterile powders.

Suitable for the other administration routes are, for example,pharmaceutical forms for inhalation (inter alia powder inhalers,nebulizers), nasal drops, solutions or sprays; tablets for lingual,sublingual or buccal administration, films/wafers or capsules,suppositories, preparations for the ears or eyes, vaginal capsules,aqueous suspensions (lotions, shaking mixtures), lipophilic suspensions,ointments, creams, transdermal therapeutic systems (e.g. patches), milk,pastes, foams, dusting powders, implants or stents.

Oral or parenteral administration is preferred, especially oraladministration.

The compounds according to the invention can be converted into thestated administration forms. This can take place in a manner known perse by mixing with inert, non-toxic, pharmaceutically suitableexcipients. These excipients include, inter alia, carriers (for examplemicrocrystalline cellulose, lactose, mannitol), solvents (e.g. liquidpolyethylene glycols), emulsifiers and dispersants or wetting agents(for example sodium dodecyl sulphate, polyoxysorbitan oleate), binders(for example polyvinylpyrrolidone), synthetic and natural polymers (forexample albumin), stabilizers (e.g. antioxidants such as, for example,ascorbic acid), colours (e.g. inorganic pigments such as, for example,iron oxides) and masking flavours and/or odours.

It has generally proved advantageous to administer on parenteraladministration amounts of about 0.001 to 5 mg/kg, preferably about 0.01to 1 mg/kg, of body weight to achieve effective results, and on oraladministration the dosage is about 0.01 to 100 mg/kg, preferably about0.01 to 20 mg/kg, and very particularly preferably 0.1 to 10 mg/kg, ofbody weight.

It may nevertheless be necessary where appropriate to deviate from thestated amounts, in particular as a function of the body weight, route ofadministration, individual response to the active ingredient, nature ofthe preparation and time or interval over which administration takesplace. Thus, it may be sufficient in some cases to make do with lessthan the aforementioned minimum amount, whereas in other cases thestated upper limit must be exceeded. It may in the event ofadministration of larger amounts be advisable to divide these into aplurality of individual doses over the day.

The following exemplary embodiments illustrate the invention. Theinvention is not restricted to the examples.

The percentage data in the following tests and examples are, unlessindicated otherwise, percentages by weight; parts are parts by weight.Solvent ratios, dilution ratios and concentration data for theliquid/liquid solutions are in each case based on volume.

A. EXAMPLES

Abbreviations

CDI carbonyldiimidazole

d doublet (in NMR)

TLC thin-layer chromatography

DCI direct chemical ionization (in MS)

dd doublet of doublets (in NMR)

DMAP 4-dimethylaminopyridine

DMF N,N-dimethylformamide

DMSO dimethyl sulphoxide

d day(s)

eq. equivalent(s)

ESI electrospray ionization (in MS)

h hour(s)

HPLC high pressure, high performance liquid chromatography

LC-MS liquid chromatography-coupled mass spectroscopy

m multiplet (in NMR)

min minute(s)

MS mass spectroscopy

NMR nuclear magnetic resonance spectroscopy

RP reversed phase (in HPLC)

RT room temperature

R_(t) retention time (in HPLC)

singulet (in NMR)

THF tetrahydrofuran

LC-MS and HPLC Methods

Method 1 (HPLC): Instrument: HP 1100 with DAD detection; column:Kromasil 100 RP-18, 60 mm×2.1 mm, 3.5 μm; mobile phase A: 5 mlperchloric acid (70% strength)/L of water, mobile phase B: acetonitrile;gradient: 0 min 2% B, 0.5 min 2% B, 4.5 min 90% B, 6.5 min 90% B, 6.7min 2% B, 7.5 min 2% B; flow rate: 0.75 ml/min; column temperature: 30°C.; detection: UV 210 nm.

Method 2 (HPLC): Instrument: HP 1100 with DAD detection; column:Kromasil 100 RP-18, 60 mm×2.1 mm, 3.5 μm; mobile phase A: 5 mlperchloric acid (70% strength)/l of water, mobile phase B: acetonitrile;gradient: 0 min 2% B, 0.5 min 2% B, 4.5 min 90% B, 9 min 90% B, 9.2 min2% B, 10 min 2% B; flow rate: 0.75 ml/min; column temperature: 30° C.;detection: UV 210 nm.

Method 3 (LC-MS): MS instrument type: Micromass ZQ; HPLC instrumenttype: Waters Alliance 2795; column: Phenomenex Synergi 2μ Hydro-RPMercury 20 mm×4 mm; mobile phase A: 1 l of water+0.5 ml 50% strength offormic acid, mobile phase B: 1 l of acetonitrile+0.5 ml 50% strength offormic acid; gradient: 0.0 min 90% A→2.5 min 30% A→3.0 min 5% A→4.5 min5% A; flow rate: 0.0 min 1 ml/min, 2.5 min/3.0 min/4.5 min 2 ml/min;oven: 50° C.; UV detection: 210 nm.

Method 4 (LC-MS): MS instrument type: Micromass ZQ; HPLC instrumenttype: HP 1100 Series; UV DAD; column: Phenomenex Synergi 2μ Hydro-RPMercury 20 mm×4 mm; mobile phase A: 1 l of water+0.5 ml 50% strength offormic acid, mobile

phase B: 1 l of acetonitrile+0.5 ml 50% strength of formic acid;gradient: 0.0 min 90% A→2.5 min 30% A→3.0 min 5% A→4.5 min 5% A; flowrate: 0.0 min 1 ml/min, 2.5 min/3.0 min/4.5 min. 2 ml/min; oven: 50° C.;UV detection: 210 nm.

Method 5 (LC-MS): Instrument: Micromass Quattro LCZ with HPLC AgilentSerie 1100; column: Phenomenex Synergi 2μ Hydro-RP Mercury 20 mm×4 mm;mobile phase A: 1 l of water+0.5 ml 50% strength of formic acid, mobilephase B: 1 l of acetonitrile+0.5 ml 50% strength of formic acid;gradient: 0.0 min 90% A→2.5 min 30% A→3.0 min 5% A→4.5 min 5% A; flowrate: 0.0 min 1 ml/min, 2.5 min/3.0 min/4.5 min 2 ml/min; oven: 50° C.;UV detection: 208-400 nm.

Method 6 (LC-MS): MS instrument type: Micromass ZQ; HPLC instrumenttype: HP 1100 Series; UV DAD; column: Phenomenex Gemini 3μ 30 mm×3.00mm; mobile phase A: 1 l of water+0.5 ml 50% strength of formic acid,mobile phase B: 1 l of acetonitrile+0.5 ml 50% strength of formic acid;gradient: 0.0 min 90% A→2.5 min 30% A→3.0 min 5% A→4.5 min 5% A; flowrate: 0.0 min 1 ml/min, 2.5 min/3.0 min/4.5 min. 2 ml/min; oven: 50° C.;UV detection: 210 nm.

Method 7 (LC-MS): Instrument: Micromass Platform LCZ with HPLC AgilentSerie 1100; column: Thermo Hypersil GOLD 3μ 20 mm×4 mm; mobile phase A:1 l of water+0.5 ml 50% strength of formic acid, mobile phase B: 1 l ofacetonitrile+0.5 ml 50% strength of formic acid; gradient: 0.0 min 100%A→0.2 min 100% A→2.9 min 30% A→3.1 min 10% A→5.5 min 10% A; oven: 50°C.; flow rate: 0.8 ml/min; UV detection: 210 nm.

Method 8 (LC-MS): MS instrument type: Waters ZQ; HPLC instrument type:Waters Alliance 2795; column: Phenomenex Onyx Monolithic C18, 100 mm×3mm; mobile phase A: 1 l of water+0.5 ml 50% strength of formic acid,mobile phase B: 1 l of acetonitrile+0.5 ml 50% strength of formic acid;gradient: 0.0 min 90% A→2 min 65% A→4.5 min 5% A→6 min 5% A; flow rate:2 ml/min; oven: 40° C.; UV detection: 210 nm.

Method 9 (GC-MS): Instrument: Micromass GCT, GC6890; column: RestekRTX-35MS, 30 m×250 μm×0.25 μm; constant helium flow: 0.88 ml/min; oven:60° C.; inlet: 250° C.; gradient: 60° C. (maintained for 0.30 min), 50°C./min→120° C., 16° C./min→250° C., 30° C./min→300° C. (maintained for1.7 min).

Method 10 (GC-MS): Instrument: Micromass GCT, GC6890; column: RestekRTX-35, 15 m×200 μm×0.33 μm; constant helium flow: 0.88 ml/min; oven:70° C.; inlet: 250° C.; gradient: 70° C., 30° C./min→310° C. (maintainedfor 3 min).

Method 11 (LC-MS): Instrument: Micromass Quattro LCZ with HPLC AgilentSerie 1100; column: Phenomenex Onyx Monolithic C18, 100 mm×3 mm. mobilephase A: 1 l of water+0.5 ml 50% strength of formic acid, mobile phaseB: 1 l of acetonitrile+0.5 ml 50% strength of formic acid; gradient: 0.0min 90% A→2 min 65% A→4.5 min 5% A→6 min 5% A; flow rate: 2 ml/min;oven: 40° C.; UV detection: 208-400 nm.

Method 12 (LC-MS): Instrument: Micromass Quattro LCZ with HPLC AgilentSerie 1100; column: Phenomenex Synergi 2.5μ MAX-RP 100A Mercury 20 mm×4mm; mobile phase A: 1 l of water+0.5 ml 50% strength of formic acid,mobile phase B: 1 l of acetonitrile+0.5 ml 50% strength of formic acid;gradient: 0.0 min 90% A→0.1 min 90% A→3.0 min 5% A→4.0 min 5% A→4.1 min90% A; flow rate: 2 ml/min; oven: 50° C.; UV detection: 208-400 nm.

Method 13 (LC-MS): MS instrument type: Micromass ZQ; HPLC instrumenttype: Waters Alliance 2795; column: Phenomenex Synergi 2.5μ MAX-RP 100AMercury 20 mm×4 mm; mobile phase A: 1 l of water+0.5 ml 50% strength offormic acid, mobile phase B: 1 l of acetonitrile+0.5 ml 50% strength offormic acid; gradient: 0.0 min 90% A→0.1 min 90% A→3.0 min 5% A→4.0 min5% A→4.01 min 90% A; flow rate: 2 ml/min; oven: 50° C.; UV detection:210 nm.

Method 14 (LC-MS): Instrument: Micromass Quattro Premier with WatersHPLC Acquity; column: Thermo Hypersil GOLD 1.9μ 50 mm×1 mm; mobile phaseA: 1 l of water+0.5 ml 50% strength of formic acid, mobile phase B: 1 lof acetonitrile+0.5 ml 50% strength of formic acid; gradient: 0.0 min90% A→0.1 min 90% A→1.5 min 10% A→2.2 min 10% A; flow rate: 0.33 ml/min;oven: 50° C.; UV detection: 210 nm.

Starting Materials

Example 1A 5-Chloro-N-[(2S)-oxiran-2-ylmethyl]thiophene-2-carboxamide

Example 1A is prepared as described in WO04/101557 (Example 6A).

Example 2A 3-(Hydroxymethyl)pyridin-2(1H)-one

At RT, 23.2 g (144 mmol) of hexamethyldisilane and 0.781 g (7.19 mmol)of chlorotrimethylsilane are added to a suspension of 10.0 g (71.9 mmol)of 2-hydroxynicotinic acid in 100 ml of toluene, and the mixture isstirred with a KPG stirrer at 110° C. for 30 min. The mixture is thencooled to −40° C., and 22.5 g (158 mmol) of a 1 molar solution ofdiisobutylaluminium hydride in dichloromethane are added dropwise to thesolution. The mixture is thawed to RT, stirred at RT for 18 h andfinally, at −10° C., adjusted to pH=4 with dilute hydrochloric acid, and500 ml of methanol are added such that the temperature does not exceed−10° C. The precipitate formed is filtered off, 100 ml of water areadded to the filtrate, the mixture is stirred at 50° C. for 1 h and theprecipitate is filtered off. Concentration of the filtrate gives 8.55 g(95% of theory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 11.53 (br. s, 1H), 7.40 (d, 1H), 7.25(d, 1H), 6.19 (dd, 1H), 5.00 (t, 1H), 4.28 (d, 2H).

HPLC (method 1): R_(t)=0.27 min.

MS (ESIpos, m/z): 148 (M+Na)⁺.

Example 3A 3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)pyridin-2(1H)-one

At RT, 0.65 g (9.59 mmol) of imidazole, 2.42 g (8.79 mmol) oft-butyldiphenylchlorosilane and 0.10 g (0.80 mmol) of DMAP are added to1.00 g (7.99 mmol) of the compound from Example 2A in 19 ml of DMF, andthe mixture is stirred for 18 h. 180 ml of water are then added, and themixture is kept at 0° C. for 3 h. After filtration, the residue obtainedis purified by chromatography on silica gel (ethylacetate/ethyldimethylamine 1000:1). This gives 801 mg (27% of theory) ofthe desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 11.61 (br. s, 1H), 7.69-7.52 (m, 5H),7.51-7.38 (m, 6H), 7.30 (d, 1H), 6.29 (dd, 1H), 4.51 (s, 2H), 1.05 (s,9H).

HPLC (method 2): R_(t)=5.27 min.

MS (DCI, m/z): 364 (M+H)⁺.

Example 4A3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-1-(2-chloro-4-nitrophenyl)pyridin-2(1H)-one

At 0° C., 0.500 g (4.46 mmol) of potassium tert-butoxide is added to1.08 g (2.97 mmol) of the compound from Example 3A in 21 ml of DMF, andthe mixture is stirred at room temperature for 30 min. 0.571 g (3.27mmol) of 2-chloro-1-fluoro-4-nitrobenzene is added, and the mixture isstirred at RT. After 4.5 h, 200 ml of water are added, and the mixtureis then extracted three times with ethyl acetate. The combined organicphases are washed with water and then dried over sodium sulphate. Afterfiltration, the solvents are removed under reduced pressure. The residueis purified by chromatography on silica gel (cyclohexane/ethyl acetate9:1). This gives 872 mg (56% of theory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.52 (d, 1H), 8.32 (dd, 1H), 7.85 (d,1H), 7.76 (dd, 1H), 7.68-7.63 (m, 4H), 7.59-7.55 (m, 1H), 7.54-7.41 (m,6H), 6.54 (dd, 1H), 4.56 (br. s, 2H), 1.07 (s, 9H).

HPLC (method 2): R_(t)=6.05 min.

MS (DCI, m/z): 519 (M+H)⁺.

Example 5A1-(4-Amino-2-chlorophenyl)-3-({[tert-butyl(diphenyl)silyl]oxy}methyl)pyridin-2(1H)-one

800 mg (1.54 mmol) of the compound from Example 4A are dissolved in 48ml of THF. 50 mg (0.05 mmol) of palladium on carbon are then added, andthe mixture is hydrogenated at RT in a hydrogen atmosphere underatmospheric pressure. The mixture is then filtered, the filter cake iswashed with THF and the filtrate is freed from the solvent. The reactionproduct (purity: 95%) is reacted further without further purification.

HPLC (method 1): R_(t)=5.55 min.

MS (ESIpos, m/z): 489 (M+H)⁺.

Example 6AN-{[(5S)-3-{4-[3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-2-oxopyridin-1(2H)-yl]-3-chloro-phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}-5-chlorothiophene-2-carboxamide

386 mg (1.77 mmol) of the compound from Example 1A are added to asolution of 789 mg (1.61 mmol) of the compound from Example 5A in 24 mlof acetonitrile. 540 mg (2.42 mmol) of magnesium perchlorate are addedto the suspension. After 19 h at RT, 193 mg (0.952 mmol) of the compoundfrom Example 1A are added, and stirring at RT is continued for a further30 h. 523 mg (2.46 mmol) of 1,1′-carbonyldiimidazole and 19 mg (0.09mmol) of DMAP are then added, and the mixture is heated at 60° C. After21 h, the mixture is diluted with water, saturated aqueous sodiumchloride solution and ethyl acetate. The aqueous phase is extractedtwice with ethyl acetate, and the combined organic phases are dried oversodium sulphate. After filtration, the solvent is removed and theresidue is purified by chromatography on silica gel (cyclohexane/ethylacetate 1:1). This gives 533 mg (45% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.97 (t, 1H), 7.85 (dd, 1H), 7.73 (dd,1H), 7.70-7.63 (m, 5H), 7.58 (dd, 1H), 7.53-7.38 (m, 8H), 7.19 (d, 1H),6.47 (dd, 1H), 4.91-4.82 (m, 1H), 4.55 (br. s, 2H), 4.24 (dd, 1H), 3.89(dd, 1H), 3.65-3.58 (m, 2H), 1.07 (s, 9H).

HPLC (method 2): R_(t)=6.07 min.

MS (ESIpos, m/z): 732 (M+H)⁺.

Example 7A3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-1-(2-methyl-4-nitrophenyl)pyridin-2(1H)-one

Analogously to Example 4A, 1.50 g (4.13 mmol) of the compound fromExample 3A are reacted with 704 mg (4.54 mmol) of2-fluoro-5-nitrotoluene. This gives 570 mg (28% of theory) of the titlecompound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.29 (d, 1H), 8.17 (dd, 1H), 7.76 (dd,1H), 7.67-7.63 (m, 4H), 7.57 (d, 1H), 7.53 (dd, 1H), 7.51-7.41 (m, 6H),6.52 (t, 1H), 4.63-4.51 (m, 2H), 2.12 (s, 3H), 1.07 (s, 9H).

HPLC (method 4): R_(t)=3.39 min.

MS (ESIpos, m/z): 499 (M+H)⁺.

Example 8A1-(4-Amino-2-methylphenyl)-3-({[tert-butyl(diphenyl)silyl]oxy}methyl)pyridin-2(1H)-one

555 mg (1.11 mmol) of the compound from Example 7A are dissolved in 15ml of THF, 150 mg of palladium on carbon are added and the mixture ishydrogenated in a hydrogen atmosphere at atmospheric pressure until thetheoretical amount of hydrogen has been taken up. The catalyst isfiltered off, which gives, after concentration under reduced pressure,520 mg (99% of theory) of the title compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 7.70-7.63 (m, 5H), 7.51-7.41 (m, 6H),7.40-7.36 (m, 1H), 6.78 (d, 1H), 6.47-6.41 (m, 2H), 6.38 (t, 1H), 5.22(s, broad, 2H), 4.59-4.48 (m, 2H), 1.81 (s, 3H), 1.06 (s, 9H).

HPLC (method 5): R_(t)=3.20 min.

MS (ESIpos, m/z): 469 (M+H)⁺.

Example 9AN-[((5S)-3-{4-[3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-2-oxopyridin-1(2H)-yl]-3-methyl-phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]-5-chlorothiophene-2-carboxamide

522 mg (1.11 mmol) of the compound from Example 8A are dissolved in 10ml of acetonitrile, and 266 mg (1.22 mmol) of the compound from Example1A are added at 0° C. 373 mg (1.67 mmol) of magnesium perchlorate areadded, and the mixture is stirred at RT for 20 h. 271 mg (1.67 mmol) of1,1′-carbonyldiimidazole and 14 mg (0.11 mmol) of DMAP are then added,and the reaction mixture is heated at 60° C. for 20 h. The mixture isthen concentrated under reduced pressure, and water and tert-butylmethyl ether are added. The mixture is extracted twice with ethylacetate. The combined organic phases are dried over sodium sulphate andconcentrated. The residue is purified by preparative HPLC. This gives562 mg (71% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.97 (t, 1H), 7.74-7.63 (m, 6H),7.58-7.41 (m, 9H), 7.23 (d, 1H), 7.19 (d, 1H), 6.45 (t, 1H), 4.89-4.80(m, 1H), 4.58-4.49 (m, 2H), 4.21 (t, 1H), 3.90-3.83 (m, 1H), 3.63-3.58(m, 2H), 1.98 (s, 3H), 1.07 (s, 9H).

HPLC (method 4): R_(t)=3.39 min.

MS (ESIpos, m/z): 712/714 (³⁵Cl/³⁷Cl) (M+H)⁺.

Example 10A5-Chloro-N-[((5S)-3-{4-[3-(hydroxymethyl)-2-oxopyridin-1(2H)-yl]-3-methylphenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]thiophene-2-carboxamide

530 mg (0.74 mmol) of the compound from Example 9A are dissolved in 9 mlTHF. 1.5 ml of a 1 molar solution of tetrabutylammonium fluoride in THFare added, and the mixture is stirred at RT for 30 min. A little wateris added, the mixture is concentrated and the product is purified bypreparative HPLC. This gives 335 mg (93% of theory) of the desiredproduct.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 9.00 (t, 1H), 7.70 (d, 1H), 7.55-7.49(m, 3H), 7.39 (d, 1H), 7.23 (d, 1H), 7.20 (d, 1H), 6.36 (t, 1H), 5.14(s, broad, 1H), 4.90-4.82 (m, 1H), 4.38-4.29 (m, 2H), 4.22 (t, 1H),3.91-3.85 (m, 1H), 3.62 (t, 2H), 2.01 (s, 3H).

HPLC (method 3): R_(t)=1.66 min.

MS (ESIpos, m/z): 474/476 (³⁵Cl/³⁷Cl) (M+H)⁺.

Example 11AN-{[(5S)-3-{4-[3-(Bromomethyl)-2-oxopyridin-1(2H)-yl]-3-methylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}-5-chlorothiophene-2-carboxamide

50 mg (0.11 mmol) of the product from Example 10A are dissolved in 1 mlof dichloromethane. 0.024 ml (0.32 mmol) of thionyl bromide is added,and the mixture is stirred at RT for 1.5 h. The mixture is diluted with1 ml of methanol and 3 ml of dichloromethane, and the solvent is thenremoved under reduced pressure. The crude product is reacted furtherwithout further purification.

Example 12A 3-Bromo-1-(2-methyl-4-nitrophenyl)pyridin-2(1H)-one

44.5 g (280 mmol) of 3-bromopyridin-2(1H)-one are dissolved in 750 ml ofanhydrous dimethyl sulphoxide, and 33.4 g (298 mmol) of potassiumtert-butoxide are added a little at a time at room temperature. Thesuspension is stirred at this temperature for 1 h, 38.5 g (280 mmol) of1-fluoro-2-methyl-4-nitrobenzene are then added and the reactionsolution is heated at 80° C. for 20 h. The solution is allowed to cooland carefully diluted with water. The resulting crystalline precipitateis filtered off, washed with a little water and dried under reducedpressure. This gives 62 g (80% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.34 (d, 1H), 8.21 (dd, 1H), 8.10(dd, 1H), 7.71-7.63 (m, 2H), 6.36 (t, 1H), 2.17 (s, 3H).

LC-MS (method 3): R_(t)=1.72 min

MS (ESIpos): m/z=309 (M+H)⁺

Example 13A 1-(2-Methyl-4-nitrophenyl)-3-vinylpyridin-2(1H)-one

50 g (162 mmol) of the compound from Example 12A are dissolved in 700 mlof anhydrous dioxane, 62 g (194 mmol) of tributylvinyltin and 4.7 g (4mmol) of tetrakis(triphenylphosphine)palladium are added and the mixtureis heated at reflux for 15 h. The mixture is allowed to cool andfiltered through kieselguhr. The filter cake is washed with ethylacetate and the combined filtrates are evaporated to dryness underreduced pressure. The residue is applied to silica gel andchromatographed on 800 g of silica gel using a gradient of cyclohexaneand ethyl acetate. This gives 27 g (62% of theory) of the desiredproduct.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.35 (d, 1H), 8.2 (dd, 1H), 7.75(dd, 1H), 7.60 (d, 1H), 7.55 (dd, 1H), 6.75 (dd, 1H), 6.45 (t, 1H), 6.15(dd, 1H), 5.30 (dd, 1H), 2.17 (s, 3H).

LC-MS (method 4): R_(t)=1.86 min

MS (ESIpos): m/z=257 (M+H)⁺

Example 14A3-(2-Hydroxyethyl)-1-(2-methyl-4-nitrophenyl)pyridin-2(1H)-one

With ice-cooling, a solution of 40 g (326 mmol) of9-borabicyclo[3.3.1]nonane in 650 ml of tetrahydrofuran is added over aperiod of 45 min to 38 g (148 mmol) of the compound from Example 13A.The mixture is stirred at this temperature for another hour, and asolution of 30 g (747 mmol) of sodium hydroxide in 740 ml of water isthen added over a period of 15 min. 151 ml of a 30% strength hydrogenperoxide solution are added such that the temperature does not exceed30° C. After the addition has ended, the cooling is removed and stirringis continued for a further 30 min. The mixture is repeatedly extractedwith ethyl acetate, the combined organic phases are washed with asolution of 780 g (1.63 mol) of sodium disulphite, the organic phase isseparated off and the aqueous phase is again extracted with ethylacetate. The combined organic phases are washed with saturated sodiumchloride solution, dried over magnesium sulphate and evaporated todryness under reduced pressure. The residue is applied to silica gel andchromatographed using a gradient of cyclohexane and ethyl acetate. Theproduct-containing fractions are combined and concentrated to drynessunder reduced pressure. This gives 38 mg (93% of theory) of the desiredproduct.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.33 (d, 1H), 8.18 (d, 1H), 7.57 (d,1H), 7.48-7.40 (m, 2H), 6.33 (t, 1H), 4.58 (t, 1H), 3.62-3.50 (m, 2H),2.62 (t, 2H), 2.15 (s, 3H).

LC-MS (method 6): R_(t)=1.57 min

MS (ESIpos): m/z=275 (M+H)⁺

Example 15A3-(2-{[tert-Butyl(diphenyl)silyl]oxy}ethyl)-1-(2-methyl-4-nitrophenyl)pyridin-2(1H)-one

38 g (138 mmol) of the compound from Example 14A are dissolved in 200 mlof anhydrous N,N-dimethylformamide, and 12.2 g (198 mmol) of imidazoleand, a little at a time, 46 g (135 mmol) oftert-butyl(chloro)diphenylsilane are added at 0° C. The mixture isstirred overnight and then diluted with water and extracted three timeswith ethyl acetate. The combined organic phases are washed twice withsaturated sodium chloride solution, dried over magnesium sulphate,filtered and evaporated under reduced pressure. The residue is appliedto silica gel and chromatographed using a gradient of cyclohexane andethyl acetate. The product-containing fractions are combined andevaporated to dryness under reduced pressure. This gives 62 g (88% oftheory) of the desired product.

LC-MS (method 5): R_(t)=3.18 min

MS (ESIpos): m/z=483 (M+H)⁺

Example 16A1-(4-Amino-2-methylphenyl)-3-(2-{[tert-butyl(diphenyl)silyl]oxy}ethyl)pyridin-2(1H)-one

62 g (121 mmol) of the compound from Example 15A are dissolved in 2 l ofa 1:1 mixture of ethanol and ethyl acetate, and 46 g (726 mmol) ofammonium formate and 0.6 g of palladium on carbon are added. The mixtureis heated at 80° C. After 45 min, the mixture is allowed to cool andfiltered through silica gel. The filter cake is washed with ethylacetate and the filtrate is evaporated to dryness under reducedpressure. This gives 36 g (61% of theory) of the desired product.

LC-MS (method 7): R_(t)=1.84 min

MS (ESIpos): m/z=221 (M+H)⁺

Example 17AN-[((5S)-3-{4-[3-(2-{[tert-Butyl(diphenyl)silyl]oxy}ethyl)-2-oxopyridin-1(2H)-yl]-3-methyl-phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]-5-chlorothiophene-2-carboxamide

35.6 g (74.1 mmol) of the compound from Example 16A are dissolved in 800ml of anhydrous acetonitrile, and 19 g (89 mmol) of the compound fromExample 1A are added at 0° C. 25 g (110 mmol) of magnesium perchlorateare added, the cooling is removed and the mixture is stirred at roomtemperature for 15 h. 24 mg (148 mmol) of 1,1-carbonyldiimidazole and180 mg (1.4 mmol) of N,N-dimethylaminopyridine are added, and themixture is heated at reflux for 2 h. The mixture is allowed to cool andthe solvent is distilled off under reduced pressure. The residue is thentaken up in ethyl acetate and washed with water and, three times, withsaturated sodium chloride solution. After drying over magnesiumsulphate, the mixture is filtered and evaporated to dryness underreduced pressure. The residue is applied to silica gel andchromatographed using a gradient of cyclohexane and ethyl acetate. Theproduct-containing fractions are combined and evaporated to drynessunder reduced pressure. This gives 46.4 g (84% of theory) of the desiredproduct.

LC-MS (method 5): R_(t)=3.31 min

MS (ESIpos): m/z=700 (M+H)⁺

Example 18A5-Chloro-N-[((5S)-3-{4-[3-(2-hydroxyethyl)-2-oxopyridin-1(2H)-yl]-3-methylphenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]thiophene-2-carboxamide

With ice-cooling, 400 ml of 1.25N hydrochloric acid in methanol areadded to 43.8 g (60.3 mmol) of the compound from Example 17A. After 1 h,the mixture is diluted with dichloromethane, and the aqueous phase isthen separated off. The organic phase is washed twice with water, driedover sodium sulphate and, after filtration, concentrated to drynessunder reduced pressure. The residue is applied to silica gel andchromatographed using a gradient of cyclohexane and ethyl acetate. Theproduct-containing fractions are combined and concentrated to drynessunder reduced pressure. This gives 19.6 g (66% of theory) of the desiredproduct.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.98 (t, 1H), 7.70 (d, 1H),7.55-7.47 (m, 2H), 7.40 (dd, 1H), 7.35 (dd, 1H), 7.25-7.17 (m, 2H), 6.26(t, 1H), 4.90-4.82 (m, 1H), 4.60 (t, 1H), 4.22 (t, 1H), 3.92-3.84 (m,1H), 3.66-3.54 (m, 4H), 2.60 (t, 2H), 2.01 (s, 3H).

LC-MS (method 5): R_(t)=1.87 min

MS (ESIpos): m/z=488 (M+H)⁺

Example 19A 3-Bromo-1-(2-methoxy-4-nitrophenyl)pyridin-2(1H)-one

70 g (403 mmol) of 3-bromopyridin-2(1H)-one are dissolved in 1 l ofanhydrous dimethyl sulphoxide, and 54 g (484 mmol) of potassiumtert-butoxide are added at room temperature. The suspension is stirredat this temperature for 1 h. 69 g (403 mmol) of1-fluoro-2-methoxy-4-nitrobenzene are added, and the reaction solutionis heated at 80° C. for 20 h. Carefully, the mixture is diluted with 5 lof water. The precipitated solid is filtered off, washed with water anddried under reduced pressure. This gives 103 g (72% of theory) of thedesired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.05 (dd, 1H), 8.1 (d, 1H), 7.95(dd, 1H), 7.7 (d, 1H), 7.6 (dd, 1H), 6.3 (t, 1H), 3.9 (s, 3H).

MS (ESIpos): m/z=342 (M+NH₄)⁺

Example 20A 1-(2-Methoxy-4-nitrophenyl)-3-vinylpyridin-2(1H)-one

100 g (308 mmol) of the compound from Example 19A are dissolved in 1.4 lof anhydrous dioxane, and 8.9 g (7.7 mmol) oftetrakis(triphenylphospine)palladium and 117 g (370 mmol) oftributylvinyltin are added. The mixture is heated at reflux for 16 h.The reaction solution is then allowed to cool and filtered throughkieselguhr. The filtrates are concentrated to dryness under reducedpressure. The residue is chromatographed on silica gel using a gradientof cyclohexane and ethyl acetate. The product-containing fractions arecombined and concentrated to dryness under reduced pressure. Petroleumether is added until crystallization sets in. The crystals are filteredoff and dried under reduced pressure. This gives 37 g (41% of theory) ofthe desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.0 (m, 2H), 7.7 (m, 2H), 7.5 (dd,1H), 6.7 (q, 1H), 6.4 (t, 1H), 6.1 (dd, 1H), 5.3 (dd, 1H), 3.9 (s, 3H).

MS (ESIpos): m/z=273 (M+H)⁺

Example 21A3-(2-Hydroxyethyl)-1-(2-methoxy-4-nitrophenyl)pyridin-2(1H)-one

At 0° C., a solution of 36 g (299 mmol) of 9-borabicyclo[3.3.1]nonane in600 ml of tetrahydrofuran is added over a period of 45 min to 37 g (136mmol) of the compound from Example 20A. After a further hour at thistemperature, a solution of 27 g (680 mmol) of sodium hydroxide (1N inwater) is added over the course of 15 min. The mixture is stirred for afurther 5 min, and 125 ml of a 30% strength hydrogen peroxide solutionare then added such that the temperature does not exceed 30° C. Coolingis removed, and the mixture is stirred for another 30 min. The mixtureis extracted repeatedly with ethyl acetate, the combined organic phasesare washed with a solution of 730 g (1.50 mol) of sodium disulphite, theorganic phase is separated off and the aqueous phase is reextracted withethyl acetate. The combined organic phases are washed with saturatedsodium chloride solution, dried over magnesium sulphate and evaporatedto dryness under reduced pressure. The residue is absorbed on silica geland chromatographed using a gradient of cyclohexane and ethyl acetate.The product fractions are combined and evaporated to dryness underreduced pressure. For crystallization, tert-butyl methyl ether is added.The crystals are filtered off and dried under reduced pressure. Thisgives 24 g (60% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.0 (d, 1H), 7.95 (dd, 1H), 7.6 (d,1H), 7.4 (d, 1H), 6.35 (t, 1H), 4.6 (t, 1H), 3.9 (s, 3H), 3.55 (m, 2H),2.6 (m, 2H).

MS (ESIpos): m/z=291 (M+H)⁺

Example 22A3-(2-{[tert-Butyl(diphenyl)silyl]oxy}ethyl)-1-(2-methoxy-4-nitrophenyl)pyridin-2(1H)-one

24 g (81 mmol) of the compound from Example 21A are dissolved in 200 mlof anhydrous N,N-dimethylformamide, and 7.2 g (106 mmol) of imidazoleand 27 g (98 mmol) of tert-butyl(chloro)diphenylsilane are added. After16 h, the mixture is diluted with 1.2 l of water and extracted threetimes with ethyl acetate. The combined organic phases are washed twicewith water, dried over magnesium sulphate, filtered and concentratedunder reduced pressure. For crystallization, tert-butyl methyl ether isadded, and the resulting crystals are filtered off and dried underreduced pressure. This gives 30 g (67% of theory) of the desiredproduct.

¹H-NMR (400 MHz, DMSO-d₆, S/ppm): δ=8.0 (d, 1H), 7.95 (dd, 1H), 7.6-7.5(m, 5H), 7.5-7.4 (m, 8H), 6.35 (t, 1H), 3.8 (m, 5H), 2.7 (m, 2H), 1.0(s, 9H).

Example 23A1-(4-Amino-2-methoxyphenyl)-3-(2-{[tert-butyl(diphenyl)silyl]oxy}ethyl)pyridin-2(1H)-one

25 g (48 mmol) of the compound from Example 22A are dissolved in 800 mlof a 1:1 mixture of ethanol and ethyl acetate, and 18 g (286 mmol) ofammonium formate and 800 mg of palladium on carbon are added. Themixture is heated at 80° C. After 60 min, the mixture is allowed to cooland filtered through silica gel. The filter cake is washed with ethylacetate, and the filtrate is concentrated to dryness under reducedpressure. This gives 27 g (98% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=7.6 (m, 4H), 7.4 (m, 6H), 7.3 (dd,1H), 7.25 (dd, 1H), 6.75 (d, 1H), 6.3 (d, 1H), 6.2 (dd, 1H), 6.1 (t,1H), 5.3 (b, 2H), 3.8 (m, 2H), 3.6 (s, 3H), 2.7 (m, 2H), 1.0 (s, 9H).

MS (ESIpos): m/z=499 (M+H)⁺

Example 24AN-{[(5S)-3-{4-[3-(2-{[tert-Butyl(diphenyl)silyl]oxy}ethyl)-2-oxopyridin-1(2H)-yl]-3-methoxy-phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}-5-chlorothiophene-2-carboxamide

29 g (58 mmol) of the compound from Example 23A are dissolved in 600 mlof anhydrous acetonitrile, and 15 g (69 mmol) of the compound fromExample 1A are added at 0° C. 19 g (87 mmol) of magnesium perchlorateare added, cooling is removed and the mixture is stirred at RT for 15 h.19.0 g (116 mmol) of 1,1-carbonyldiimidazole and 141 mg (1.21 mmol) ofN,N-dimethylaminopyridine are then added, and the mixture is heated atreflux. After 2 h, the mixture is allowed to cool and the solvent isdistilled off under reduced pressure. The residue is taken up in ethylacetate and washed with water and three times with saturated sodiumchloride solution. After drying over magnesium sulphate, the mixture isfiltered and evaporated to dryness under reduced pressure. The residueis chromatographed on silica gel using a gradient of cyclohexane andethyl acetate. The product-containing fractions are combined andconcentrated to dryness under reduced pressure. This gives 37 g (85% oftheory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆): δ=9.0 (t, 1H), 7.7 (d, 1H), 7.6 (m, 4H),7.5-7.3 (m, 9H), 7.2 (m, 2H), 7.1 (m, 1H), 6.2 (t, 1H), 4.8 (m, 1H), 4.4(t, 1H), 3.9 (m, 1H), 3.8 (b, 2H), 3.7 (s, 3H), 3.65 (m, 2H), 2.7 (m,2H), 1.0 (s, 9H).

LC-MS (method 8): R_(t)=4.53 min

MS (ESIpos): m/z=742 (M+H)⁺

Example 25A5-Chloro-N-{[(5S)-3-{4-[3-(2-hydroxyethyl)-2-oxopyridin-1(2H)-yl]-3-methoxyphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

At 0° C., 37 g (49 mmol) of the compound from Example 24A are dissolvedin 313 ml of 1.25N hydrochloric acid in methanol. After 1 h, thesolution is evaporated under reduced pressure and diluted withdichloromethane. The organic phase is washed twice with water, driedover magnesium sulphate and, after filtration, evaporated to drynessunder reduced pressure. The residue is chromatographed on silica gelusing a gradient of dichloromethane and methanol. The product fractionsare combined and evaporated to dryness under reduced pressure. Thisgives 19 g (78% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=9.00 (t, 1H), 7.70 (d, 1H), 7.45 (d,1H), 7.35 (dd, 1H), 7.30 (dd, 1H), 7.25 (d, 1H), 7.20 (d, 1H), 7.15-7.08(m, 1H), 6.19 (t, 1H), 4.91-4.83 (m, 1H), 4.60 (t, 1H), 4.25 (t, 1H),3.94-3.87 (m, 1H), 3.73 (s, 3H), 3.66-3.53 (m, 4H), 2.62-2.55 (m, 2H).

MS (ESIpos): m/z=504 (M+H)⁺

Example 26A 2-(Bromomethyl)-1-fluoro-4-nitrobenzene

186 g (1.20 mol) of 2-fluoro-5-nitrotoluene are dissolved in 1.2 l ofcarbon tetrachloride, and 214 g (1.20 mol) of N-bromosuccinimide areadded. 19.7 g (120 mmol) of azodiisobutyronitrile are added, and themixture is heated under reflux. After 16 h, the mixture is allowed tocool, filtered and evaporated to dryness under reduced pressure. Theresidue is dissolved in 300 ml of dichloromethane, and 300 g of sea sandare added. Once more, the mixture is then concentrated to dryness underreduced pressure, and the residue is applied to a 1 kg silica gelcolumn. The product is chromatographed using a 20:1 mixture ofcyclohexane and ethyl acetate, and the product fractions are evaporatedto dryness under reduced pressure. The residue is crystallized withcyclohexane and dried under reduced pressure. This gives 92 g (32% oftheory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.57-8.52 (m, 1H), 8.33-8.27 (m,1H), 7.56 (t, 1H), 4.62 (s, 2H).

GC-MS (method 9): R_(t)=7.79 min

MS (ESIpos): m/z=154 (M−Br)⁺

Example 27A 1-Fluoro-2-(methoxymethyl)-4-nitrobenzene

30 g (128 mmol) of the compound from Example 26A are dissolved in 1.3 lof anhydrous toluene, and 45 g (192 mmol) of silver(I) oxide and 24.6 g(769 mmol) of anhydrous methanol are added. The mixture is heated at 60°C. for 16 h. The mixture is then allowed to cool and filtered throughsilica gel. The product is eluted fractionally using a gradient ofcyclohexane and cyclohexane/ethyl acetate 25:1. The product fractionsare evaporated to dryness under reduced pressure and dried under reducedpressure. This gives 17 g (72% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.41-8.36 (m, 1H), 8.22-8.16 (m,1H), 7.26 (t, 1H), 4.58 (s, 2H), 3.49 (s, 3H).

GC-MS (method 9): R_(t)=6.52 min

MS (ESIpos): m/z=154 (M−OCH₃)⁺

Example 28A 3-Bromo-1-[2-(methoxymethyl)-4-nitrophenyl]pyridin-2(1H)-one

38 g (391 mmol) of 3-bromo-2-hydroxypyridine are dissolved in 1250 ml ofanhydrous dimethyl sulphoxide, and 53 g (469 mmol) of potassiumtert-butoxide are added a little at a time. The mixture is stirred foranother hour, and 72.4 g (391 mmol) of the compound from Example 27A arethen added. After the addition has ended, the mixture is heated at 80°C. for 3 h. The mixture is then allowed to cool, and stirring iscontinued at room temperature for a further 16 h. The reaction solutionis then cooled to 15° C., and at this temperature the pH is carefullyadjusted with 1N hydrochloric acid to pH=3.4 l of water are added, andthe mixture is extracted three times with 2 l of ethyl acetate. Thecombined organic phases are washed with saturated sodium chloridesolution and dried over magnesium sulphate. The solutions are thenevaporated to dryness under reduced pressure, and tert-butyl methylether is added for crystallization. The crystals are filtered off anddried under reduced pressure. This gives 94 g (71% of theory) of thedesired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.37 (d, 1H), 8.33 (dd, 1H), 8.10(dd, 1H), 7.73-7.67 (m, 2H), 6.35 (t, 1H), 4.3 (q, 2H), 3.3 (s, 3H).

LC-MS (method 6): R_(t)=1.88 min

MS (ESIpos): m/z=339 (M+H⁺)⁺

Example 29A 1-[2-(Methoxymethyl)-4-nitrophenyl]-3-vinylpyridin-2(1H)-one

94 g (277 mmol) of the compound from Example 28A are dissolved in 1.2 lof anhydrous dioxane, and 8 g (6.9 mmol) oftetrakis(triphenylphosphine)palladium(0) are added. At room temperature,105 g (333 mmol) of tributylvinyltin are added slowly, and after theaddition has ended, the mixture is heated at reflux for 21 h. Thereaction solution is allowed to cool and filtered through kieselguhr.The filter cake is washed with ethyl acetate and the combined organicfiltrates are concentrated to dryness under reduced pressure. Theresidue that remains is dissolved in dichloromethane and applied tokieselguhr. The product is chromatographed on 1.2 kg of silica gel usinga gradient of cyclohexane and ethyl acetate. The product-containingfractions are combined and concentrated to dryness under reducedpressure. This gives 23 g (29% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.36 (d, 1H), 8.31 (dd, 1H), 7.77(dd, 1H), 7.67 (d, 1H), 7.56 (dd, 1H), 6.80-6.71 (m, 1H), 6.45 (t, 1H),6.14 (dd, 1H), 5.33 (dd, 1H), 4.37-4.22 (m, 2H), 3.26 (s, 3H).

LC-MS (method 6): R_(t)=2.07 min

MS (ESIpos): m/z=387 (M+H⁺)⁺

Example 30A3-(2-Hydroxyethyl)-1-[2-(methoxymethyl)-4-nitrophenyl]pyridin-2(1H)-one

23 g (80 mmol) of the compound from Example 29A are dissolved in 80 mlof anhydrous tetrahydrofuran and cooled to 5° C. Over a period of 15min, 21 g (176 mmol) of 9-borabicyclo[3.3.1]nonane (0.5M solution intetrahydrofuran) are added. Cooling is removed, and the mixture isstirred at room temperature for another 2 h. The mixture is then againcooled to 5° C., and 400 ml of 1N aqueous sodium hydroxide solution areadded. After the addition has ended, 81 ml of 30% strength hydrogenperoxide solution are added a little at a time at this temperature.After dilution with 500 ml of ethyl acetate, the mixture is washed with32 ml of 40% strength sodium bisulphite solution to destroy theperoxides. The organic phase is separated off, and the aqueous phase isextracted four times with ethyl acetate. The combined organic phases arewashed with saturated sodium chloride solution, dried over magnesiumsulphate and, after filtration, concentrated to dryness under reducedpressure. The residue is chromatographed on silica gel using a gradientof cyclohexane and ethyl acetate. The product-containing fractions arecombined and concentrated to dryness under reduced pressure. This gives20 g (77% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.36 (d, 1H), 8.30 (dd, 1H), 7.62(d, 1H), 7.45 (d, 1H), 6.33 (t, 1H), 4.60 (t, 1H), 4.35-4.20 (m, 2H),3.62-3.55 (m, 2H), 3.32 (s, 3H), 2.62 (t, 2H).

LC-MS (method 8): R_(t)=1.60 min

MS (ESIpos): m/z=305 (M+H⁺)⁺

Example 31A3-(2-{[tert-Butyl(diphenyl)silyl]oxy}ethyl)-1-[2-(methoxymethyl)-4-nitrophenyl]pyridin-2(1H)-one

20 g (65 mmol) of the compound from Example 30A are dissolved in 75 mlof anhydrous N,N-dimethylformamide, and, with ice-cooling, first 5.3 g(78 mmol) of imidazole and then, a little at a time over a period of 3min, 19 g (72 mmol) of tert-butyldiphenylchlorosilane are added. Coolingis removed, and the mixture is stirred at room temperature for a further19 h. The reaction solution is diluted with ethyl acetate and washedthree times with water and twice with saturated sodium chloridesolution. The mixture is then dried over magnesium sulphate, filteredand concentrated to dryness under reduced pressure. tert-Butyl methylether is added to the residue, and the resulting crystals are filteredoff and dried under reduced pressure. This gives 39 g (90% of theory) ofthe desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.35 (d, 1H), 8.31 (dd, 1H),7.65-7.35 (m, 13H), 6.35 (t, 1H), 4.32-4.14 (m, 2H), 3.92-3.80 (m, 2H),3.32 (s, 3H), 2.78-2.71 (m, 2H), 0.97 (s, 9H).

LC-MS (method 8): R_(t)=4.59 min

MS (ESIpos): m/z=543 (M+H⁺)⁺

Example 32A1-[4-Amino-2-(methoxymethyl)phenyl]-3-(2-{[tert-butyl(diphenyl)silyl]oxy}ethyl)pyridin-2(1H)-one

25 g (48 mmol) of the compound from Example 31A are dissolved in 500 mlof ethyl acetate and 500 ml of ethanol. 18 g (286 mmol) of ammoniumformate and 1 g of palladium on carbon are added, and the mixture isheated at reflux for 45 min. The reaction solution is then allowed tocool and filtered through silica gel. The filtrate is concentrated todryness under reduced pressure. This gives 25 g (100% of theory) of thedesired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=7.65-7.20 (m, 12H), 6.79 (d, 1H),6.68 (d, 1H), 6.54 (dd, 1H), 6.20 (t, 1H), 5.46-5.25 (m, 2H), 4.04-3.91(m, 2H), 3.87-3.77 (m, 2H), 3.07 (s, 3H), 2.75-2.68 (m, 2H), 0.95 (s,9H).

LC-MS (method 6): R_(t)=3.22 min

MS (ESIpos): m/z=513 (M+H⁺)⁺

Example 33AN-{[(5S)-3-{4-[3-(2-{[tert-Butyl(diphenyl)silyl]oxy}ethyl)-2-oxopyridin-1(2H)-yl]-3-(methoxy-methyl)phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}-5-chlorothiophene-2-carboxamide

25 g (47 mmol) of the compound from Example 32A are dissolved in 500 mlof anhydrous acetonitrile, and 15 g (61 mmol) of the compound fromExample 1A and 16 g (71 mmol) of magnesium perchlorate are added. Themixture is stirred at room temperature for 5 h, and another 1 g (4.1mmol) of the compound from Example 1A is then added. After 21 h, 15.3 g(95 mmol) of carbonyldiimidazole and 116 mg (0.65 mmol) of4-dimethylaminopyridine are added, and the mixture is heated at refluxfor 3.5 h. The solvent is then removed under reduced pressure, and theresidue is taken up in 800 ml of ethyl acetate. The solution is washedwith water and twice with saturated sodium chloride solution, dried overmagnesium sulphate and then concentrated under reduced pressure. Theresidue is separated on silica gel using a gradient of cyclohexane andethyl acetate. The product-containing fractions are combined andconcentrated to dryness under reduced pressure. This gives 26.5 g (72%of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=9.00 (t, 1H), 7.73-7.35 (m, 15H),7.23 (d, 1H), 7.19 (d, 1H), 6.28 (t, 1H), 4.90-4.81 (m, 1H), 4.28-3.80(m, 6H), 3.62 (t, 2H), 3.11 (s, 3H), 2.79-2.71 (m, 2H), 0.97 (s, 9H).

LC-MS (method 6): R_(t)=3.39 min

MS (ESIpos): m/z=756 (M+H⁺)⁺

Example 34AN-{[(5S)-3-{4-[3-(2-{[tert-Butyl(diphenyl)silyl]oxy}ethyl)-2-oxopyridin-1(2H)-yl]-3-(methoxy-methyl)phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}-5-chlorothiophene-2-carboxamide

With ice-cooling, 135 ml of 1.25N hydrochloric acid in methanol areadded to 27 g (34 mmol) of the compound from Example 33A. The mixture isstirred at this temperature for a further 45 min. With ice-cooling, themixture is adjusted to pH 7 using 1N aqueous sodium hydroxide solution,and the cold solution is extracted repeatedly with dichloromethane. Thecombined organic phases are washed with saturated sodium chloridesolution and dried over magnesium sulphate. The mixture is evaporated todryness under reduced pressure, and the residue is chromatographed onsilica gel using a gradient of dichloromethane and methanol. Theproduct-containing fractions are combined and concentrated to drynessunder reduced pressure. This gives 16.4 g (89% of theory) of the desiredproduct.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.98 (t, 1H), 7.72-7.66 (m, 2H),7.62-7.56 (m, 1H), 7.40 (dd, 1H), 7.36 (dd, 1H), 7.27 (d, 1H), 7.20 (d,1H), 6.25 (t, 1H), 4.90-4.82 (m, 1H), 4.60 (t, 1H), 4.27-4.08 (m, 3H),3.94-3.87 (m, 1H), 3.65-3.55 (m, 4H), 3.18 (s, 3H), 2.60 (t, 2H).

LC-MS (method 6): R_(t)=1.96 min

MS (ESIpos): m/z=518 (M+H⁺)⁺

Example 35A 3-Allyl-1-(2-methyl-4-nitrophenyl)pyridin-2(1H)-one

In a flask which had been dried by heating, 1.50 g (4.85 mmol) of thecompound from Example 12A, 1.44 g (9.46 mmol) of caesium fluoride and0.56 g (0.48 mmol) of tetrakis-(triphenylphosphine)palladium(0) areinitially charged in 30 ml of degassed THF. A solution of 2.04 g (12.1mmol) of 2-allyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in 5 ml ofdegassed THF is added dropwise, and the mixture is heated at refluxovernight. The mixture is then diluted with dichloromethane, and wateris added. After phase separation, the aqueous phase is extracted threetimes with dichloromethane. The combined organic phases are dried oversodium sulphate and concentrated. The product is purified bychromatography on silica gel, giving 1.18 g (62% of theory) of the titlecompound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.31 (d, 1H), 8.18 (dd, 1H), 7.57 (d,1H), 7.46 (dd, 1H), 7.44-7.38 (m, 1H), 6.35 (t, 1H), 5.96 (dddd, 1H),5.16-5.06 (m, 2H), 3.20 (d, 2H), 2.15 (s, 3H).

HPLC (method 2): R_(t)=4.05 min.

MS (ESIpos, m/z): 271 (M+H)⁺.

Example 36A3-(3-Hydroxypropyl)-1-(2-methyl-4-nitrophenyl)pyridin-2(1H)-one

At 0° C., 18.5 ml (9.25 mmol) of a 0.5 molar solution of9-borabicyclo[3.3.1]nonane in THF are slowly added dropwise to 1.00 g(3.70 mmol) of the compound from Example 35A in 4 ml THF. After one hourat room temperature, the mixture is again cooled to 0° C., and 18.5 ml(18.5 mmol) of a 1 molar solution of sodium hydroxide in water are addeddropwise. The mixture is stirred at 0° C. for a further 30 min, and 3.24ml of a 30% strength hydrogen peroxide solution are then added such thatthe temperature does not exceed 30° C. The mixture is stirred withice-cooling for 30 min, and ethyl acetate and then 11 g (40 mmol) ofsodium bisulphite solution are then added. The organic phase isseparated off, and the aqueous phase is extracted twice with ethylacetate. The combined organic phases are washed with saturated aqueoussodium chloride solution. The organic phase is dried over sodiumsulphate and then evaporated to dryness under reduced pressure. Theresidue is chromatographed on silica gel (cyclohexane/ethyl acetate1:4). This gives 1.03 g (83% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.31 (d, 1H), 8.18 (dd, 1H),7.66-7.51 (m, 1H), 7.47-7.38 (m, 2H), 6.33 (t, 1H), 4.46 (t, 1H),3.46-3.38 (q, 2H), 2.52-2.45 (m, 2H), 2.15 (s, 3H), 1.73-1.62 (m, 2H).

HPLC (method 1): R_(t)=3.51 min.

MS (DCI, m/z)=289 (M+H)⁺

Example 37A1-(4-Amino-2-methylphenyl)-3-(3-hydroxypropyl)pyridin-2(1H)-one

475 mg (1.65 mmol) of the compound from Example 36A are dissolved in 48ml of THF. 50 mg (0.05 mmol) of palladium on carbon are then added, andthe mixture is hydrogenated at RT in a hydrogen atmosphere underatmospheric pressure. The mixture is then filtered, the filter cake iswashed three times with THF and the filtrate is freed from the solvent.The reaction product is reacted further without further purification.

HPLC (method 1): R_(t)=2.82 min.

MS (DCI, m/z): 259 (M+H)⁺.

Example 38A5-Chloro-N-{[(5S)-3-{4-[3-(3-hydroxypropyl)-2-oxopyridin-1(2H)-yl]-3-methylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

580 mg (2.24 mmol) of the compound from Example 37A are dissolved in12.7 ml of anhydrous acetonitrile, and 538 mg (2.47 mmol) of thecompound from Example 1A and 751 mg (3.37 mmol) of magnesium perchlorateare added. The mixture is stirred at room temperature for 3.5 h. 437 mg(2.69 mmol) of carbonyldiimidazole and 27 mg (0.23 mmol) of4-dimethylaminopyridine are then added, and the mixture is heated atreflux for 18 h. The mixture is then added to 100 ml of water, and themixture is extracted three times with 50 ml of ethyl acetate. Thecombined organic phases are then washed with saturated sodium chloridesolution, dried over sodium sulphate and then concentrated under reducedpressure. The residue is purified by preparative HPLC. This gives 175 mg(16% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.99 (t, 1H), 7.70 (d, 1H),7.57-7.47 (m, 2H), 7.40-7.31 (m, 2H), 7.23 (d, 1H), 7.20 (d, 1H), 6.26(t, 1H), 4.90-4.81 (m, 1H), 4.46 (dd, 1H), 4.22 (t, 1H), 3.91-3.85 (m,1H), 3.62 (t, 2H), 3.42 (ddd, 2H), 3.31 (s, 1H), 2.48-2.42 (m, 1H), 2.01(s, 3H), 1.67 (ddd, 2H).

HPLC (method 2): R_(t)=3.92 min

MS (DCI, m/z)=502 (M+H)⁺

Example 39A 3-Methoxy-1-(2-methyl-4-nitrophenyl)pyridin-2(1H)-one

28.5 g (228 mol) of 3-methoxypyridin-2(1H)-one are dissolved in 850 mlof dimethyl sulphoxide, and 31 g (273 mmol) of potassium tert-butoxideare added at RT. The suspension is stirred at RT for 30 min, and 35 g(228 mmol) of 1-fluoro-2-methyl-4-nitrobenzene are then added, and thereaction solution is heated at 80° C. for 20 h. The solution is thencarefully diluted with 1 l of water and adjusted to pH 1-2 using 1Nhydrochloric acid. The solution is extracted repeatedly withdichloromethane. The combined organic extracts are washed with water andsaturated sodium chloride solution, dried over sodium sulphate, filteredand evaporated under reduced pressure. The solid obtained is washed witha little tert-butyl methyl ether, filtered off and dried under reducedpressure. This gives 42.8 g (72% of theory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.35 (d, 1H), 8.18 (dd, 1H), 7.57(d, 1H), 7.13 (dd, 1H), 6.95 (dd, 1H), 6.32 (t, 1H), 3.75 (s, 3H), 2.25(s, 3H).

LC-MS (method 3): R_(t)=1.45 min

MS (ESIpos): m/z=261 (M+H)⁺

Example 40A 3-Hydroxy-1-(2-methyl-4-nitrophenyl)pyridin-2(1H)-one

23.3 g (90 mmol) of Example 39A are dissolved in 730 ml of anhydrousdichloromethane and cooled to 0° C. Over a period of 10 minutes, 224 ml(224 mmol) of a 1N boron tribromide solution in dichloromethane areadded dropwise, and the mixture is then stirred at this temperature fora further 1.5 h. 200 ml of water are added to the reaction, and theaqueous phase is extracted three times with dichloromethane. Thecombined organic phases are washed with saturated sodium chloridesolution, dried over sodium sulphate and filtered off. The solvent isremoved under reduced pressure, and the solid obtained is washed withtert-butyl methyl ether and filtered off. This gives 20.1 g (91% oftheory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=9.50 (s, 1H), 8.42 (d, 1H), 8.20(dd, 1H), 7.6 (d, 1H), 7.05 (d, 1H), 6.85 (dd, 1H), 6.25 (t, 1H), 2.25(s, 3H).

LC-MS (method 3): R_(t)=1.45 min

MS (ESIpos): m/z=246 (M+H)⁺

Example 41A3-[(2-Methoxyethoxy)methoxy]-1-(2-methyl-4-nitrophenyl)pyridin-2(1H)-one

10.0 g (41 mmol) of Example 40A are dissolved in anhydrousdichloromethane, and 13.6 g (89 mmol) of1,8-diazabicyclo(5.4.0)undec-7-ene are added. At 25° C., 8.6 g (69 mmol)of 1-(chloromethoxy)-2-methoxyethane are added slowly, a little at atime, to this solution. After a further hour, the solution is filteredthrough silica gel and evaporated to dryness under reduced pressure.This gives 20.1 g (91% of theory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.32 (d, 1H), 8.19 (dd, 1H), 7.6 (d,1H), 7.22 (dd, 1H), 7.15 (dd, 1H), 6.3 (t, 1H), 5.25 (s, 2H), 3.78-3.72(m, 2H), 3.51-3.45 (m, 2H), 3.23 (s, 3H), 2.15 (s, 3H).

LC-MS (method 3): R_(t)=1.79 min

MS (ESIpos): m/z=335 (M+H)⁺

Example 42A1-(4-Amino-2-methylphenyl)-3-[(2-methoxyethoxy)methoxy]pyridin-2(1H)-one

12 g (36 mmol) of Example 41A are dissolved in 1.2 l of a 1:1 mixture ofethyl acetate and ethanol, and 0.1 equivalent of palladium on carbon and11.3 g (180 mmol) of ammonium formate are added. The mixture is heatedat 80° C. for two hours. The mixture is allowed to cool and is filteredthrough silica gel, and the solvent is removed under reduced pressure.This gives 10.6 g (88% of theory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=7.12-7.05 (m, 1H), 6.80 (d, 1H),6.51-6.42 (m, 2H), 6.17 (t, 1H), 5.21 (s, 2H), 3.76-3.71 (m, 2H),3.49-3.45 (m, 2H), 3.23 (s, 3H), 1.85 (s, 3H).

LC-MS (method 3): R_(t)=1.10 min

MS (ESIpos): m/z=305 (M+H)⁺

Example 43A5-Chloro-N-[((5S)-3-{4-[3-[(2-methoxyethoxy)methoxy]-2-oxopyridin-1(2H)-yl]-3-methylphenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]thiophene-2-carboxamide

9.2 g (30 mmol) of Example 42A are dissolved in 580 ml of acetonitrileand cooled to 0° C. At this temperature, 7.3 g (34 mmol) of Example 1Aare added, and the mixture is then stirred for a further 10 minutes.10.2 g (46 mmol) of magnesium perchlorate are added, cooling is removedand the mixture is stirred for a further 17 h. 14.8 g (91 mmol) ofcarbonyldiimidazole and 0.37 g (3 mmol) of N,N-4-dimethylaminopyridineare then added, and the mixture is heated at 60° C. for 4 h. Aftercooling, the mixture is stirred at RT for a further 16 h and thenevaporated to dryness under reduced pressure. 1N hydrochloric acid andethyl acetate are added to the residue, and the mixture is stirredvigorously. After 15 min, the phases are separated, the aqueous phase isextracted three times with ethyl acetate and the organic phases arecombined. After washing with saturated sodium chloride solution, themixture is dried and evaporated to dryness under reduced pressure. Thisgives 17.2 g (95% of theory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=9.0 (t, 1H), 7.70 (d, 1H), 7.56-7.49(m, 2H), 7.26 (d, 1H), 7.20 (d, 1H), 6.95 (dd, 1H), 6.80 (dd, 1H), 6.20(t, 1H), 4.90-4.81 (m, 1H), 4.24 (t, 1H), 3.92-3.85 (m, 1H), 3.70-3.55(m, 3H), 3.52-3.25 (m, 2H), 2.55 (s, 3H), 2.08-2.02 (m, 3H), 1.91 (s,3H).

LC-MS (method 4): R_(t)=2.13 min

MS (ESIpos): m/z=548 (M+H)⁺

Example 44A5-Chloro-N-({(5S)-3-[4-(3-hydroxy-2-oxopyridin-1(2H)-yl)-3-methylphenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide

18 g (33 mmol) of Example 43A are dissolved in 50 ml of trifluoroaceticacid and stirred for 3 h, and the mixture is then evaporated to drynessunder reduced pressure. The residue (22.3 g) is, in portions of 2 geach, dissolved in each case in 8.5 ml of dimethyl sulphoxide andpurified by preparative HPLC using a water/acetonitrile gradient. Theproduct fractions are combined and freed from acetonitrile, and thecrystals formed are filtered off. The filtrate is extracted with ethylacetate, and the ethyl acetate phases are combined, washed withsaturated sodium chloride solution, dried and evaporated under reducedpressure. The residue is combined with the crystals and dried underreduced pressure. This gives 9.95 g (65% of theory) of the desiredcompound.

¹H-NMR (400 MHz, DMSO-d₆, S/ppm): δ=9.2 (br. s, 1H), 9.00 (t, 1H), 7.70(d, 1H), 7.56-7.48 (m, 2H), 7.26 (d, 1H), 7.20 (d, 1H), 6.95 (dd, 1H),6.86 (dd, 1H), 6.2 (t, 1H), 4.92-4.80 (m, 1H), 4.22 (t, 1H), 3.92-3.82(m, 1H), 3.62 (t, 2H), 2.04 (s, 3H).

LC-MS (method 4) R_(t)=2.09 min

MS (ESIpos): m/z=460 (M+H)⁺

Example 45A5-Chloro-N-[((5S)-3-{4-[3-(2-hydroxyethoxy)-2-oxopyridin-1(2H)-yl]-3-methylphenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]thiophene-2-carboxamide

2.0 g (4.35 mmol) of Example 44A are dissolved in 9 ml of anhydrousN,N-dimethylformamide, 3.6 g (26.1 mmol) of potassium carbonate areadded and the mixture is stirred for 30 min. The mixture is diluted witha further 3 ml of anhydrous N,N-dimethylformamide, 3.1 g (13.05 mmol) of(2-bromoethoxy)(tert-butyl)dimethylsilane are added and the mixture isheated at 60° C. for 7 h. The mixture is allowed to cool, filtered andpurified by preparative HPLC using a water/acetonitrile gradient. Theproduct fractions are evaporated to dryness under reduced pressure, andthe residue is dried under reduced pressure. This gives 1.17 g (53% oftheory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=9.00 (t, 1H), 7.70 (d, 1H),7.55-7.48 (m, 2H), 7.25-7.18 (m, 2H), 7.05 (dd, 1H), 6.93 (dd, 1H), 6.22(t, 1H), 4.91 (t, 1H), 4.89-4.82 (m, 1H), 4.22 (t, 1H), 4.00-3.85 (m,3H), 3.75-3.70 (m, 2H), 3.61 (t, 2H), 2.0 (s, 3H).

LC-MS (method 5): R_(t)=1.93 min

MS (ESIpos): m/z=504 (M+H)⁺

Example 46A5-Chloro-N-{[(5S)-3-{4-[3-(2-chloroethoxy)-2-oxopyridin-1(2H)-yl]-3-methylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

4.5 g (7.5 mmol) of Example 44A and 1.4 g (9.8 mmol) of 2-chloroethylbromide are dissolved in 45 ml of absolute N,N-dimethylformamide, and3.1 g (22.6 mmol) of potassium carbonate are added. The reaction isdivided into three reaction vials and stirred at 80° C. in a microwaveoven (300 W) for 40 minutes. In three portions, a total of 1.4 g (9.8mmol) of 2-chloroethyl bromide is added to the cooled reaction vials,and the mixtures are stirred at 80° C. in a microwave oven (300 W) for afurther 60 minutes. Water is added to the reaction, the mixture isextracted with dichloromethane and the separated organic phase is washedwith 1N hydrochloric acid and saturated sodium chloride solution. Thedichloromethane phase is dried over sodium sulphate, the drying agent isfiltered off and the solvent is distilled off on a rotary evaporator.The residue is then chromatographed on silica gel 60 using the mobilephase dichloromethane/acetonitrile 10/1, rinsing withdichloromethane/methanol 10/1. The product-containing fraction isconcentrated to dryness. Fine-purification by preparative RP-HPLC usingan acetonitrile/water mixture gives 1.4 g of product (35% of theory).

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.96 (t, 1H), 7.69 (d, 1H), 7.55-7.46(m, 2H), 7.23 (d, 1H), 7.20 (d, 1H), 7.12 (d, 1H), 6.98 (d, 1H), 6.23(t, 1H), 4.86 (m, 1H), 4.32-4.17 (m, 3H), 3.97 (m, 2H), 3.92-3.84 (m,1H), 3.62 (t, 2H), 2.01 (s, 3H).

LC-MS (method 6): R_(t)=2.31 min, 2.36 min

MS (ESIpos): m/z=522 (M+H)⁺

Example 47A (2-Fluoro-5-nitrobenzyl)(triphenyl)phosphonium bromide

20 g (85.5 mmol) of the compound from Example 26A are dissolved in 250ml of anhydrous toluene, and 22.4 g (85.5 mmol) of triphenylphosphineare added. The solution is heated under reflux for 16 h, resulting inthe formation of a precipitate. The mixture is allowed to cool, and theprecipitate is filtered off. After washing with diethyl ether, theprecipitate is dried under reduced pressure. This gives 39 g (92% oftheory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.30-8.23 (m, 1H), 7.98-7.88 (m,4H), 7.81-7.70 (m, 12H), 7.45 (t, 1H), 5.32 (d, 2H).

Example 48A 1-Fluoro-4-nitro-2-[prop-1-en-1-yl]benzene

At 10° C., 5.99 g (32.7 mmol) sodium bis(trimethylsilyl)amide are addeddropwise to a solution of 13.5 g (27.3 mmol) of the compound fromExample 47A in 145 ml of dioxane. The mixture is stirred at thistemperature for 1 h. A solution of 2.40 g (54.5 mmol) of acetaldehyde in5 ml of dioxane is then added, and the reaction is stirred at RT for 1h. 400 ml of water are then added, the mixture is extracted three timeswith dichloromethane and the combined organic phases are washed twicewith saturated aqueous sodium chloride solution. After drying oversodium sulphate and subsequent filtration, the solvent is removed underreduced pressure. The product is purified by chromatography on silicagel (mobile phase: cyclohexane/ethyl acetate=40:1). This gives 5.2 g(100% of theory) of the desired product as an E/Z isomer mixture.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.47-8.05 (m, 2H), 7.58-7.42 (m,1H), 6.70-6.05 (m, 2H), 1.90-1.78 (m, 3H).

GC-MS (method 10): R_(t)=2.64 and 2.70 min

MS (ESIpos): m/z=181 (M+H⁺)⁺

Example 49A3-Methoxy-1-{4-nitro-2-[prop-1-en-1-yl]phenyl}pyridin-2(1H)-one

14.0 g (111.9 mmol) of 3-methoxypyridin-2(1H)-one are dissolved in 350ml of dimethyl sulphoxide, 15.4 g (134.3 mmol) of potassiumtert-butoxide are added and the suspension is stirred at roomtemperature for 30 minutes. 20.2 g (111.9 mmol) of Example 48A are addedto the reaction mixture. The mixture is heated to 80° C. and stirred atthis temperature for 12 hours. Using 150 ml of 1N hydrochloric acid andslight cooling, the reaction is adjusted to pH 3, the mixture is dilutedwith 800 ml of water and extracted with dichloromethane and the organicphase is washed successively with water and saturated sodium chloridesolution. The dichloromethane phase is then dried over sodium sulphate,the drying agent is filtered off and the solvent is removed completelyon a rotary evaporator. The residue gives, after recrystllization withtert-butyl methyl ether, 17.9 g of product (45% of theory).

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.50 (d, 0.75H), 8.17 (dd, 0.25H),8.22-8.13 (m, 1H), 7.17 (d, 0.25H), 7.57 (d, 0.75H), 7.09 (dd, 1H), 6.96(dd, 0.75H) 6.91 (d, 0.25H), 6.59 (m, 0.75H), 6.35-6.23 (m, 1H),6.09-5.85 (m, 1.25H), 3.78 (s, 2.25H), 3.75 (s, 0.75H), 1.81 (dd,2.25H), 1.73 (dd, 0.75H).

LC-MS (method 3): R_(t)=2.75 min, 2.79 min

MS (ESIpos): m/z=273 (M+H)⁺

Example 50A3-Hydroxy-1-{4-nitro-2-[prop-1-en-1-yl]phenyl}pyridin-2(1H)-one

17.8 g (50.6 mmol) of Example 49A are dissolved in 300 ml ofdichloromethane. 31.7 g (126.5 mmol) of boron tribromide, dissolved in100 ml of dichloromethane, are added dropwise to the ice-cooledsolution, and the mixture is stirred at 0° C. for 1.5 hours. Ice isadded to the stirred reaction. The mixture is then diluted with waterand subsequently extracted repeatedly with dichloromethane/methanol 10/1and chloroform. The combined organic phases are dried over sodiumsulphate, the drying agent is filtered off and the solvent is distilledoff on a rotary evaporator. The residue gives, after recrystallizationwith tert-butyl methyl ether/dichloromethane (10/1), 9.4 g of product(67% of theory).

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 9.43 (br. s, 1H), 8.50 (d, 0.75H),8.27 (dd, 0.25H), 8.22-8.13 (m, 1H), 7.19 (d, 0.25H), 7.59 (d, 0.75H),6.99 (dd, 1H), 6.85 (d, 0.75H) 6.81 (d, 0.25H), 6.58 (m, 0.75H),6.31-6.19 (m, 1H), 6.11-5.85 (m, 1.25H), 1.81 (dd, 2.25H), 1.73 (dd,0.75H).

LC-MS (method 3): R_(t)=1.78 min

MS (ESIpos): m/z=287 (M+H)⁺

Example 51A3-[(2-Methoxyethoxy)methoxy]-1-{4-nitro-2-[prop-1-en-1-yl]phenyl}pyridin-2(1H)-one

15.0 g (48.9 mmol) of Example 50A are dissolved in 700 ml ofdichloromethane, and 16.4 g (107 mmol) of1,8-diazabicyclo[5.4.0]undec-7-ene are added. A solution of 100 ml ofdichloromethane and 10.4 g (83.2 mmol) of1-(chloromethoxy)-2-methoxyethane is added dropwise to the water-cooledmixture, and the mixture is stirred at room temperature for 4 hours. Forwork-up, the reaction solution is applied directly to silica gel 60 andchromatographed using a mobile phase gradient of cyclohexane and ethylacetate (2/1→1/2). This gives 9.6 g (43% of theory) of product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.50 (d, 0.5H), 8.27 (dd, 0.5H),8.22-8.13 (m, 1H), 7.19 (d, 0.5H), 7.59 (d, 0.5H), 7.23-7.10 (m, 2H),6.58 (m, 0.5H) 6.85-6.25 (m, 1H), 6.60-5.85 (m, 1.5H), 5.28 (s, 1H),5.23 (s, 1H), 3.75 (m, 2H), 3.48 (m, 2H), 3.25 (s, 3H), 1.80 (dd, 1.5H),1.72 (dd, 1.5H).

LC-MS (method 6): R_(t)=2.09 min

MS (ESIpos): m/z=361 (M+H)⁺

Example 52A1-(4-Amino-2-propylphenyl)-3-[(2-methoxyethoxy)methoxy]pyridin-2(1H)-one

2.9 g (7.0 mmol) of Example 51A are dissolved in a mixture of 56 ml ofethyl acetate and 35 ml of ethanol, and 2.2 g (35.0 mmol) of ammoniumformate and a catalytic amount of 10% palladium on carbon are addedsuccessively. The reaction is stirred at 80° C. for 2 hours. Forwork-up, the cooled suspension is filtered through silica gel 60, thefilter cake is washed with ethanol and the filtrate is concentrated todryness on a rotary evaporator. The residue is dissolved in a mixture of56 ml of ethyl acetate and 35 ml of ethanol, and 2.2 g (35.0 mmol) ofammonium formate and a catalytic amount of 10% palladium on carbon areadded. After a reaction time of 24 hours and at a temperature of 80° C.,the starting material is reduced completely. The cooled suspension isagain filtered through silica gel 60 eluting with ethanol, and thesolvent is removed completely on a rotary evaporator. This gives 3.0 gof crude product.

LC-MS (method 6): R_(t)=1.73 min, 1.81 min

MS (ESIpos): m/z=333 (M+H)⁺

Example 53A5-Chloro-N-({(5S)-3-[4-(3-hydroxy-2-oxopyridin-1(2H)-yl)-3-propylphenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide

3.0 g (9.0 mmol) of Example 52A are dissolved in 125 ml of acetonitrile.2.6 g (9.9 mmol) of Example 1A are added to the ice-cooled solution, themixture is stirred for 10 min and 3.0 g (13.5 mmol) of magnesiumperchlorate are then added a little at a time. The mixture is stirred atroom temperature overnight, and 4.4 g (27.1 mmol) of 1,1-carbonyldiimidazole and 0.1 g (0.9 mmol) of 4-dimethylaminopyridine are thenadded. After 4 hours at 60° C., the suspension is filtered, the filterresidue is washed with acetonitrile and the filtrate is concentrated todryness on a rotary evaporator. The residue is taken up in ethyl acetateand extracted with 50 ml of 1N hydrochloric acid, the aqueous acidicphase is extracted repeatedly with ethyl acetate and the combinedorganic phases are washed with saturated sodium chloride solution. Theethyl acetate phase is then dried over sodium sulphate, the drying agentis filtered off and the solvent is removed completely on a rotaryevaporator. Fine-purification by preparative RP-HPLC using anacetonitrile/water mixture gives 1.1 g (19% of theory) of product.

LC-MS (method 11): R_(t)=3.26 min

MS (ESIpos): m/z=488 (M+H)⁺

Example 54A5-Chloro-N-{[(5S)-3-{4-[3-(2-chloroethoxy)-2-oxopyridin-1(2H)-yl]-3-propylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

241 mg (0.50 mmol) of Example 53A and 270 mg (1.4 mmol) of1-chloro-2-iodoethane are dissolved in 9 ml of N,N-dimethylformamide,and 131 mg (0.90 mmol) of potassium carbonate are added. The reaction isstirred at 60° C. for 4 hours. For work-up, water is added to thesuspension, and the mixture is extracted with dichloromethane. Theseparated organic phase is washed successively with 1N hydrochloric acidand saturated sodium chloride solution and then dried over sodiumchloride, the drying agent is filtered off and the solvent is removedcompletely on a rotary evaporator. Drying of the residue under reducedpressure gives 30 mg (12% of theory) of the product.

LC-MS (method 6): R_(t)=2.36 min

MS (ESIpos): m/z=550 (M+H)⁺

Example 55A 1-(4-Amino-2-propylphenyl)-3-methoxypyridin-2(1H)-one

27.0 g (87.7 mmol) of Example 49A are dissolved in 702 ml of ethylacetate and 441 ml of ethanol, 16.6 g (263 mmol) of ammonium formate and0.093 g (0.09 mmol) of palladium/carbon (10%) are added and the mixtureis stirred at 80° C. for 16 h. Because of incomplete conversion, 5.5 g(87 mmol) of ammonium formate and 0.03 g (0.03 mmol) of palladium/carbon(10%) are added. After a further 16 h of stirring at 80° C., the sameamounts are added, and the mixture is stirred at 80° C. for 16 h. Forwork-up, the reaction solution is brought to room temperature and passedthrough a silica gel frit. The filter cake is washed with ethanol, thefiltrate is concentrated under reduced pressure and the residue ischromatographed on silica gel 60 using a gradient of dichloromethane andmethanol (100/1→30/1). This gives 17.3 g of product; however, the ¹H-NMRspectrum of this product still contains signals for the intermediate,which contains a double bond. Accordingly, the impure material isdissolved in 360 ml of ethyl acetate and 226 ml of ethanol, 12.8 g (202mmol) of ammonium formate and 0.072 g (0.07 mmol) of palladium/carbon(10%) are added, and the mixture is stirred at 80° C. for 36 h. Aftercooling, the mixture is filtered through a silica gel frit, the filtercake is washed with ethanol and the filtrate is concentrated underreduced pressure. The residue is chromatographed on silica gel 60 usinga gradient of dichloromethane and methanol (100/1→10/1). This gives 8.35g of product (47% of theory).

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 6.97 (dd, 1H), 6.85 (dd, 1H), 6.75 (d,1H), 6.50 (d, 1H), 6.45 (dd, 1H), 6.15 (t, 1H), 5.22 (s, 2H) 3.71 (s,3H), 2.12 (t, 2H), 1.45-1.30 (m, 2H), 0.76 (t, 3H).

LC-MS (method 6): R_(t)=1.53 min

MS (ESIpos): m/z=259 (M+H)⁺.

Example 56A5-Chloro-N-({(5S)-3-[4-(3-methoxy-2-oxopyridin-1(2H)-yl)-3-propylphenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide

1.00 g (3.87 mmol) of Example 55A is dissolved in 23.5 ml of anhydrousacetonitrile, and 926 mg (4.26 mmol) of Example 1A and 1.30 g (5.81mmol) of magnesium perchlorate are added. The mixture is stirred at roomtemperature for 3.5 h. 1.57 g (9.68 mmol) of carbonyldiimidazole and 47mg (0.38 mmol) of 4-dimethylaminopyridine are then added, and themixture is stirred at 60° C. for 4 h and then at RT for 18 h. Themixture is then diluted with 300 ml of water and 150 ml of ethylacetate, and the aqueous phase is extracted twice with 150 ml of ethylacetate. The combined organic phases are dried over sodium sulphate andconcentrated under reduced pressure, and the residue obtained ispurified by chromatography on silica gel (dichloromethane/methanol20:1). This gives 1.81 g (92% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.99 (t, 1H), 7.70 (d, 1H),7.58-7.47 (m, 2H), 7.26-7.15 (m, 2H), 7.04 (dd, 1H), 6.90 (dd, 1H), 6.23(dd, 1H), 4.91-4.81 (m, 1H), 4.23 (dd, 1H), 3.93-3.85 (m, 1H), 3.74 (s,3H), 3.62 (dd, 2H), 2.31-2.23 (m, 2H), 1.50-1.36 (m, 2H), 0.78 (t, 3H).

HPLC (method 2): R_(t)=4.19 min

MS (ESI pos, m/z)=502 (M+H)⁺

Example 57A5-Chloro-N-({(5S)-3-[4-(3-hydroxy-2-oxopyridin-1(2H)-yl)-3-propylphenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide

1.79 g (3.56 mmol) of Example 56A are dissolved in 104 ml of anhydrousdichloromethane and cooled to −78° C. At this temperature, 28.5 ml (28.5mmol) of a 1N boron tribromide solution in dichloromethane are addedsuch that the temperature does not exceed −65° C. The mixture is stirredat −78° C. for 2 h and then at RT for 1 h and then carefully added to200 ml of saturated aqueous sodium bicarbonate solution. After phaseseparation, the aqueous phase is extracted three times withdichloromethane, and the combined organic phases are washed withsaturated sodium chloride solution, dried over sodium sulphate, filteredand evaporated to dryness under reduced pressure. This gives 1.75 g (97%of theory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=9.21 (s, 1H), 8.99 (t, 1H), 7.70 (d,1H), 7.56-7.47 (m, 2H), 7.29-7.15 (m, 2H), 6.94 (dd, 1H), 6.80 (dd, 1H),6.19 (dd, 1H), 4.91-4.81 (m, 1H), 4.23 (dd, 1H), 3.93-3.85 (m, 1H), 3.62(dd, 2H), 2.35-2.26 (m, 2H), 1.50-1.36 (m, 2H), 0.78 (t, 3H).

HPLC (method 2): R_(t)=4.21 min

MS (DCI): m/z=488 (M+H)⁺

Example 58A5-Chloro-N-{[(5S)-3-{4-[3-(2-chloroethoxy)-2-oxopyridin-1(2H)-yl]-3-propylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

1.70 g (3.48 mmol) of Example 57A and 2.49 g (17.4 mmol) of1-bromo-2-chloroethane are dissolved in 55 ml of 1-methyl-2-pyrrolidone.2.27 g (6.96 mmol) of caesium carbonate are added to the solution, andthe mixture is stirred at 60° C. for 2 hours. 500 ml of water, 100 ml ofsaturated aqueous sodium chloride solution and 200 ml of tert-butylmethyl ether and 200 ml of ethyl acetate are then added. After phaseseparation, the aqueous phase is extracted twice with 200 ml of ethylacetate. The combined organic phases are washed successively with 1Nsodium hydroxide solution and saturated sodium chloride solution andthen dried over sodium sulphate, the drying agent is filtered off andthe solvent is removed completely on a rotary evaporator. The residue ispurified by chromatography on silica gel (dichloromethane/ethanol 40:1).This gives 1.78 g (85% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.99 (t, 1H), 7.70 (d, 1H),7.56-7.47 (m, 2H), 7.29-7.13 (m, 2H), 7.12 (dd, 1H), 6.99 (dd, 1H), 6.22(dd, 1H), 4.91-4.82 (m, 1H), 4.30-4.14 (m, 1H), 3.98-3.85 (m, 1H), 3.61(dd, 2H), 2.35-2.26 (m, 2H), 2.18 (t, 2H), 1.95-1.85 (m, 2H), 1.50-1.36(m, 2H), 0.78 (t, 3H).

HPLC (method 2): R_(t)=4.44 min

MS (ESIpos): m/z=550 (M+H)⁺

Example 59A 3-Bromo-1-(2,6-dimethyl-4-nitrophenyl)pyridin-2(1H)-one

2.81 g (16.1 mmol) of 3-bromopyridin-2(1H)-one (O. S. Tee, M. Pavent, J.Am. Chem. Soc. 1982, 104, 4142-4146.) are dissolved in 100 ml of DMF.The mixture is cooled to 0° C., and 2.71 g (24.2 mmol) of potassiumtert-butoxide are added. The ice bath is removed, and the mixture isstirred at room temperature for 30 min. 3.00 g (17.7 mmol) of1-fluoro-2,5-dimethyl-4-nitrobenzene are added, and the mixture isstirred at 80° C. for 18 h, at 100° C. for 36 h and at 120° C. for 18 h.The mixture is then added to water and extracted three times with ethylacetate. The combined organic phases are dried over sodium sulphate. Theresidue is purified by chromatography on silica gel (cyclohexane/ethylacetate 4:1). This gives 2.04 g (38% of theory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.19 (s, 2H), 8.14 (dd, 1H), 7.62(dd, 1H), 6.43 (t, 1H), 2.11 (s, 6H).

HPLC (method 1): R_(t)=4.13 min.

MS (ESIpos, m/z): 323 (M+H)⁺.

Alternative Synthesis:

150 g (750 mmol) of 3-bromopyridin-2(1H)-one (O. S. Tee, M. Pavent, J.Am. Chem. Soc. 1982, 104, 4142-4146.) and 207 g (1.50 mol) of potassiumcarbonate are dissolved in 2.9 l of dimethyl sulphoxide and heated to120° C. At this temperature, a solution of 317 g (750 mmol) of1-fluoro-2,5-dimethyl-4-nitrobenzene in 700 ml of dimethyl sulphoxide isadded dropwise over a period of 60 min, and the mixture is stirred at120° C. for 3.5 h. After cooling, the reaction solution is stirred intoa water/hydrochloric acid mixture. The mixture is extracted with ethylacetate, the phases are separated and the aqueous phase is once moreextracted with ethyl acetate. The combined organic phases are thenwashed with water. The phases are separated, and the organic phase isdried over sodium sulphate. After concentration under reduced pressure,the residue is purified by chromatography on silica gel(dichloromethane, then ethyl acetate/dichloromethane 1:20). Theproduct-containing fractions are combined, the solvents are removed andthe residue is triturated with diethyl ether. This gives 112 g (46% oftheory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.19 (s, 2H), 8.14 (dd, 1H), 7.62(dd, 1H), 6.43 (t, 1H), 2.11 (s, 6H).

HPLC (method 13): R_(t)=1.59 min.

MS (ESIpos, m/z): 323 (M+H)⁺.

Example 60A 1-(2,6-Dimethyl-4-nitrophenyl)-3-vinylpyridin-2(1H)-one

2.00 g (6.19 mmol) of the compound from Example 59A are dissolved in 31ml of anhydrous dioxane, and 2.36 g (7.42 mmol) of tributylvinyltin and143 mg (0.124 mmol) of tetrakis(triphenylphosphine)palladium are addedand the mixture is stirred at 100° C. for 5 h. The mixture is allowed tocool and filtered through kieselguhr. The filter cake is washed threetimes with ethyl acetate, and the combined filtrates are concentrated todryness under reduced pressure. The residue is purified bychromatography on silica gel (cyclohexane/ethyl acetate 4:1). This gives846 mg (51% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.17 (s, 2H), 7.78 (dd, 1H), 7.48(dd, 1H), 6.75 (dd, 1H), 6.48 (dd, 1H), 6.14 (dd, 1H), 5.33 (dd, 1H),2.10 (s, 6H).

HPLC (method 1): R_(t)=4.25 min

MS (ESIpos): m/z=271 (M+H)⁺

Alternative Synthesis:

132 g (408 mmol) of the compound from Example 59A (alternativesynthesis) are dissolved in 1.27 l of anhydrous dioxane, 136 g (428mmol) of tributylvinyltin and 9.44 g (8.17 mmol) oftetrakis(triphenylphosphine)palladium are added and the mixture isstirred at 100° C. for 4 h. The mixture is allowed to cool and filteredthrough kieselguhr. The mixture is concentrated to dryness under reducedpressure. The residue is dissolved in dichloromethane and purified bychromatography on silica gel (petroleum ether/ethyl acetate 9:1, then8:2, then 7:3). The product-containing fractions are combined, thesolvents are removed and the residue is triturated with petroleumether/diethyl ether (10:1). This gives 83 g (75% of theory) of thedesired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.17 (s, 2H), 7.78 (dd, 1H), 7.48(dd, 1H), 6.75 (dd, 1H), 6.48 (dd, 1H), 6.14 (dd, 1H), 5.33 (dd, 1H),2.10 (s, 6H).

HPLC (method 13): R_(t)=1.70 min

MS (ESIpos): m/z=271 (M+H)⁺

Example 61A1-(2,6-Dimethyl-4-nitrophenyl)-3-(2-hydroxyethyl)pyridin-2(1H)-one

With ice-cooling, a solution of 902 mg (7.40 mmol) of9-borabicyclo[3.3.1]nonane in 14.8 ml tetrahydrofuran is added to 800 mg(2.96 mmol) of the compound from Example 60A. The mixture is stirred atroom temperature for 3 h and then cooled to 0° C., and an aqueoussolution of 591 mg (14.8 mmol) of sodium hydroxide is added over aperiod of 15 min. 2.60 ml of a 30% strength hydrogen peroxide solutionare added such that the temperature does not exceed 30° C. After theaddition has ended, the mixture is stirred at 0° C. for 30 min. Withice-cooling, a solution of 8.73 g (32.6 mol) of sodium bisulphite in 12ml of water is added to the reaction mixture. The mixture is dilutedwith 50 ml of ethyl acetate, the organic phase is removed and theaqueous phase is extracted twice with ethyl acetate. The combinedorganic phases are washed with saturated sodium chloride solution, driedover sodium sulphate and evaporated to dryness under reduced pressure.The residue is purified by chromatography on silica gel(cyclohexane/ethyl acetate 1:2). This gives 765 mg (89% of theory) ofthe desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.15 (s, 2H), 7.46 (dd, 1H), 7.35(dd, 1H), 6.37 (dd, 1H), 4.62 (dd, 1H), 4.25 (d, 1H), 2.62 (dd, 2H),2.08 (s, 6H).

HPLC (method 1): R_(t)=3.59 min

MS (ESIpos): m/z=289 (M+H)⁺

Alternative Synthesis:

With ice-cooling, 1.15 l (575 mmol) of a 0.5 molar solution of9-borabicyclo[3.3.1]nonane in tetrahydrofuran are added to 70.7 g (262mmol) of the compound from Example 60A (alternative synthesis) such thatthe internal temperature does not exceed 10-15° C. The mixture is thenwarmed to RT and stirred at room temperature for 1.5 h. The mixture isthen cooled and, at 0° C.-5° C., 653 ml (1.31 mol) of a 2-molar aqueoussolution of sodium hydroxide are added. The mixture is stirred briefly,and 296 g (2.51 mol) of a 30% strength hydrogen peroxide solution arethen added such that the temperature does not exceed 30° C. and does notfall below 25° C. After the addition has ended, the mixture is stirredfor another 30 min. Water and ethyl acetate are added to the reactionmixture. After phase separation, the aqueous phase is once moreextracted with ethyl acetate. The combined organic phases are washedwith an aqueous sodium bisulphite solution. The organic phase is removedand evaporated to dryness under reduced pressure. The residue isdissolved in dichloromethane and purified by chromatography on silicagel (cyclohexane/ethyl acetate 1:2, then ethyl acetate). This gives 66.5g (88% of theory) of the desired product.

¹H-NMR (400 MHz, CDCl₃, S/ppm): δ=8.07 (s, 2H), 7.43 (dd, 1H), 6.98(ddd, 1H), 6.38 (dd, 1H), 3.88 (ddd, 2H), 3.55 (dd, 1H), 2.89 (dd, 2H),2.19 (s, 6H).

HPLC (method 14): R_(t)=0.83 min

MS (ESIpos): m/z=289 (M+H)⁺

Example 62A3-(2-{[tert-Butyl(diphenyl)silyl]oxy}ethyl)-1-(2,6-dimethyl-4-nitrophenyl)pyridin-2(1H)-one

760 mg (2.64 mmol) of the compound from Example 61A and 0.55 ml (3.9mmol) of triethylamine are dissolved in 7 ml of anhydrousN,N-dimethylformamide. 16 mg (0.13 mmol) of 4-dimethylaminopyridine and1.09 g (3.95 mmol) of tert-butyl(chloro)diphenylsilane are added, andthe mixture is stirred at RT for 2 h. The mixture is then added to waterand, after phase separation, extracted three times with ethyl acetate.The combined organic phases are washed twice with water, dried oversodium sulphate, filtered, and evaporated under reduced pressure. Theresidue is purified by chromatography on silica gel (cyclohexane/ethylacetate 5:1). This gives 971 mg (58% of theory) of the desired product.

HPLC (method 2): R_(t)=5.97 min

MS (ESIpos): m/z=527 (M+H)⁺

Alternative Synthesis:

100 g (346 mmol) of the compound from Example 61A (alternativesynthesis) and 30.7 g (450 mmol) of imidazole are dissolved in 1 l ofanhydrous N,N-dimethylformamide. A solution of 117 g (416 mmol) oftert-butyl(chloro)diphenylsilane in 150 ml of N,N-dimethylformamide isadded dropwise, and the mixture is stirred at RT for 3 h. Water andethyl acetate are then added, the phases are separated and the organicphase is washed with water, dried over sodium sulphate, filtered andevaporated under reduced pressure. The residue is triturated withpetroleum ether/diethyl ether (10:1). After filtration, the residue iswashed with petroleum ether and then air-dried. This gives 150 g (82% oftheory) of the desired product.

¹H-NMR (400 MHz, CDCl₃, S/ppm): δ=8.04 (s, 2H), 7.68-7.62 (m, 4H),7.46-7.33 (m, 7H), 6.92 (dd, 1H), 6.30 (dd, 1H), 3.95 (dd, 2H), 2.86(dd, 2H), 2.16 (s, 6H), 1.02 (s, 9H).

HPLC (method 13): R_(t)=2.98 min

MS (ESIpos): m/z=527 (M+H)⁺

Example 63A1-(4-Amino-2,6-dimethylphenyl)-3-(2-{[tert-butyl(diphenyl)silyl]oxy}ethyl)pyridin-2(1H)-one

970 mg (1.84 mmol) of the compound from Example 62A are dissolved in 20ml of THF. 200 mg of palladium on carbon are then added, and the mixtureis hydrogenated at RT in a hydrogen atmosphere under atmosphericpressure. The mixture is then filtered through kieselguhr, the filtercake is washed three times with THF and the filtrate is freed from thesolvent. The reaction product (1.00 g) is reacted further withoutfurther purification.

HPLC (method 2): R_(t)=4.99 min

MS (ESIpos): m/z=497 (M+H)⁺

Alternative Synthesis:

143 g (271 mmol) of the compound from Example 62A (alternativesynthesis) are dissolved in 1.43 l of tetrahydrofuran and flushed withargon. 17 g of palladium on carbon (50%, moistened with water) areadded, and the mixture is then hydrogenated at RT in a hydrogenatmosphere under atmospheric pressure. The mixture is then filteredthrough kieselguhr, the filter cake is washed with tetrahydrofuran andthe filtrate is freed from the solvent. The reaction product (134 g) isreacted further without further purification.

HPLC (method 6): R_(t)=3.11 min

MS (ESIpos): m/z=497 (M+H)⁺

Example 64AN-[((5S)-3-{4-[3-(2-{[tert-Butyl(diphenyl)silyl]oxy}ethyl)-2-oxopyridin-1(2H)-yl]-3,5-dimethyl-phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]-5-chlorothiophene-2-carboxamide

800 mg (1.61 mmol) of the compound from Example 63A are dissolved in 15ml of anhydrous acetonitrile, and 385 g (1.77 mmol) of the compound fromExample 1A and 539 mg (2.41 mmol) of magnesium perchlorate are added.The mixture is stirred at room temperature for 5.5 h. 652 mg (4.03 mmol)of 1,1-carbonyldiimidazole and 19 mg (0.16 mmol) ofN,N-dimethylaminopyridine are then added, and the mixture is heated atreflux for 18 h. The mixture is allowed to cool and added to 100 ml ofwater and 100 ml of ethyl acetate. After phase separation, the aqueousphase is extracted twice with ethyl acetate and the combined organicphases are dried over sodium sulphate. After filtration, the mixture isevaporated to dryness under reduced pressure. The residue is purified bychromatography on silica gel (cyclohexane/ethyl acetate 1:2). This gives664 mg (55% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.99 (t, 1H), 7.70 (d, 1H),7.63-7.45 (m, 4H), 7.48-7.31 (m, 9H), 7.28 (dd, 1H), 7.20 (d, 1H), 6.32(t, 1H), 4.90-4.81 (m, 1H), 4.22 (dd, 1H), 3.89-3.82 (m, 3H), 3.62 (t,2H), 2.76 (dd, 2H), 1.94 (s, 6H), 0.95 (s, 9H).

HPLC (method 2): R_(t)=5.92 min

MS (ESIpos): m/z=740 (M+H)⁺

Alternative Synthesis:

102 g (171 mmol) of the compound from Example 68A are dissolved in 1.45l of dichloromethane, and 44.7 ml (257 mmol) ofN,N-diisopropylethylamine are added. A solution of 37.1 g (205 mmol) of5-chlorothiophene-2-carbonyl chloride in a little dichloromethane isslowly added dropwise, and the mixture is stirred at room temperaturefor one hour. Water is then added, the phases are separated and theorganic phase is dried over sodium sulphate. After filtration, thefiltrate is evaporated to dryness under reduced pressure. The residue isreacted further without further purification.

HPLC (method 6): R_(t)=3.33 min

MS (ESIpos): m/z=740 (M+H)⁺

Example 65A5-Chloro-N-[((5S)-3-{4-[3-(2-hydroxyethyl)-2-oxopyridin-1(2H)-yl]-3,5-dimethylphenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]thiophene-2-carboxamide

660 mg (0.891 mmol) of the compound from Example 64A are dissolved in 20ml of THF, and 512 mg (1.96 mmol) of tetrabutylammonium fluoride areadded. After 1 h, the mixture is concentrated to dryness under reducedpressure. The residue is purified by chromatography on silica gel(dichloromethane/methanol 10:1; 1% triethylamine). This gives 396 mg(85% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.98 (t, 1H), 7.69 (d, 1H), 7.42(dd, 1H), 7.38 (d, 1H), 7.25 (dd, 1H), 7.19 (d, 1H), 6.29 (t, 1H),4.90-4.81 (m, 1H), 4.60 (t, 1H), 4.20 (t, 1H), 3.86 (dd, 1H), 3.64-3.52(m, 4H), 2.62 (t, 2H), 1.95 (s, 6H).

HPLC (method 1): R_(t)=3.92 min

MS (ESIpos): m/z=502 (M+H)⁺

Alternative Synthesis:

157 g (174 mmol) of the compound from Example 64A (alternativesynthesis) are dissolved in 1.44 l of dichloromethane. At 15-20° C., 453ml (5.32 mol) of concentrated hydrochloric acid are added dropwise, andthe mixture is stirred at room temperature for 1 h. The phases areseparated, the organic phase is discarded. The aqueous phase is washedtwice with dichloromethane. Dichloromethane is then added to the aqueousphase, and the mixture is adjusted with cooling to pH=10 using 1:1dilute aqueous sodium hydroxide solution. The phases are separated, andthe organic phase is washed twice with water and then dried over sodiumsulphate. After filtration, the filtrate is concentrated to drynessunder reduced pressure. The residue is triturated with acetone, cooledto 10° C., filtered off at this temperature and washed with coldacetone. Drying gives 75 g (85% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.98 (t, 1H), 7.69 (d, 1H), 7.42(dd, 1H), 7.42-7.38 (m, 2H), 7.25 (dd, 1H), 7.19 (d, 1H), 6.29 (t, 1H),4.90-4.81 (m, 1H), 4.60 (t, 1H), 4.20 (t, 1H), 3.86 (dd, 1H), 3.64-3.52(m, 4H), 2.62 (t, 2H), 1.95 (s, 6H).

HPLC (method 6): R_(t)=1.93 min

MS (ESIpos): m/z=502 (M+H)⁺

Example 66A2-[(2R)-3-({4-[3-(2-{[tert-Butyl(diphenyl)silyl]oxy}ethyl)-2-oxopyridin-1(2H)-yl]-3,5-dimethyl-phenyl}amino)-2-hydroxypropyl]-1H-isoindole-1,3(2H)-dione

65 g (131 mmol) of the compound from Example 63A (alternative synthesis)are dissolved in 1.3 l of acetonitrile, and 27.9 g (137 mmol) of(S)-epoxyphthalimide and 43.8 g (196 mmol) of magnesium perchlorate areadded. The mixture is stirred at room temperature for 15 h. Water anddichloromethane are then added, the phases are separated and the organicphase is dried over sodium sulphate. After filtration, the mixture isevaporated to dryness under reduced pressure. The residue is reactedfurther without further purification.

HPLC (method 14): R_(t)=1.73 min

MS (ESIpos): m/z=701 (M+H)⁺

Example 67A2-{[(5S)-3-{4-[3-(2-{[tert-Butyl(diphenyl)silyl]oxy}ethyl)-2-oxopyridin-1(2H)-yl]-3,5-dimethyl-phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}-1H-isoindole-1,3(2H)-dione

190 g (204 mmol) of the compound from Example 66A are dissolved in 1.01l of toluene. 66.0 g (407 mmol) of 1,1′-carbonyldiimidazole are thenadded, and the mixture is heated at reflux for one hour. The mixture isthen cooled to room temperature, and water and dichloromethane areadded. The phases are separated and the organic phase is dried oversodium sulphate. After filtration, the mixture is evaporated to drynessunder reduced pressure. The residue is triturated with methanol, and thesolid which remains is filtered off and washed with methanol. This gives130 g (87% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=7.99-7.82 (m, 4H), 7.65-7.56 (m,4H), 7.48-7.28 (m, 10H), 6.32 (t, 1H), 5.03-4.93 (m, 1H), 4.24 (dd, 1H),4.00 (dd, 1H), 3.97-3.88 (m, 2H), 3.85 (t, 2H), 2.76 (t, 2H), 1.94 (s,6H), 0.95 (s, 9H).

HPLC (method 14): R_(t)=1.74 min

MS (ESIpos): m/z=726 (M+H)⁺

Example 68A1-{4-[(5S)-5-(Aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]-2,6-dimethylphenyl}-3-(2-{[tert-butyl-(diphenyl)silyl]oxy}ethyl)pyridin-2(1H)-one

130 g (179 mmol) of the compound from Example 67A are dissolved in 650ml of ethanol, 193 ml (2.68 mol) of a 40% strength aqueous methanaminesolution are added and the mixture is heated at 50-55° C. for one hour.After cooling to room temperature, water and dichloromethane are added,the phases are separated and the organic phase is dried over sodiumsulphate. After filtration, the mixture is evaporated to dryness underreduced pressure. The residue (117 g, 89% of theory) is reacted furtherwithout further purification.

HPLC (method 6): R_(t)=2.05 min

MS (ESIpos): m/z=597 (M+H)⁺

Example 69A 1-(2,6-Dimethyl-4-nitrophenyl)-3-methoxypyridin-2(1H)-one

At 0° C., 452 mg (4.03 mmol) of potassium tert-butoxide are added to 336mg (2.69 mmol) of 3-methoxypyridinone in 10 ml of DMF, and the mixtureis stirred at room temperature for 30 min. 500 mg (2.96 mmol) of1-fluoro-2,5-dimethyl-4-nitrobenzene are added, and the mixture isstirred at 80° C. After 22 h, the mixture is heated at 120° C. andstirred for a further 20 h. The mixture is then cooled and added to 100ml of water and 15 ml of saturated aqueous sodium chloride solution. Themixture is extracted three times with in each case 300 ml of ethylacetate, and the combined organic phases are dried over sodium sulphate.After filtration, the solvents are removed under reduced pressure andthe residue is purified by chromatography on silica gel(cyclohexane/ethyl acetate 1:1). This gives 383 mg (52% of theory) ofthe desired compound.

¹H-NMR (300 MHz, DMSO-d₆, S/ppm): δ=8.16 (s, 2H), 7.04 (dd, 1H), 6.97(dd, 1H), 6.38 (dd, 1H), 3.77 (s, 3H), 2.08 (s, 6H).

HPLC (method 1): R_(t)=2.84 min.

MS (DCI, m/z): 275 (M+H)⁺.

Example 70A 1-(4-Amino-2,6-dimethylphenyl)-3-methoxypyridin-2(1H)-one

2.05 g (7.47 mmol) of the compound from Example 69A are dissolved in 70ml of ethyl acetate and 70 ml of ethanol, 2.35 g (37.4 mmol) of ammoniumformate and 0.39 g (0.37 mmol) of palladium/carbon (10%) are added andthe mixture is stirred at 80° C. for 2 h. For work-up, the reactionsolution is brought to room temperature and passed through a silica gelfrit. The filter cake is washed with ethanol and the filtrate isconcentrated under reduced pressure. The reaction product (1.65 g) isreacted without further purification.

¹H-NMR (300 MHz, DMSO-d₆, δ/ppm): δ=6.93-6.83 (m, 2H), 6.33 (s, 2H),6.19 (dd, 1H), 5.12 (br.s, 2H), 3.72 (s, 3H), 1.78 (s, 6H).

LC-MS (method 1): R_(t)=2.90 min.

MS (DCI, m/z): 245 (M+H)⁺.

Example 71A5-Chloro-N-({(5S)-3-[4-(3-methoxy-2-oxopyridin-1(2H)-yl)-3,5-dimethylphenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide

544 mg (2.50 mmol) of the compound from Example 1A are added to asolution of 555 mg (2.27 mmol) of the compound from Example 70A in 28 mlof acetonitrile. 761 mg (3.41 mmol) of magnesium perchlorate are added,and the suspension is then stirred at RT for 5.5 h. 736 mg (4.54 mmol)of 1,1′-carbonyldiimidazole and 28 mg (0.23 mmol) of DMAP are thenadded, and the mixture is heated at 60° C. After 18 h, another 28 mg(0.23 mmol) of DMAP are added. After 2 h at 70° C., the mixture iscooled and diluted with 100 ml of water. The aqueous phase is extractedthree times with in each case 100 ml of ethyl acetate, and the combinedorganic phases are dried over sodium sulphate. After filtration, thefiltrate is freed from the solvent and the residue is purified bychromatography on silica gel (dichloromethane/ethanol 20:1). Removal ofthe solvents gives 840 mg (69% of theory) of the desired product.

¹H-NMR 300 MHz, DMSO-d₆, S/ppm): δ=8.98 (t, 1H), 7.69 (d, 1H), 7.42-7.32(m, 2H), 7.20 (dd, 1H), 7.00-6.88 (m, 2H), 6.28 (dd, 1H), 4.91-4.80 (m,1H), 4.20 (dd, 1H), 3.90-3.82 (m, 1H), 3.75 (s, 3H), 3.60 (dd, 2H), 1.95(s, 6H).

HPLC (method 14): R_(t)=1.02 min.

MS (ESIpos, m/z): 488 (M+H)⁺.

Example 72A5-Chloro-N-({(5S)-3-[4-(3-hydroxy-2-oxopyridin-1(2H)-yl)-3,5-dimethylphenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide

830 mg (1.70 mmol) of the compound from Example 71A are dissolved in 50ml of anhydrous dichloromethane and cooled to −78° C. At thistemperature, 3.40 ml (3.40 mmol) of a 1 normal boron tribromide solutionin dichloromethane are added dropwise such that the temperature does notexceed −65° C. The mixture is stirred at −78° C. for 2 h and then at RTfor 2.5 h and kept at −20° C. for 15 h. At room temperature, thesolution is carefully added to a saturated aqueous sodium bicarbonatesolution. After phase separation, the aqueous phase is extracted threetimes with dichloromethane, and the combined organic phases are washedwith saturated sodium chloride solution, dried over sodium sulphate,filtered and evaporated to dryness under reduced pressure. This gives907 mg (69% of theory, purity according to LC-MS 61%) of the desiredcompound.

LC-MS (method 6): R_(t)=2.09 min.

MS (ESIpos, m/z)=474 (M+H)⁺

Example 73A5-Chloro-N-{[(5S)-3-{4-[3-(2-chloroethoxy)-2-oxopyridin-1(2H)-yl]-3,5-dimethylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

900 mg (1.89 mmol) of the compound from Example 72A and 1.36 g (9.49mmol) of 1-bromo-2-chloroethane are dissolved in 30 ml of1-methyl-2-pyrrolidone. 1.55 g (4.75 mmol) of caesium carbonate areadded to the solution, and the mixture is stirred at 60° C. for 15hours. Water is then added, and, after phase separation, the aqueousphase is extracted three times with tert-butyl methyl ether and threetimes with dichloromethane. The combined organic phases are washedsuccessively with 1N aqueous sodium hydroxide solution and saturatedsodium chloride solution and then dried over sodium sulphate. The dryingagent is filtered off and the solvent is removed completely on a rotaryevaporator. The residue is purified by chromatography on silica gel(cyclohexane/ethyl acetate 1:5). This gives 464 mg (45% of theory,purity according to LC-MS 74%) of the desired product.

HPLC (method 6): R_(t)=2.26 min

MS (ESIpos): m/z=536 (M+H)⁺

WORKING EXAMPLES Example 15-Chloro-N-{[(5S)-3-{4-[3-{[(2-hydroxyethyl)amino]methyl}-2-oxopyridin-1(2H)-yl]-3-methyl-phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

At −10° C., 38 mg (0.63 mmol) of aminoethanol are added to a solution of56 mg (0.11 mmol) of the compound from Example 11A in 1 ml of DMF. After30 min at −10° C., the mixture is added to water and then extractedthree times with ethyl acetate. The organic phases are combined and thenfreed from the solvent under reduced pressure. The product is purifiedby preparative HPLC using an acetonitrile/water mixture. This gives 14.5mg (26% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 9.00 (t, 1H), 8.28-8.15 (m, 2H), 7.70(d, 1H), 7.60-7.48 (m, 3H), 7.45 (d, 1H), 7.23 (d, 1H), 7.20 (d, 1H),6.35 (dd, 1H), 4.90-4.82 (m, 1H), 4.22 (dd, 1H), 3.88 (dd, 1H),3.71-3.45 (m, 6H), 2.68 (dd, 2H), 2.02 (s, 3H).

HPLC (method 2): R_(t)=3.71 min.

MS (ESIpos, m/z): 517/519 (³⁵Cl/³⁷Cl) (M+H)⁺.

Example 25-Chloro-N-{[(5S)-3-{3-methyl-4-[3-(2-morpholin-4-ylethyl)-2-oxopyridin-1(2H)-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

100 mg (0.21 mmol) of Example 18A are dissolved in 5 ml of anhydrousdichloromethane and cooled to −78° C. At this temperature, 66 mg (0.62mmol) of 2,6-dimethylpyridine and 69 mg (0.25 mmol) oftrifluoromethanesulphonic anhydride are added, and the mixture isstirred for a further 10 min. 179 mg (2.05 mmol) of morpholine are thenadded, after 5 min, cooling is removed and the mixture is stirred atroom temperature for 16 h. The solvent is removed under reducedpressure, and the residue is dissolved in a little methanol and purifiedby preparative HPLC using a gradient of acetonitrile and water. Theproduct-containing fractions are combined and concentrated to drynessunder reduced pressure. This gives 104 mg (91% of theory) of the desiredcompound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=9.0 (t, 1H), 7.7 (d, 1H), 7.5 (m,2H), 7.45 (dd, 1H), 7.35 (dd, 1H), 7.2 (m, 2H), 6.25 (t, 1H), 4.85 (m,1H), 4.2 (t, 1H), 3.9 (m, 1H), 3.65 (t, 2H), 3.55 (m, 4H), 2.3-2.7 (m,8H), 2.0 (s, 3H).

LC-MS (method 3): R_(t)=1.30 min

MS (ESIpos): m/z=556 (M+H⁺)⁺

Using the appropriate amine, the examples of the table below areprepared analogously to Example 2.

Exam- ple Structure Characterization 3

LC-MS (method 6): R_(t) = 1.42 min MS (ESIpos): m/z = 515 (M + H⁺)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ = 9.0 (t, 1H), 7.7 (d, 1H), 7.5 (m,2H), 7.45 (dd, 1H), 7.35 (dd, 1H), 7.2 (m, 2H), 6.25 (t, 1H), 4.85 (m,1H), 4.2 (t, 1H), 3.9 (m, 1H), 3.65 (t, 2H), 2.45 (m, 4H), 2.15 (s, 6H),2.0 (s, 3H). 4

LC-MS (method 6): R_(t) = 1.44 min MS (ESIpos): m/z = 585 (M + H⁺)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ = 9.0 (t, 1H), 8.3 (s, 1H), 7.7 (d,1H), 7.3-7.55 (m, 4H), 7.2 (m, 2H), 6.3 (t, 1H), 4.85 (m, 1H), 4.2 (t,1H), 3.9 (m, 1H), 3.65 (t, 2H), 3.3 (m, 1H), 2.9 (t, 2H), 2.7 (m, 4H),2.0 (s, 3H), 1.7-1.9 (m, 4H), 1.2 (m, 4H). 5

LC-MS (method 11): R_(t) = 1.80 min MS (ESIpos): m/z = 531 (M + H⁺)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ = 9.0 (t, 1H), 8.3 (s, 1H), 7.7 (d,1H), 7.55 (m, 2H), 7.45 (dd, 1H), 7.4 (dd, 1H), 7.2 (m, 2H), 6.3 (t,1H), 4.85 (m, 1H), 4.2 (t, 1H), 3.9 (m, 1H), 3.65 (t, 2H), 3.55 (t, 2H),2.95 (m, 2H), 2.8 (t, 2H), 2.75 (m, 2H), 2.0 (s, 3H).

Example 65-Chloro-N-{[(5S)-3-{4-[3-{2-[(trans-4-hydroxycyclohexyl)amino]ethyl}-2-oxopyridin-1(2H)-yl]-3-methoxyphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

19 g (38 mmol) of Example 25A are dissolved in 1000 ml of anhydrousdichloromethane and cooled to −78° C. At this temperature, 12.3 g (115mmol) of 2,6-dimethylpyridine and 16 g (57 mmol) oftrifluoromethanesulphonic anhydride are added. The mixture is stirred at−78° C. for 1.5 h, and 44 g (383 mmol) of trans-4-aminocyclohexanol,dissolved in 250 ml of dichloromethane and 50 ml ofN,N-dimethylformamide, are then added. Cooling is removed, the mixtureis stirred at room temperature for 16 h and the solvent is then removedunder reduced pressure. The residue is dissolved in a little methanoland purified by preparative HPLC using a gradient of acetonitrile andwater. The product-containing fractions are combined and concentrated todryness under reduced pressure. This gives 15.2 g (73% of theory) of thedesired compound.

¹H-NMR (400 MHz, CDCl₃, S/ppm): δ=7.72-7.52 (m, 1H), 7.50-7.37 (m, 2H),7.32 (dd, 1H), 7.21 (d, 1H), 7.10 (dd, 1H), 6.92-6.84 (m, 2H), 6.20 (t,1H), 4.81-4.66 (m, 1H), 4.10-3.95 (m, 1H), 3.87-3.66 (m, 6H), 3.64-3.50(m, 2H), 2.95-2.84 (m, 2H), 2.78-2.68 (m, 2H), 2.52-2.41 (m, 1H),1.98-1.78 (m, 5H), 1.33-1.05 (m, 4H).

LC-MS (method 6): R_(t)=1.40 min

MS (ESIpos): m/z=602 (M+H⁺)⁺

Using the appropriate amine, the examples of the table below areprepared analogously to Example 6.

Exam- ple Structure Characterization 7

LC-MS (method 6): R_(t) = 1.41 min MS (ESIpos): m/z = 573 (M + H⁺)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ = 9.0 (t, 1H), 7.7 (d, 1H), 7.45 (d,1H), 7.35 (dd, 1H), 7.3 (dd, 1H), 7.25 (d, 1H), 7.2 (d, 1H), 7.1 (d,1H), 6.2 (t, 1H), 4.85 (m, 1H), 4.25 (t, 1H), 3.9 (m, 1H), 3.75 (s, 3H),3.65 (t, 2H), 3.5 (m, 4H), 2.4-2.6 (m, 6H), 2.4 (m, 2H). 8

LC-MS (method 6): R_(t) = 1.40 min MS (ESIpos): m/z = 531 (M + H⁺)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ = 9.0 (t, 1H), 7.7 (d, 1H), 7.45 (d,1H), 7.35 (dd, 1H), 7.3 (dd, 1H), 7.25 (d, 1H), 7.2 (d, 1H), 7.1 (d,1H), 6.2 (t, 1H), 4.85 (m, 1H), 4.25 (t, 1H), 3.9 (m, 1 H), 3.75 (s,3H), 3.65 (t, 2H), 2.4-2.6 (m, 4H), 2.1 (s, 6H).

Example 95-Chloro-N-{[(5S)-3-{4-[3-{2-[(2-hydroxyethyl)amino]ethyl}-2-oxopyridin-1(2H)-yl]-3-(methoxy-methyl)phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

14 g (27 mmol) of Example 34A are dissolved in 660 ml of anhydrousdichloromethane and cooled to −78° C. At this temperature, 8.7 g (81mmol) of 2,6-dimethylpyridine and 13 g (46 mmol) oftrifluoromethanesulphonic anhydride are added. After 10 min at −78° C.,8.2 g (135 mmol) of 2-aminoethanol are added, after a further 5 mincooling is removed, and the mixture is then stirred at room temperaturefor 16 h. The solvent is removed under reduced pressure, and the residueis dissolved in a little methanol and purified by preparative HPLC usinga gradient of acetonitrile and water. The product-containing fractionsare combined and concentrated to dryness under reduced pressure. Thisgives 11.1 g (73% of theory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.98 (t, 1H), 7.71-7.65 (m, 2H),7.62-7.55 (m, 1H), 7.40 (dd, 1H), 7.35 (dd, 1H), 7.28 (d, 1H), 7.20 (d,1H), 6.25 (t, 1H), 4.90-4.82 (m, 1H), 4.42 (t, 1H), 4.27-4.08 (m, 3H),3.94-3.88 (m, 1H), 3.63 (t, 2H), 3.45 (dt, 2H), 3.18 (s, 3H), 2.75-2.68(m, 2H), 2.61-2.43 (m, 4H).

LC-MS (method 6): R_(t)=1.34 min

MS (ESIpos): m/z=561 (M+H⁺)⁺

Example 105-Chloro-N-{[(5S)-3-{4-[3-{2-[(trans-4-hydroxycyclohexyl)amino]ethyl}-2-oxopyridin-1(2H)-yl]-3-(methoxymethyl)phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

900 mg (1.7 mmol) of Example 34A are dissolved in 42 ml of anhydrousdichloromethane and cooled to −78° C. 560 mg (5.2 mmol) of2,6-dimethylpyridine and 833 mg (2.9 mmol) of trifluoromethanesulphonicanhydride are added, and the mixture is stirred at −78° C. for 1.5 h. 1g (8.7 mmol) of trans-4-aminocyclohexanol is added, cooling is removedafter 5 min and the mixture is then stirred at room temperature for 18h. The mixture is diluted with water and dichloromethane, and theorganic phase is separated off, dried over sodium sulphate, filtered andevaporated under reduced pressure. The residue is taken up in a littlemethanol and purified by preparative HPLC using a gradient ofacetonitrile and water. The product-containing fractions are combinedand concentrated to dryness under reduced pressure. This gives 655 mg(61% of theory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.98 (t, 1H), 7.71-7.65 (m, 2H),7.62-7.55 (m, 1H), 7.40 (dd, 1H), 7.35 (dd, 1H), 7.27 (d, 1H), 7.20 (d,1H), 6.25 (t, 1H), 4.90-4.82 (m, 1H), 4.44 (d, 1H), 4.27-4.07 (m, 3H),3.93-3.83 (m, 1H), 3.62 (t, 2H), 3.18 (s, 3H), 2.76-2.65 (m, 2H),2.57-2.48 (m, 2H), 2.36-2.27 (m, 2H), 1.84-1.72 (m, 4H), 1.19-1.06 (m,2H), 1.03-0.91 (m, 2H).

LC-MS (method 6): R_(t)=1.68 min

MS (ESIpos): m/z=615 (M+H⁺)⁺

Using the appropriate amine, the examples of the table below areprepared analogously to Example 10.

Exam- ple Structure Characterization 11

LC-MS (method 11): R_(t) = 1.94 min MS (ESIpos): m/z = 557 (M + H⁺)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ = 9.0 (t, 1H), 7.7 (m, 2H), 7.6 (m,1H), 7.4 (dd, 1H), 7.35 (dd, 1H), 7.25 (d, 1H), 7.2 (d, 1H), 6.25 (t,1H), 4.85 (m, 1H), 4.2 (m, 2H), 4.1 (d, 1H), 3.9 (m, 1H), 3.6 (t, 2H),3.3 (m, 2H), 3.2 (s, 3H), 2.8 (m, 2H), 2.1 (m, 2H), 0.45 (m, 2H), 0.2(m, 2H). 12

LC-MS (method 11): R_(t) = 1.86 min MS (ESIpos): m/z = 517 (M + H⁺)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ = 9.0 (t, 1H), 7.7 (m, 2H), 7.6 (m,1H), 7.4 (m, 2H), 7.25 (d, 1H), 7.2 (d, 1H), 6.25 (t, 1H), 4.85 (m, 1H),4.2 (m, 2H), 4.1 (d, 1H), 3.9 (m, 1H), 3.6 (t, 2H), 3.2 (s, 3H), 2.8 (m,2H), 2.55 (m, 2H). 13

LC-MS (method 11): R_(t) = 1.69 min MS (ESIpos): m/z = 600 (M + H⁺)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ = 9.0 (t, 1H), 7.7 (m, 2H), 7.6 (m,1H), 7.4 (dd, 1H), 7.35 (dd, 1H), 7.25 (d, 1H), 7.2 (d, 1H), 6.25 (t,1H), 4.85 (m, 1H), 4.2 (m, 2H), 4.1 (d, 1H), 3.9 (m, 1H), 3.6 (t, 2H),3.2 (s, 3H), 2.2-2.8 (m, 12H), 2.15 (s, 3H). 14

LC-MS (method 11): R_(t) = 1.91 min MS (ESIpos): m/z = 545 (M + H⁺)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ = 9.0 (t, 1H), 7.7 (m, 2H), 7.6 (m,1H), 7.4 (m, 2H), 7.25 (d, 1H), 7.2 (d, 1H), 6.25 (t, 1H), 4.85 (m, 1H),4.2 (m, 2H), 4.1 (d, 1H), 3.9 (m, 1H), 3.6 (t, 2H), 3.2 (s, 3H), 2.3-2.7(m, 4H), 2.15 (s, 6H). 15

LC-MS (method 11): R_(t) = 1.87 min MS (ESIpos): m/z = 587 (M + H⁺)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ = 9.0 (t, 1H), 7.7 (m, 2H), 7.6 (m,1H), 7.4 (dd, 1H), 7.35 (dd, 1H), 7.25 (d, 1H), 7.2 (d, 1H), 6.25 (t,1H), 4.85 (m, 1H), 4.2 (m, 2H), 4.1 (d, 1H), 3.9 (m, 1H), 3.6 (t, 2H),3.55 (m, 4H), 3.2 (s, 3H), 2.3-2.8 (m, 8H). 16

LC-MS (method 11): R_(t) = 1.89 min MS (ESIpos): m/z = 575 (M + H⁺)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ = 9.0 (t, 1H), 7.7 (m, 2H), 7.6 (m,1H), 7.4 (dd, 1H), 7.35 (dd, 1H), 7.25 (d, 1H), 7.2 (d, 1H), 6.25 (t,1H), 4.85 (m, 1H), 4.2 (m, 2H), 4.1 (d, 1H), 3.9 (m, 1H), 3.6 (t, 2H),3.45 (t, 2H), 3.2 (s, 3H), 2.7 (t, 2H), 2.4-2.6 (m, 6H), 1.5 (m, 2H). 17

LC-MS (method 11): R_(t) = 1.89 min MS (ESIpos): m/z = 601 (M + H⁺)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ = 9.0 (t, 1H), 7.7 (m, 2H), 7.6 (m,1H), 7.4 (dd, 1H), 7.35 (dd, 1H), 7.25 (d, 1H), 7.2 (d, 1H), 6.25 (t,1H), 4.85 (m, 1H), 4.2 (m, 2H), 4.1 (d, 1H), 3.9 (m, 1H), 3.6 (t, 2H),3.45 (m, 1H), 3.2 (s, 3H), 2.7 (m, 2H), 2.3-2.6 (m, 4H), 2.0 (t, 2H),1.7 (m, 2H), 1.3 (m, 2H).

Example 185-Chloro-N-{[(5S)-3-{4-[3-{3-[(trans-4-hydroxycyclohexyl)amino]propyl}-2-oxopyridin-1(2H)-yl]-3-methylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

92.4 mg (0.18 mmol) of Example 38A are dissolved in 4.5 ml of anhydrousdichloromethane and cooled to −78° C., and 67 mg (0.55 mmol) of2,6-dimethylpyridine and 78 mg (0.28 mmol) of trifluoromethanesulphonicanhydride are added. After 1 h at −78° C., 106 mg (0.920 mmol) oftrans-4-aminocyclohexanol are added, cooling is removed and the mixtureis stirred at room temperature for 72 h. After addition of 2.5 ml ofmethanol, the mixture is stirred for 5 min and the solvent is thenremoved under reduced pressure. The residue is purified by preparativeHPLC using a gradient of acetonitrile and 0.2% strengthtrifluoromethanesulphonic acid in water. This gives 7.5 mg (7% oftheory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.99 (t, 1H), 8.37-8.21 (m, 2H),7.70 (d, 1H), 7.58-7.47 (m, 2H), 7.45-7.36 (m, 2H), 7.22 (d, 1H), 7.20(d, 1H), 6.32 (dd, 1H), 4.92-4.78 (m, 1H), 4.21 (dd, 1H), 4.00-3.48 (m,4H), 3.41-3.30 (m, 1H), 2.98-2.85 (m, 2H), 2.02 (s, 3H), 2.00-1.91 (m,2H), 1.88-1.80 (m, 4H), 1.37-1.15 (m, 6H).

LC-MS (method 6): R_(t)=1.45 min

MS (ESIpos): m/z=601 (M+H)⁺

Example 195-Chloro-N-{[(5S)-3-{4-[3-{3-[(2-hydroxyethyl)amino]propyl}-2-oxopyridin-1(2H)-yl]-3-methyl-phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

92.4 mg (0.18 mmol) of Example 38A are dissolved in 4.5 ml of anhydrousdichloromethane and cooled to −78° C., and 67 mg (0.55 mmol) of2,6-dimethylpyridine and 78 mg (0.28 mmol) of trifluoromethanesulphonicanhydride are added. After 1 h at −78° C., 112 mg (1.84 mmol) ofaminoethanol are added, cooling is removed and the mixture is stirred atroom temperature for 72 h. After addition of 2.5 ml of methanol, themixture is stirred for 5 min and the solvent is then removed underreduced pressure. The residue is purified by preparative HPLC using agradient of acetonitrile and 0.2% strength trifluoromethanesulphonicacid in water. This gives 14 mg (14% of theory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.99 (t, 1H), 8.51-8.37 (m, 2H),7.70 (d, 1H), 7.58-7.47 (m, 2H), 7.45-7.38 (m, 2H), 7.22 (d, 1H), 7.20(d, 1H), 6.32 (dd, 1H), 4.91-4.82 (m, 1H), 4.22 (dd, 1H), 3.95-3.50 (m,7H), 3.05-2.89 (m, 4H), 2.02 (s, 3H), 1.93-1.82 (m, 2H).

LC-MS (method 6): R_(t)=1.45 min

MS (ESIpos): m/z=546 (M+H)⁺

Example 205-Chloro-N-{[(5S)-3-{3-methyl-4-[2-oxo-3-{2-[(tetrahydrofuran-2-ylmethyl)amino]ethoxy}pyridin-1(2H)-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

80.0 mg (153 μmol) of Example 46A, 23 mg (153 μmol) of sodium iodide and105 μl (77.4 mg, 766 μmol) of 1-(tetrahydrofuran-2-yl)methanamine in 2ml of absolute 1,2-dimethoxyethane are stirred at 90° C. for 8 hours.For work-up, the concentrated reaction solution is subjected to finepurification by preparative RP-HPLC using an acetonitrile/water mixture.This gives 60 mg (67% of theory) of product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.97 (t, 1H), 7.69 (d, 1H), 7.55-7.46(m, 2H), 7.25-7.18 (m, 2H), 7.04 (d, 1H), 6.93 (d, 1H), 6.21 (t, 1H),4.87 (m, 1H), 4.22 (dd, 1H), 3.97 (m, 2H), 3.90-3.81 (m, 2H), 3.72 (m,2H), 3.66-3.55 (m, 3H), 2.90 (m, 2H), 2.62 (d, 2H), 2.01 (s, 3H),1.95-1.80 (m, 3H), 1.57-1.96 (m, 1H).

LC-MS (method 3): R_(t)=1.45 min

MS (ESIpos): m/z=587 (M+H)⁺

Example 215-Chloro-N-{[(5S)-3-{4-[3-{2-[(trans-4-hydroxycyclohexyl)amino]ethoxy}-2-oxopyridin-1(2H)-yl]-3-methylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

70.0 mg (134 μmol) of Example 46A, 20.0 mg (134 μmol) of sodium iodideand 77.2 mg (670 μmol) of trans-4-aminocyclohexanol in 1.75 ml ofabsolute 1,2-dimethoxyethane are stirred at 90° C. for 8 hours. Forwork-up, the concentrated reaction solution is subjected to finepurification by preparative RP-HPLC using an acetonitrile/water mixture.This gives 57 mg (69% of theory) of product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.97 (t, 1H), 7.69 (d, 1H), 7.53-7.50(m, 2H), 7.23-7.18 (m, 2H), 7.04 (d, 1H), 6.92 (d, 1H), 6.22 (t, 1H),4.89-4.81 (m, 1H), 4.44 (d, 1H), 4.22 (t, 1H), 3.99-3.82 (m, 3H), 3.62(t, 3H), 2.87 (t, 2H), 2.41-2.31 (m, 1H), 2.01 (s, 3H), 1.80 (t, 4H),1.53 (bs, 1H), 1.19-0.93 (m, 4H).

LC-MS (method 3): R_(t)=1.41 min

MS (ESIpos): m/z=601 (M+H)⁺.

Using the appropriate amine, the examples of the table below areprepared analogously to Example 21.

Exam- ple Structure Characterization 22

LC-MS (method 3): R_(t) = 1.56 min, MS (ESIpos): m/z = 557 (M + H)⁺¹H-NMR (400 MHz, DMSO-d₆, δppm): 10.67 (broad s, 1H), 9.06 (t, 1H), 7.73(d, 1H), 7.58- 7.48 (m, 2H), 7.28-7.13 (m, 3H), 7.10 (d, 1H), 6.28 (t,1H), 4.86 (m, 1H), 4.32 (m, 2H), 4.22 (t, 1H), 3.90 (m, 1H), 3.68-3.53(m, 5H), 3.10 (m, 2H), 2.08-1.93 (m, 5H, darin 2.01 (s, 3H)), 1.92- 1.80(m, 2H). 23

LC-MS (method 11): R_(t) = 2.13 min, MS (ESIpos): m/z = 557 (M + H)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.97 (t, 1H), 7.69 (d, 1H), 7.55-7.46(m, 2H), 7.25- 7.18 (m, 2H), 7.04 (d, 1H), 6.92 (d, 1H), 6.21 (t, 1H),4.87 (m, 1H), 4.22 (dd, 1H), 3.97-3.83 (m, 3H), 3.60 (t, 2H), 3.20 (m,1H), 2.80 (t, 2H), 2.16-2.05 (m, 2H), 2.01 (s, 3H), 1.72-1.48 (m, 4H).24

LC-MS (method 11): R_(t) = 2.03 min, MS (ESIpos): m/z = 543 (M + H)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.97 (t, 1H), 7.69 (d, 1H), 7.55-7.46(m, 2H), 7.25- 7.18 (m, 2H), 7.04 (d, 1H), 6.21 (d, 1H), 6.72 (t, 1H),4.87 (m, 1H), 4.22 (dd, 1H), 3.98 (m, 2H), 3.89 (m, 1H), 3.60 (t, 2H),2.94 (t, 2H), 2.14 (m, 1H), 2.01 (s, 3H), 0.38 (m, 2H), 0.22 (m, 2H). 25

LC-MS (method 11): R_(t) = 2.03 min, MS (ESIpos): m/z = 621 (M + H)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.97 (broad s, 1H), 7.70 (d, 1H),7.55-7.46 (m, 2H), 7.25-7.18 (m, 2H), 7.06 (d, 1H), 6.95 (d, 1H), 6.21(t, 1H), 4.86 (m, 1H), 4.22 (dd, 1H), 4.03 (m, 2H), 3.78 (m, 1H), 3.61(t, 2H), 3.12-2.98 (m, 8H), 2.93 (t, 2H), 2.01 (s, 3H). 26

LC-MS (method 11): R_(t) = 2.03 min, MS (ESIpos): m/z = 621 (M + H)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.96 (t, 1H), 7.70 (d, 1H), 7.55-7.46(m, 2H), 7.25- 7.18 (m, 2H), 7.06 (d, 1H), 6.92 (d, 1H), 6.70 (t, 1H),4.86 (m, 1H), 4.22 (dd, 1H), 3.95 (m, 2H), 3.88 (m, 1H), 3.78-3.50 (m,7H), 3.41 (td, 1H), 3.18 (t, 1H), 2.82 (m, 2H), 2.65-2.45 (m, 4H), 2.02(s, 3H), 0.95 (t, 3H). 27

LC-MS (method 6): R_(t) = 1.41 min, MS (ESIpos): m/z = 586 (M + H)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.97 (t, 1H), 7.70 (d, 1H), 7.55-7.46(m, 2H), 7.25- 7.18 (m, 2H), 7.06 (d, 1H), 6.95 (d, 1H), 6.22 (t, 1H),4.86 (m, 1H), 4.22 (dd, 1H), 4.03 (m, 2H), 3.88 (m, 1H), 3.61 (t, 2H),2.68 (t, 2H), 2.48 (m, 4H), 2.29 (m, 4H), 2.15 (s, 3H), 2.01 (s, 3H). 28

LC-MS (method 6): R_(t) = 1.43 min, MS (ESIpos): m/z = 503 (M + H)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.97 (t, 1H), 7.70 (d, 1H), 7.55-7.46(m, 2H), 7.25- 7.18 (m, 2H), 7.06 (d, 1H), 6.92 (d, 1H), 6.21 (t, 1H),4.86 (m, 1H), 4.22 (dd, 1H), 3.93-3.80 (m, 3H), 3.61 (t, 2H), 2.88 (t,2H), 2.02 (s, 3H). 29

LC-MS (method 6): R_(t) = 1.44 min, MS (ESIpos): m/z = 561 (M + H)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.96 (t, 1H), 7.69 (d, 1H), 7.56-7.44(m, 2H), 7.26- 7.15 (m, 2H), 7.05 (d, 1H), 6.92 (d, 1H), 6.22 (t, 1H),4.86 (m, 1H), 4.21 (dd, 1H), 3.97 (m, 2H), 3.88 (m, 1H), 3.61 (t, 2H),3.38 (t, 2H), 3.22 (s, 3H), 2.88 (t, 2H), 2.72 (t, 2H), 2.02 (s, 3H). 30

LC-MS (method 11): R_(t) = 2.14 min, MS (ESIpos): m/z = 601 (M + H)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.96 (t, 1H), 7.69 (d, 1H), 7.56-7.47(m, 2H), 7.26- 7.15 (m, 2H), 7.04 (d, 1H), 6.92 (d, 1H), 6.21 (t, 1H),4.86 (m, 1H), 4.21 (dd, 1H), 4.07-3.83 (m, 3H), 3.61 (t, 2H), 3.38-3.13(m, 5H: darin 3.26 (s, 3H)), 3.09 (m, 1H), 2.65 (m, 2H), 2.28 (m, 1H),2.02 (s, 3H), 1.38-1.75 (m, 1H), 1.72-1.57 (m, 2H), 1.49- 1.39 (m, 1H).31

LC-MS (method 3): R_(t) = 1.40 min, MS (ESIpos): m/z = 547 (M + H)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.98 (t, 1H), 7.70 (d, 1H), 7.55-7.46(m, 2H), 7.25- 7.17 (m, 2H), 7.05 (d, 1H), 6.97 (d, 1H), 6.24 (t, 1H),4.86 (m, 1H), 4.61 (m, 1H), 4.22 (dd, 1H), 4.02 (m, 2H), 3.88 (m, 1H),3.61 (t, 2H), 3.48 (m, 2H), 2.98 (m, 2H), 2.72 (t, 2H), 2.02 (s, 3H). 32

LC-MS (method 3): R_(t) = 1.33 min, MS (ESIpos): m/z = 587 (M + H)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.97 (t, 1H), 7.70 (d, 1H), 7.54-7.47(m, 2H), 7.25- 7.17 (m, 2H), 7.05 (d, 1H), 6.93 (d, 1H), 6.21 (t, 1H),4.86 (m, 1H), 4.22 (dd, 1H), 4.02 (m, 2H), 3.70-3.57 (m, 6H), 2.89 (t,2H), 2.75 (m, 4H), 2.02 (s, 3H), 1.78 (m, 2H). 33

LC-MS (method 6): R_(t) = 1.46 min, MS (ESIpos): m/z = 575 (M + H)⁺¹H-NMR (400 MHz, DMSO-d₆, δ/ppm). 8.96 (t, 1H), 7.69 (d, 1H), 7.55-7.46(m, 2H), 7.25- 7.17 (m, 2H), 7.05 (d, 1H), 6.93 (d, 1H), 6.21 (t, 1H),4.86 (m, 1H), 4.22 (dd, 1H), 4.02 (m, 2H), 3.88 (m, 1H), 3.62 (t, 3H),3.41 (t, 2H), 3.25 (s, 3H), 2.75 (m, 2H), 2.58 (t, 2H), 2.28 (s, 3H),2.02 (s, 3H).

Example 345-Chloro-N-{[(5S)-3-(4-{3-[2-(4-hydroxypiperidin-1-yl)ethoxy]-2-oxopyridin-1(2H)-yl}-3-methylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

88.0 mg (175 μmol) of Example 45A are dissolved in 5 ml of anhydrousdichloromethane and cooled to −78° C., and 42 μl (69.7 mg, 244 μmol) oftrifluoromethanesulphonic anhydride and 56 mg (524 μmol) of2,6-dimethylpyridine are added. After one hour of stirring at −78° C.,another 15 μl (24.7 mg, 88 μmol) of trifluoromethanesulphonic anhydrideare added dropwise, and the mixture is stirred at this temperature foranother half an hour. At −78° C., 180 mg (1.74 mmol) of4-hydroxypiperidine are then added to the reaction, and the mixture isstirred for 5 minutes, warmed to room temperature and stirred at thistemperature overnight. For work-up, the reaction is concentrated on arotary evaporator and the residue is purified twice by preparativeRP-HPLC using an acetonitrile/water mixture. This gives 30.0 mg (29% oftheory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): 8.96 (t, 1H), 8.15 (s, 1H), 7.69 (d,1H), 7.55-7.46 (m, 2H), 7.25-7.15 (m, 2H), 7.04 (d, 1H), 6.93 (d, 1H),6.21 (t, 1H), 4.86 (m, 1H), 4.22 (dd, 1H), 4.01 (m, 2H), 3.92-3.84 (m,1H), 3.62 (t, 2H), 3.45 (m, 1H), 2.80 (m, 2H), 2.70 (t, 2H), 2.17 (m,2H), 2.01 (s, 3H), 1.75-1.64 (m, 2H), 1.45-1.32 (m, 2H).

LC-MS (method 3): R_(t)=1.38 min

MS (ESIpos): m/z=587 (M+H)⁺

Example 355-Chloro-N-{[(5S)-3-{4-[3-{2-[(trans-4-hydroxycyclohexyl)amino]ethoxy}-2-oxopyridin-1(2H)-yl]-3-propylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

30 mg (54 μmol) of Example 58A, 8.2 mg (54 μmol) of sodium iodide and31.4 mg (272 μmol) of trans-4-aminohexanol are initially charged in 750μl of 1,2-dimethoxyethane. The reaction is stirred at 90° C. for 8hours. For work-up, the reaction solution is concentrated completely ona rotary evaporator and subjected to fine purification by preparativeRP-HPLC using an acetonitrile/water mixture. This gives 15.0 mg (41% oftheory) of the product.

¹H-NMR (400 MHz, methanol-d₄, δ/ppm): 7.61 (dd, 1H), 7.52 (m, 2H), 7.20(d, 1H), 7.07 (d, 2H), 7.01 (d, 1H), 6.92 (t, 1H), 6.42 (t, 1H), 4.27(t, 1H), 4.08 (m, 2H), 3.98 (m, 1H), 3.73 (m, 2H), 3.58-3.45 (m, 1H),3.02 (m, 2H), 2.50 (m, 1H), 2.35 (m, 2H), 1.97 (m, 4H), 1.50 (m, 2H),1.38-1.11 (m, 5H), 0.83 (t, 3H).

LC-MS (method 8): R_(t)=2.06 min

MS (ESIpos): m/z=629 (M+H)⁺

Example 365-Chloro-N-{[(5S)-3-{4-[3-{2-[(2-hydroxyethyl)amino]ethoxy}-2-oxopyridin-1(2H)-yl]-3-propyl-phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

500 mg (0.908 mmol) of Example 58A, 142 mg (0.954 mmol) of sodium iodideand 277 mg (4.54 mmol) of 2-aminoethanol are dissolved in 8 ml of1,2-dimethoxyethane and stirred at 90° C. for 4 hours. The reactionsolution is concentrated and then taken up in 100 ml of dichloromethaneand water and stirred at RT for 1 h. The phases are separated, and theaqueous phase is extracted with dichloromethane. The combined organicphases are washed with saturated sodium chloride solution and then driedover sodium sulphate. The drying agent is filtered off, and the solventis removed completely on a rotary evaporator. The residue is purified bychromatography on silica gel (dichloromethane/ethanol 5:1; addition of0.1% by volume of ethyldimethylamine). This gives 241 mg (46% of theory)of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=9.01 (t, 1H), 7.70 (d, 1H),7.58-7.45 (m, 2H), 7.23-7.17 (m, 2H), 7.06 (dd, 1H), 6.95 (dd, 1H), 6.22(dd, 1H), 4.91-4.82 (m, 1H), 4.65-4.55 (m, 1H), 4.24 (dd, 1H), 4.10-3.85(m, 3H), 3.62 (dd, 2H), 3.52-3.43 (m, 2H), 2.93 (t, 2H), 2.68 (t, 2H),2.35-2.20 (m, 2H), 1.50-1.35 (m, 2H), 0.78 (t, 3H).

HPLC (method 2): R_(t)=4.00 min

MS (ESIpos): m/z=575 (M+H)⁺

Example 375-Chloro-N-{[(5S)-3-{4-[3-{2-[(2-hydroxyethyl)amino]ethyl}-2-oxopyridin-1(2H)-yl]-3,5-dimethylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

100 mg (0.20 mmol) of Example 65A are dissolved in 3 ml of anhydrousdichloromethane and cooled to −78° C., and 64 mg (0.59 mmol) of2,6-dimethylpyridine and 84 mg (0.29 mmol) of trifluoromethanesulphonicanhydride are added. After 1 h at −78° C., 121 mg (1.99 mmol) of2-aminoethanol are added, cooling is removed after 5 min and the mixtureis stirred at room temperature for 18 h. The solvent is then removedunder reduced pressure and the residue is purified twice by preparativeHPLC using a gradient of acetonitrile and 0.3% strength formic acid inwater. This gives 27 mg (25% of theory) of the desired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=9.01 (t, 1H), 8.30 (s, 1H), 7.70 (d,1H), 7.46 (d, 1H), 7.41-7.34 (m, 2H), 7.31 (d, 1H), 7.19 (d, 1H), 6.33(dd, 1H), 4.91-4.82 (m, 1H), 4.20 (dd, 1H), 3.86 (dd, 1H), 3.61 (t, 2H),3.54 (t, 2H), 2.94 (t, 2H), 2.81 (t, 2H), 2.72 (t, 2H), 1.96 (s, 6H).

LC-MS (method 12): R_(t)=1.22 min

MS (ESIpos): m/z=545 (M+H)⁺

Example 385-Chloro-N-{[(5S)-3-{4-[3-{2-[(trans-4-hydroxycyclohexyl)amino]ethyl}-2-oxopyridin-1(2H)-yl]-3,5-dimethylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

100 mg (0.20 mmol) of Example 65A are dissolved in 3 ml of anhydrousdichloromethane and cooled to −78° C., and 64 mg (0.59 mmol) of2,6-dimethylpyridine and 84 mg (0.29 mmol) of trifluoromethanesulphonicanhydride are added. After 1 h at −78° C., 114 mg (0.97 mmol) oftrans-4-aminohexanol are added, cooling is removed after 5 min and themixture is stirred at room temperature for 18 h. The solvent is thenremoved under reduced pressure and the residue is purified twice bypreparative HPLC using a gradient of acetonitrile and 0.3% strengthformic acid in water. This gives 15 mg (13% of theory) of the desiredcompound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=9.00 (t, 1H), 8.28 (s, 1H), 7.70 (d,1H), 7.51-7.42 (m, 1H), 7.41-7.34 (m, 2H), 7.31 (d, 1H), 7.19 (d, 1H),6.33 (dd, 1H), 4.91-4.82 (m, 1H), 4.20 (t, 1H), 3.86 (dd, 1H), 3.64-3.55(m, 2H), 3.52 (dd, 1H), 3.38-3.29 (m, 2H), 2.95-2.86 (m, 2H), 2.78 (dd,1H), 2.74-2.60 (m, 3H), 1.96 (s, 6H), 1.94-1.75 (m, 2H), 1.20-1.10 (m,3H). The spectrum contains signals of formic acid and/or the formate ofthe title compound.

LC-MS (method 12): R_(t)=1.24 min

MS (ESIpos): m/z=599 (M+H)⁺

Alternative Synthesis 1:

600 mg (1.19 mmol) of Example 65A are dissolved in 18 ml of anhydrousdichloromethane and cooled to −78° C., and 384 mg (3.58 mmol) of2,6-dimethylpyridine and 573 mg (2.03 mmol) of trifluoromethanesulphonicanhydride are added. After 1 h at −78° C., 688 mg (5.97 mmol) oftrans-4-aminohexanol are added, cooling is removed after 5 min and themixture is stirred at room temperature for 18 h. The solvent is thenremoved under reduced pressure and the residue is purified bypreparative HPLC using a 1:1 mixture of acetonitrile/0.1% strengthdiisopropylethylamine in water. This gives 263 mg (36% of theory) of thedesired compound.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.98 (t, 1H), 7.70 (d, 1H),7.48-7.33 (m, 3H), 7.25 (d, 1H), 7.19 (d, 1H), 6.28 (dd, 1H), 4.91-4.82(m, 1H), 4.44 (d, 1H), 4.20 (t, 1H), 3.86 (dd, 1H), 3.64-3.55 (m, 2H),2.72 (dd, 2H), 2.64-2.50 (m, 3H), 2.35-2.23 (m, 1H), 1.96 (s, 6H),1.82-1.71 (m, 4H), 1.20-0.89 (m, 4H).

LC-MS (method 14): R_(t)=0.83 min

MS (ESIpos): m/z=599 (M+H)⁺

Alternative Synthesis 2:

39 g (77 mmol) of Example 65A (alternative synthesis) are dissolved in1.171 of anhydrous dichloromethane and cooled to below −60° C. First,24.9 g (233 mmol) of 2,6-dimethylpyridine are added, and 22.3 ml (132mmol) of trifluoromethanesulphonic anhydride are then added dropwise.After 15 min at −70° C., a solution of 46.1 g (388 mmol) oftrans-4-aminohexanol in 360 ml of dichloromethane and 360 ml ofisopropanol is then added quickly at below −50° C. The mixture isstirred in a dry-ice bath for 15 min, and the cooling bath is thenremoved. After 3 h, the solvent is removed under reduced pressure andthe residue is purified by chromatography on silica gel(dichloromethane/methanol/25% strength ammonia solution 9:1:0.2). Theproduct-containing fractions are combined, freed from the solvent andre-purified by chromatography on silica gel(dichloromethane/methanol/25% strength ammonia solution 9:1:0.2). Theproduct-containing fractions are combined and freed from the solventunder reduced pressure. To remove any methanol still present, twice, ineach case 130 ml of water are added and the solvent is then removed at50° C. under reduced pressure, and the product is dried under highvacuum. This gives 34.1 g (73% of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.98 (t, 1H), 7.70 (d, 1H),7.48-7.33 (m, 3H), 7.25 (d, 1H), 7.19 (d, 1H), 6.28 (dd, 1H), 4.91-4.82(m, 1H), 4.44 (d, 1H), 4.20 (t, 1H), 3.86 (dd, 1H), 3.64-3.55 (m, 2H),2.72 (dd, 2H), 2.64-2.50 (m, 3H), 2.35-2.23 (m, 1H), 1.96 (s, 6H),1.82-1.71 (m, 4H), 1.20-0.89 (m, 4H).

Example 395-Chloro-N-{[(5S)-3-{4-[3-{2-[(trans-4-hydroxycyclohexyl)amino]ethoxy}-2-oxopyridin-1(2H)-yl]-3,5-dimethylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

211 mg (0.393 mmol) of Example 73A, 62 mg (0.41 mmol) of sodium iodideand 226 mg (1.97 mmol) of trans-4-aminohexanol are initially charged in3.5 ml of 1,2-dimethoxyethane. The reaction is stirred at 90° C. for 15hours. For work-up, the reaction solution is concentrated completely ina rotary evaporator and then taken up in a dichloromethane/water mixtureand stirred at RT for 10 min. After phase separation, the aqueous phaseis extracted with dichloromethane. The combined organic phases arewashed with a saturated aqueous sodium chloride solution. After dryingover sodium sulphate, the drying agent is filtered off and the solventis removed completely on a rotary evaporator. The residue ispre-purified by chromatography on silica gel (dichloromethane/ethanol10:1, addition of 1% ethyldimethylamine). Subsequent purification bypreparative HPLC using an acetonitrile/water mixture gives 104 mg (43%of theory) of the desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=8.99 (t, 1H), 7.61 (dd, 1H),7.43-7.36 (m, 2H), 7.20 (d, 1H), 7.15-7.07 (m, 2H), 6.34 (t, 1H),4.88-4.80 (m, 1H), 4.23-4.15 (m, 3H), 3.92-3.65 (m, 1H), 3.61 (dd, 4H),3.40-3.31 (m, 3H), 3.13-3.03 (m, 1H), 2.07-1.95 (m, 2H), 1.96 (s, 6H),1.88-1.80 (m, 2H), 1.41-130 (m, 2H), 1.23-1.12 (m, 2H).

HPLC (method 2): R_(t)=3.84 min

MS (ESIpos): m/z=615 (M+H)⁺

Example 405-Chloro-N-{[(5S)-3-{4-[3-{2-[(2-hydroxyethyl)amino]ethoxy}-2-oxopyridin-1(2H)-yl]-3,5-dimethylphenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

255 mg (0.475 mmol) of Example 73A, 74 mg (0.50 mmol) sodium iodide and145 mg (2.38 mmol) of 2-aminoethanol are dissolved in 4.2 ml of1,2-dimethoxyethane and stirred at 90° C. for 15 hours. For work-up, thereaction solution is concentrated completely on a rotary evaporator andthe residue is taken up in 100 ml of a dichloromethane/water mixture andstirred at RT for 10 min. After phase separation, the aqueous phase isextracted with dichloromethane. The combined organic phases are washedwith a saturated aqueous sodium chloride solution. After drying oversodium sulphate, the drying agent is filtered off and the solvent isremoved completely on a rotary evaporator. The residue is purified bychromatography on silica gel (dichloromethane/ethanol 10:1->5:1,addition of 1% ethyldimethylamine). This gives 168 mg (58% of theory) ofthe desired product.

¹H-NMR (400 MHz, DMSO-d₆, δ/ppm): δ=9.07 (t, 1H), 7.78-7.72 (m, 1H),7.41-7.35 (m, 2H), 7.20 (d, 1H), 7.08-7.02 (m, 2H), 6.31 (dd, 1H),4.92-4.81 (m, 1H), 4.22-4.12 (m, 2H), 3.92-3.86 (dd, 1H), 3.63-3.56 (m,4H), 3.40-3.27 (m, 3H), 3.23-3.17 (m, 2H), 2.97-2.92 (m, 2H), 1.96 (s,6H).

HPLC (method 2): R_(t)=3.80 min

MS (ESIpos): m/z=561 (M+H)⁺

B. Evaluation Of the Pharmacological Activity

The suitability of the compounds according to the invention for treatingthromboembolic disorders can be demonstrated using the following assaysystems:

a) Test Descriptions (In Vitro)

a.1) Measurement of the Factor Xa Inhibition in Buffer

To determine the factor Xa inhibition of the substances listed above, abiological test system is constructed in which the conversion of afactor Xa substrate is used for determining the enzymatic activity ofhuman factor Xa. Here, factor Xa cleaves aminomethylcoumarin, which ismeasured fluorescently, from the peptidic substrate. The determinationsare carried out in microtitre plates.

Substances to be tested are dissolved in various concentrations indimethyl sulphoxide and incubated for 30 min with human factor Xa (1.3nmol/l dissolved in 50 mmol/l of Tris buffer[C,C,C-tris(hydroxymethyl)aminomethane], 100 mmol/l of sodium chloride,5 mmol/l of calcium chloride, 0.1% BSA [bovine serum albumin], pH 7.4)at 22° C. The substrate (5 μmol/l Boc-Ile-Glu-Gly-Arg-AMC from Bachem)is then added. After 30 min of incubation, the sample is excited at awavelength of 360 nm and the emission is measured at 460 nm. Themeasured emissions of the test batches with test substance are comparedto the control batches without test substance (only dimethyl sulphoxideinstead of test substance in dimethyl sulphoxide) and the IC₅₀ valuesare calculated from the concentration/activity relationships.

a.2) Measurement of Thrombin Inhibition in Buffer

To determine the thrombin inhibition of the substances listed above, abiological test system is constructed in which the conversion of athrombin substrate is used for determining the enzymatic activity ofhuman thrombin. Here, thrombin cleaves aminomethylcoumarin, which ismeasured fluorescently, from the peptidic substrate. The determinationsare carried out in microtitre plates.

Substances to be tested are dissolved in various concentrations indimethyl sulphoxide and incubated for 15 min with human thrombin (0.06nmol/l dissolved in 50 mmol/l of Tris buffer[C,C,C-tris(hydroxymethyl)aminomethane], 100 mmol/l of sodium chloride,0.1% BSA [bovine serum albumin], pH 7.4) at 22° C. The substrate (5μmol/l Boc-Asp(OBzl)-Pro-Arg-AMC from Bachem) is then added. After 30min of incubation, the sample is excited at a wavelength of 360 nm andthe emission is measured at 460 nm. The measured emissions of the testbatches with test substance are compared to the control batches withouttest substance (only dimethyl sulphoxide instead of test substance indimethyl sulphoxide) and the IC₅₀ values are calculated from theconcentration/activity relationships.

a.3) Determination of the Selectivity

To demonstrate the selectivity of the substances with respect tothrombin and factor Xa inhibition, the test substances are examined fortheir inhibition of other human serine proteases, such as factor XIIa,factor XIa, trypsin and plasmin. To determine the enzymatic activity offactor XIIa (10 nmol/l from Kordia), factor XIa (0.4 nmol/l fromKordia), trypsin (83 mU/ml from Sigma) and plasmin (0.1 μg/ml fromKordia), these enzymes are dissolved (50 mmol/l of Tris buffer[C,C,C-tris(hydroxymethyl)aminomethane], 100 mmol/l of sodium chloride,0.1% BSA [bovine serum albumin], 5 mmol/l of calcium chloride, pH 7.4)and incubated for 15 min with test substance in various concentrationsin dimethyl sulphoxide and also with dimethyl sulphoxide without testsubstance. The enzymatic reaction is then started by addition of theappropriate substrates (5 μmol/l of H-Pro-Phe-Arg-AMC from Bachem forfactor XIIa, 5 μmol/l of Boc-Ile-Glu-Gly-Arg-AMC from Bachem forTrypsin, 5 μmol/l of Boc-Glu(OBzl)-Ala-Arg-AMC from Bachem for factorXIa, 50 μmol/l of MeOSuc-Ala-Phe-Lys-AMC from Bachem for plasmin). Afteran incubation time of 30 min at 22° C., fluorescence is measured(excitation: 360 nm, emission: 460 nm). The measured emissions of thetest batches with test substance are compared to the control batcheswithout test substance (only dimethyl sulphoxide instead of testsubstance in dimethyl sulphoxide), and the IC₅₀ values are calculatedfrom the concentration/activity relationships.

a.4) Determination of the Factor Xa-inhibitory Activity of the PotentialInhibitors in Plasma Samples

To determine the inhibition of factor Xa in plasma samples, the factor Xpresent in plasma is activated by a protease from rattlesnake toxin. Thefactor Xa activity or its inhibition by potential inhibitors is thenmeasured by addition of a chromogenic substrate.

Various concentrations of the substances to be tested are dissolved indimethyl sulphoxide and mixed with an aqueous refludan solution (10μg/ml). In clear 96-well plates having a flat bottom, 30 μl of citrateplasma (Octapharma) are mixed with 10 μl of the substance dilution.Then, either 20 μl of a solution of a rattlesnake toxin (Russel vipervenom (RVV); RVV reagent: Pentapharm 121-06, final concentration 0.6 mU)in an aqueous calcium chloride solution buffer (final concentration ofcalcium chloride 0.05 M) or 20 μl of the aqueous calcium chloridesolution (final concentration of calcium chloride 0.05 M) without RVVreagent (as reference for an unstimulated sample) are added. Afteraddition of 20 μl of ChromozymX substrate (final concentration 1.6mmol/l, Bachem L-1565, diluted in water) the samples are measured in aSpectraFluor Reader using a measurement filter of 405 nm each minuteover a period of 20 minutes. The IC₅₀ value is determined when about 70%of the maximum signal is reached (about 12 min).

Representative activity data from this test are listed in Table 1 below:

TABLE 1 Example No. IC₅₀ [nM] 6 31 9 11 10 15 13 17 16 18 21 11 36 29 3729 38 34a.5) Determination of the Thrombin-inhibitory Activity of the PotentialInhibitors in Plasma Samples

Various concentrations of the substances to be tested are dissolved indimethyl sulphoxide and diluted with water. In white 96-well plateshaving a flat bottom, 20 μl of substance dilution are mixed with 20 μlof ecarin solution (ecarin reagent, from Sigma E-0504, finalconcentration 20 mU per batch) in Ca buffer (200 mM Hepes+560 mM sodiumchloride+10 mM calcium chloride+0.4% PEG) or with 20 μl of Ca buffer (asunstimulated control). Furthermore, 20 μl of fluorogenic thrombinsubstrate (from Bachem I-1120, final concentration 50 μmol/l) and 20 μlof citrate plasma (from Octapharma) are added and homogenizedthoroughly. The plate is measured in a SpectraFluorplus Reader using anexcitation filter of 360 nm and an emission filter of 465 nm each minuteover a period of 20 minutes. The IC₅₀ value is determined when about 70%of the maximum signal is reached (about 12 min).

Representative activity data from this test are listed in Table 2 below:

TABLE 2 Example No. IC₅₀ [nM] 6 143 9 10 10 24 13 16 16 10 21 34 36 3637 15 38 30a.6) Thrombin Generation Assay (Thrombogram)

The effect of the test substances on the thrombogram (thrombingeneration assay according to Hemker) is determined in vitro in humanplasma (Octaplas® from Octapharma). In the thrombin generation assayaccording to Hemker, the activity of thrombin in coagulating plasma isdetermined by measuring the fluorescent cleavage products of thesubstrate I-1140 (Z-Gly-Gly-Arg-AMC, Bachem). Reagents fromThrombinoscope (PPP reagent: 30 μM recombinant tissue factor, 24 μMphospholipids in HEPES) are used to start the coagulation reaction. Thereaction is carried out in the presence of varying concentrations oftest substance or the corresponding solvent. Moreover, a thrombincalibrator from Thrombinoscope is used whose amidolytic activity isrequired for calculating the thrombin activity in a plasma sample.

The test is carried out according to the specifications of themanufacturer (Thrombinoscope BV): 4 μl of the test substance or of thesolvent, 76 μl of plasma and 20 μl of PPP reagent or thrombin calibratorare incubated at 37° C. for 5 min. After addition of 20 μl of 2.5 mMthrombin substrate in 20 mM Hepes, 60 mg/ml of BSA, 102 mM calciumchloride, the thrombin generation is measured every 20 s over a periodof 120 min. Measurement is carried out using a fluorometer (FluoroskanAscent) from Thermo Electron fitted with a 390/460 nm filter pair and adispenser. Using the Thrombinoscope software, the thrombogram iscalculated and presented graphically. What is calculated are thefollowing parameters: lag time, time to peak, peak, ETP (endogenousthrombin potential) and start tail.

a.7) Determination of the Anticoagulatory Activity

The anticoagulatory activity of the test substances is determined invitro in human plasma, rabbit plasma and rat plasma. To this end, bloodis drawn off in a mixing ratio of sodium citrate/blood of 1/9 using a0.11 molar sodium citrate solution as receiver. Immediately after theblood has been drawn off, it is mixed thoroughly and centrifuged atabout 4000 g for 15 minutes. The supernatant is pipetted off.

The prothrombin time (PT, synonyms: thromboplastin time, quick test) isdetermined in the presence of varying concentrations of test substanceor the corresponding solvent using a commercial test kit (Neoplastin®from Boehringer Mannheim or Hemoliance® RecombiPlastin fromInstrumentation Laboratory). The test compounds are incubated with theplasma at 37° C. for 3 minutes. Coagulation is then started by additionof thromboplastin, and the time when coagulation occurs is determined.The concentration of test substance which effected a doubling of theprothrombin time is determined.

The thrombin time (TT) is determined in the presence of varyingconcentrations of test substance or the corresponding solvent using acommercial test kit (thrombin reagent from Roche). The test compoundsare incubated with the plasma at 37° C. for 3 minutes. Coagulation isthen started by addition of the thrombin reagent, and the time whencoagulation occurs is determined. The concentration of test substancewhich effects a doubling of the thrombin time is determined.

The activated partial thromboplastin time (APTT) is determined in thepresence of varying concentrations of test substance or thecorresponding solvent using a commercial test kit (PTT reagent fromRoche). The test compounds are incubated with the plasma and the PTTreagent (cephalin, kaolin) at 37° C. for 3 minutes. Coagulation is thenstarted by addition of 25 mM calcium chloride, and the time whencoagulation occurs is determined. The concentration of test substancewhich effects a doubling of the APTT is determined.

a.8) Thromboelastography (Thromboelastogram)

The thromboelastography is carried out with the aid of thethromboelastograph ROTEM from Pentapharm and its accessories, cup andpin. The measurement is carried out in whole blood drawn off beforehandinto sodium citrate monovettes from Sarstedt. The blood in themonovettes is kept in motion using a shaker and preincubated at 37° C.for 30 min. A 2 molar stock solution of calcium chloride in water isprepared. This is diluted 1:10 with an aqueous 0.9% strength sodiumchloride solution. For the measurement, 20 μl of this 200 mM calciumchloride solution are initially charged into the cups (finalconcentration of calcium chloride 12.5 mM). 3.2 μl of substance orsolvent are added. The measurement is started by addition of 300 μl ofwhole blood. After the addition, using the tip of the pipette, themixture is briefly drawn into the pipette and released again withoutgenerating air bubbles. The measurement is carried out over a period of2.5 hours or is stopped when fibrinolysis sets in. For evaluation, thefollowing parameters are determined: CT (clotting time/[sec.]), CFT(clotting formation time/[sec.]), MCF (maximum clot firmness/[mm]) andthe alpha angle [°]. The measurement points are determined every 3seconds and represented graphically, with the y axis for MCF [mm] andthe x axis for time [sec.].

a.9) Inhibition of the Thrombus-bound Coagulation Factors Thrombin andFactor Xa

Blood clots formed either prior to initiation of therapy withanticoagulants, during therapy breaks or in spite of therapy containlarge amounts of coagulation factors which may favour the progressingthrombus formation. These coagulation factors are bound firmly to thethrombus and cannot be washed out. In certain clinical situations, thismay result in a risk for the patient. In the tests carried out below,both thrombin and factor Xa having biological (procoagulatory) activitycan be demonstrated in human thrombi.

Thrombi Formed In Vitro

Thrombi are formed in vitro from human plasma and examined for theactivity of the bound coagulation factors thrombin and factor Xa. Tothis end, 300 μl of plasma are mixed with 30 μl of lipid vesicles and 30μl of an aqueous calcium chloride solution in a 48-well MTP plate andincubated for 30 min. This and the following steps are carried out at37° C. and with constant agitation (300 rpm). The thrombi formed aretransferred into a new 48-well MTP plate and washed twice with 0.9%strength sodium chloride solution over a period of 10 min, the thrombusbeing dabbed on filter paper during the washing steps. The thrombus istransferred into buffer B (Owens Veronal Buffer, 1% BSA) and incubatedfor 15 min, dabbed on filter paper and incubated in test substance ofvarious concentrations in buffer B for 30 min. The clots are then washedtwice as described above. The thrombi are dabbed and transferred intobuffer D: (240 μl Owren's Veronal Buffer, 1% BSA and 15.6 mM calciumchloride) and incubated with or without 0.6 μM prothrombin for 45 min.The reaction is stopped by addition of 75 μl of a 1% EDTA solution. Thethrombin activity is measured separately in the thrombus in buffer A(7.5 mM Na₂EDTA×2H₂O, 175 mM sodium chloride, 1% BSA, pH 8.4) or in thesupernatant from the last step. To this end, the substrate I-1120 inused in a final concentration of 50 μM, and the resulting fluorescenceis measured in a fluorescence plate reader (360/465 nm).

The activity of this thrombus-bound thrombin cannot be suppressed by aselective factor Xa inhibitor in therapeutically relevantconcentrations. In contrast, it can be inhibited with dual factorIIa/factor Xa inhibitors or a factor IIa reference inhibitor.

After addition of prothrombin, if thrombus-bound factor Xa is present(prothrombinase complex), new thrombin is formed which is detected bythe fluorescent substrate. This renewed formation of thrombin cannot beprevented by a pure thrombin inhibitor; however, it can be inhibited bydual factor IIa/factor Xa inhibitors or by the selective factor Xareference inhibitor.

The biological activity of the thrombus-bound thrombin activity istested by adding fluorescently labelled fibrinogen which, by activethrombin, is converted into fibrin and bound to the thrombus. To thisend, the thrombus is formed as described above and incubated in 250 μlof a fibrinogen solution (100 μg/ml) labelled with Alexa488 and 30 μl ofan aqueous 100 mM calcium chloride solution (with or without variousconcentrations of test substances). The fluorescence of the supernatantis measured in a fluorescence plate reader at a suitable wavelength.Moreover, the thrombi are washed four times with in each case 15 min andevaluated by fluorescence microscopy. The decrease of the fluorescencefrom the supernatant and the increase of the fluorescence of the thrombican be inhibited by dual factor IIa/factor Xa inhibitors, but not by thefactor Xa reference inhibitor.

Intracardial Thrombi Formed In Vivo (Patient Material)

The experiments are repeated with thrombi taken from the left ventricleof patients during heart surgery. To this end, the thrombi were thawedand divided into pieces (wet weight 10-100 mg). Depending on theprotocol, the thrombi are used after repeated washing or withoutwashing, and the thrombin activity is measured analogously to the methoddescribed above using the substrate I-1120 (final concentration 100 μM).

a.10) Specific Diagnosis of Impaired Coagulation and Organ Function inEndotoxaemic Mice and Rats

Thrombin/Antithrombin Complexes

Thrombin/antithrombin complexes (hereinbelow referred to as “TAT”) are ameasure for the thrombin formed endogenously by coagulation activation.TAT are determined using an ELISA assay (Enzygnost TAT micro,Dade-Behring). Plasma is obtained from citrate blood by centrifugation.50 μl of TAT sample buffer are added to 50 μl of plasma, and the sampleis shaken briefly and incubated at room temperature for 15 min. Thesamples are filtered off with suction, and the well is washed 3 timeswith wash buffer (300 μl/well). During the washings, the liquid isremoved by tapping the plate. Conjugate solution (100 μl) is added, andthe plate is incubated at room temperature for 15 min. The samples aresucked off, and the well is washed 3 times with wash buffer (300μl/well). Chromogenic substrate (100 μl/well) is then added, the plateis incubated in the dark at room temperature for 30 min, stop solutionis added (100 μl/well) and the colour development is measured at 492 nm(Saphire plate reader).

Parameters for Organ Function

Various parameters are determined who allow conclusions to be drawn withrespect to a restriction of the function of various internal organs byadministration of LPS and which allow the therapeutic effect of testsubstances to be estimated. Citrate blood or, if appropriate,lithium/heparin blood is centrifuged, and the parameters are determinedfrom the plasma. Typically, the following parameters are determined:creatinin, urea, aspartate aminotransferase (AST), alanineaminotransferase (ALT), total bilirubin, lactate dehydrogenase (LDH),total protein, total albumin and fibrinogen. The values give indicationsconcerning the function of the kidneys, the liver, the cardiovascularsystem and the blood vessels.

Parameters for Inflammation

The extent of the inflammatory reaction triggered by endotoxin can bedetected by the increase of inflammation mediators, for exampleinterleukins (1, 6, 8 and 10), tumour necrosis factor alpha or monocytechemoattractant protein-1 in the plasma. To this end, ELISAs or theluminex system may be used.

b) Determination of the Antithrombotic Activity (In Vivo)

b.1) Arteriovenous Shunt and Haemorrhage Model (Combi-model Rat)

Fasting male rats (strain: HSD CPB:WU) having a weight of 300-350 g areanaesthetized using Inactin (150-180 mg/kg). Thrombus formation isinitiated in an arteriovenous shunt in accordance with the methoddescribed by Christopher N. Berry et al., Br. J. Pharmacol. (1994), 113,1209-1214. To this end, the left jugular vein and the right carotidartery are exposed. The two vessels are connected by an extracorporealshunt using a polyethylene tube (PE 60) of a length of 10 cm. In themiddle, this polyethylene tube is attached to a further polyethylenetube (PE 160) of a length of 3 cm which contains a roughened nylonthread arranged to form a loop, to form a thrombogenic surface. Theextracorporeal circulation is maintained for 15 minutes. The shunt isthen removed and the nylon thread with the thrombus is weighedimmediately. The weight of the nylon thread on its own is determinedbefore the experiment is started.

To determine the bleeding time, immediately after opening of the shuntcirculation, the tip of the tail of the rats is docked by 3 mm using arazor blade. The tail is then placed into physiological saline kept at atemperature of 37° C., and the bleeding from the cut is observed over aperiod of 15 min. What is determined are the time until bleeding ceasesfor at least 30 seconds (initial bleeding time), total bleeding timeover a period of 15 minutes (cumulative bleeding time) and thequantitative blood loss via photometric determination of the collectedhaemoglobin.

Before the extracorporeal circulation is set up and the tip of the tailis docked, the test substances are administered to the animals whileawake either intravenously via the contralateral jugular vein as asingle bolus or as a bolus with subsequent continuous infusion or orallyusing a pharyngeal tube.

c) Solubility Assay

Reagents Required:

-   -   PBS buffer pH 7.4: 90.00 g of NaCl p.a. (for example Merck Art.        No. 1.06404.1000), 13.61 g of KH₂PO₄ p.a. (for example Merck        Art. No. 1.04873.1000) and 83.35 g of 1N NaOH (for example Bernd        Kraft GmbH Art. No. 01030.4000) are weighed into a 1 l measuring        flask, the flask is filled with water and the mixture is stirred        for about 1 hour.    -   Acetate buffer pH 4.6: 5.4 g of sodium acetate×3H₂O p.a. (for        example Merck Art. No. 1.06267.0500) are weighed into a 100 ml        measuring flask and dissolved in 50 ml of water, 2.4 g of        glacial acetic acid are added, the mixture is made up to 100 ml        with water, the pH is checked and, if required, adjusted to pH        4.6.    -   Dimethyl sulphoxide (for example Baker Art. No. 7157.2500)    -   Destilled water        Preparation of the Calibration Solutions:

Preparation of the stock solution for calibration solutions: About 0.5mg of the active compound are weighed accurately into a 2 ml EppendorfSafe-Lock tube (Eppendorf Art. No. 0030 120.094), DMSO is added to aconcentration of 600 μg/ml (for example 0.5 mg of active compound+833 μlof DMSO) and the mixture is vortexed until everything has gone intosolution.

Calibration solution 1 (20 μg/ml): 1000 μl of DMSO are added to 34.4 μlof the stock solution, and the mixture is homogenized.

Calibration solution 2 (2.5 μg/ml): 700 μl of DMSO are added to 100 μlof calibration solution 1, and the mixture is homogenized.

Preparation of the Sample Solutions:

Sample solution for solubilities of up to 10 g/l in PBS buffer pH 7.4:About 5 mg of the active compound are weighed accurately into a 2 mlEppendorf Safe-Lock tube (Eppendorf Art. No. 0030 120.094), and PBSbuffer pH 7.4 is added to a concentration of 5 g/l (for example 5 mg ofactive compound+500 μl of PBS buffer pH 7.4).

Sample solution for solubilities of up to 10 g/l in acetate buffer pH4.6: About 5 mg of the active compound are weighed accurately into a 2ml Eppendorf Safe-Lock tube (Eppendorf Art. No. 0030 120.094), andacetate buffer pH 4.6 is added to a concentration of 5 g/l (for example5 mg of active compound+500 μl of acetate buffer pH 4.6).

Sample solution for solubilities of up to 10 g/l in water: About 5 mg ofthe active compound are weighed accurately into a 2 ml EppendorfSafe-Lock tube (Eppendorf Art. No. 0030 120.094), and water is added toa concentration of 5 g/l (for example 5 mg of active compound+500 μl ofwater).

Practice:

The sample solutions prepared in this manner are shaken at 1400 rpm in atemperature-adjustable shaker (for example Eppendorf Thermomixer comfortArt. No. 5355 000.011 with interchangeable block Art. No. 5362.000.019)at 20° C. for 24 hours. In each case 180 μl are taken from thesesolutions and transferred into Beckman Polyallomer centrifuge tubes(Art. No. 343621). These solutions are centrifuged at about 223 000*gfor 1 hour (for example Beckman Optima L-90K ultracentrifuge with type42.2 Ti rotor at 42 000 rpm). From each of the sample solutions, 100 μlof the supernatant are removed and diluted 1:5, 1:100 and 1:1000 withthe respective solvent used (water, PBS buffer 7.4 or acetate buffer pH4.6). From each dilution, a sample is transferred into a vessel suitablefor HPLC analysis.

Analysis:

The samples are analysed by RP-HPLC. Quantification is carried out usinga two-point calibration curve of the test compound in DMSO. Thesolubility is expressed in mg/l.

Analysis Sequence:

-   Calibration solution 2.5 mg/ml-   Calibration solution 20 μg/ml-   Sample solution 1:5-   Sample solution 1:100-   Sample solution 1:1000    HPLC Method for Acids:

Agilent 1100 with DAD (G1315A), quat. pump (G1311A), autosampler CTC HTSPAL, degasser (G1322A) and column thermostat (G1316A); column:Phenomenex Gemini C18, 50×2 mm, 5μ; temperature: 40° C.; mobile phase A:water/phosphoric acid pH 2; mobile phase B: acetonitrile; flow rate: 0.7ml/min; gradient: 0-0.5 min 85% A, 15% B; ramp: 0.5-3 min 10% A, 90% B;3-3.5 min 10% A, 90% B; ramp: 3.5-4 min 85% A, 15% B; 4-5 min 85% A, 15%B.

HPLC Method for Bases:

Agilent 1100 with DAD (G1315A), quat. pump (G1311A), autosampler CTC HTSPAL, degasser (G1322A) and column thermostat (G1316A); column:VDSoptilab Kromasil 100 C18, 60×2.1 mm, 3.5μ; temperature: 30° C.;mobile phase A: water+5 ml perchloric acid/l; mobile phase B:acetonitrile; flow rate: 0.75 ml/min; gradient: 0-0.5 min 98% A, 2% B;ramp: 0.5-4.5 min 10% A, 90% B; 4.5-6 min 10% A, 90% B; ramp: 6.5-6.7min 98% A, 2% B; 6.7-7.5 min 98% A, 2% B.

d) Determination of Pharmacokinetics (In Vivo)

To determine the in vivo pharmacokinetics, the test substances aredissolved in various formulating compositions (for example plasma,ethanol, DMSO, PEG400, etc.) or mixtures of these solubilizers andadministered intravenously or perorally to mice, rats, dogs or monkeys.Intravenous administration is carried out either as a bolus injection oras an infusion. The doses administered are in the range from 0.1 to 5mg/kg. Blood samples are taken by means of a catheter or as sacrificeplasma at various times over a period of up to 26 h. Furthermore, insome cases, samples of organs, tissue and urine are also taken.Quantitative determination of the substances in the test samples takesplace using calibration samples adjusted in the matrix in question.Proteins present in the samples are removed by precipitation withacetonitrile or methanol. The samples are then fractionated by HPLCusing reversed-phase columns in a 2300 HTLC system (CohesiveTechnologies, Franklin, Mass., USA). The HPLC system is coupled via aturbo ion spray interface to an API 3000 Triple Quadropole massspectrometer (Applied Biosystems, Darmstadt, Germany). The plasmaconcentration time course is analysed using a validated kinetic analysisprogram.

The affinity of a substance for a transport protein is examined by invitro testing in a flux assay using Caco-2 cells or cells which areoverexpressed in a specific transporter (Troutman M D, Thakker D R,Pharm. Res. 20 (8) 1210-1224 (2003); Schwab D, Fischer H, Tabatabaei A,Poli S, Huwyler J, J. Med. Chem. 46, 1716-1725 (2003); Merino G, JonkerJ W, Wagenaar E, Pulido M M, Molina A J, Alvarez A I, Schinkel A H, DrugMetab. Dispos. 33 (5) 614-618 (2005)). To this end, the cells arecultivated on 24- or 96-well filter plates for 4 to 15 days. Todetermine the permeation, the substances in HEPES buffer are addedeither apically (A) or basally (B) to the cells, and the mixture isincubated for 2 h. After 0 h and 2 h, samples are taken from the cis-and trans-compartments and analysed by LC-MS/MS. The Papp value iscalculated using the formula published by Schwab et al. A substance isclassified as actively transported when the ratio of Papp (B−A)/Papp(A−B) is >2 or <0.5.

e) Determination of the Endotoxinaemia Activity (In Vivo)

The examination is carried out using rats or mice. In the mouse model(NMRI, male), LPS (Escherichia coli serotype 055:B5, Sigma-Aldrich) isinjected 50 mg/kg intraperitoneally. The test substances areadministered up to one hour prior to the LPS injection eitherintravenously via the tail vein, subcutaneously, intraperitoneally ororally using a stomach tube. Four hours after the LPS administration,the animal is anaesthetized (Ketavet/Rompun) and the abdomen is openedby surgery. Sodium citrate solution (3.2% w/v) (formula: body weight ing/13 times 100 μl) is injected into the lower vena carva, and a bloodsample (about 1 ml) is taken after 30 sec. Various parameters, forexample cellular blood components (in particular erythrocytes,leukocytes and platelets), lactate concentration, coagulation activation(TAT) or parameters of organ dysfunction or organ failure and mortalityare determined from the blood.

f) Description of the Method Used for DIC Tests on Rats

LPS (E. coli 055 B5, manufactured by Sigma, dissolved in PBS) isadministered to male Wistar rats at a dosage of 250 μg/kg intravenouslyinto the tail vein (administration volume 2 ml/kg). The test substanceis dissolved in PEG 400/H₂O 60%/40% and administered orally(administration volume 5 ml/kg) 30 minutes prior to the LPS injection.1, 5 or 4 hours after the LPS injection, the animals are exsanguinatedby puncture of the heart in terminal anaesthesia (Trapanal® 100 mg/kgi.p.), and citrate plasma is obtained for the determination offibrinogen, PT, TAT and platelet number. Optionally, serum is obtainedfor the determination of liver enzymes, kidney function parameters andcytokines. TNFα and IL-6 are determined using commercially availableELISAs (R&D Systems).

It is also possible to measure direct parameters of organ function, forexample left- and right-ventricular pressures, arterial pressures, urineexcretion, kidney perfusion and blood gases and acid/base state.

C. Exemplary Embodiments of Pharmaceutical Compositions

The compounds according to the invention can be converted intopharmaceutical preparations in the following ways:

Tablet:

Composition:

100 mg of the compound according to the invention, 50 mg of lactose(monohydrate), 50 mg of corn starch (native), 10 mg ofpolyvinylpyrrolidone (PVP 25) (from BASF, Ludwigshafen, Germany) and 2mg of magnesium stearate.

Tablet weight 212 mg. Diameter 8 mm, radius of curvature 12 mm.

Preparation:

The mixture of the compound according to the invention, lactose andstarch is granulated with a 5% strength solution (m/m) of PVP in water.The granules are dried and then mixed with the magnesium stearate for 5minutes. This mixture is compressed using a conventional tablet press(see above for format of the tablet). As guideline, a compressive forceof 15 kN is used for the compression.

Oral Suspension:

Composition:

1000 mg of the compound according to the invention, 1000 mg of ethanol(96%), 400 mg of Rhodigel® (xanthan gum from FMC, Pennsylvania, USA) and99 g of water.

10 ml of oral suspension are equivalent to a single dose of 100 mg ofthe compound according to the invention.

Preparation:

The Rhodigel is suspended in ethanol, and the compound according to theinvention is added to the suspension. The water is added while stirring.The mixture is stirred for about 6 h until the swelling of the Rhodigelis complete.

Oral Solution:

Composition:

500 mg of the compound according to the invention, 2.5 g of polysorbateand 97 g of polyethylene glycol 400.20 g of oral solution are equivalentto a single dose of 100 mg of the compound according to the invention.

Production:

The compound according to the invention is suspended in the mixture ofpolyethylene glycol and polysorbate while stirring. Stirring iscontinued until the compound according to the invention is completelydissolved.

i.v. Solution:

The compound according to the invention is dissolved at a concentrationbelow saturation solubility in a physiologically acceptable solvent (forexample isotonic sodium chloride solution, glucose solution 5% and/orPEG 400 solution 30%). The solution is sterilized by filtration andfilled into sterile and pyrogen-free injection containers.

1. A compound of the formula

in which R¹ represents chlorine, trifluoromethoxy, methyl, ethyl,n-propyl, methoxy, methoxymethyl or ethoxymethyl, R² represents hydrogenor methyl, and R³ represents a group of the formula

where * is the point of attachment to the oxopyridine ring, n representsthe number 1, 2, 3 or 4, m represents the number 1 or 2, R⁴ represents,methyl, ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl,3-hydroxyprop-1-yl, 2-methoxyeth-1-yl, 3-methoxyprop-1-yl,4-hydroxycyclohex-1-yl, tetrahydrofuran-2-ylmethyl or1,4-dioxan-2-ylmethyl, R⁵ represents hydrogen, methyl or ethyl, or R⁴and R⁵ together with the nitrogen atom to which they are attached form apyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring, amorpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a4-hydroxypiperidin-1-yl ring, R⁶ represents hydrogen, methyl, ethyl,cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl,2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl,tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl, R⁷ representshydrogen, methyl or ethyl, R⁶ and R⁷ together with the nitrogen atom towhich they are attached form a pyrrolidin-1-yl ring, a2-methoxymethylpyrrolidin-1-yl ring, a morpholin-4-yl ring, a1,1-dioxothiomorpholin-4-yl ring, a 1,4-oxazepan-4-yl ring, a4-methylpiperazin-1-yl or a 4-hydroxypiperidin-1-yl ring, or one of itssalt.
 2. A compound according to claim 1, wherein R¹ representschlorine, trifluoromethoxy, methyl, ethyl, n-propyl, methoxy ormethoxymethyl, R² represents hydrogen or methyl, and R³ represents agroup of the formula

where * is the point of attachment to the oxopyridine ring, n is thenumber 1, 2 or 3, m represents the number 1 or 2, R⁴ represents, methyl,ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl,2-methoxyeth-1-yl, 3 -methoxyprop-1-yl, 4-hydroxycyclohex-1-yl,tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl, R⁵ representshydrogen, methyl or ethyl, or R⁴ and R⁵ together with the nitrogen atomto which they are attached form a pyrrolidin-1-yl ring, a2-methoxymethylpyrrolidin-1-yl ring, a morpholin-4-yl ring, a1,1-dioxothiomorpholin-4-yl ring, a 1,4-oxazepan-4-yl ring, a4-methylpiperazin-1-yl or a 4-hydroxypiperidin-1-yl ring, R⁶ representshydrogen, methyl, ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl,3-hydroxyprop-1-yl, 2-methoxyeth-1-yl, 3-methoxyprop-1-yl,4-hydroxycyclohex-1-yl, tetrahydrofuran-2-ylmethyl or1,4-dioxan-2-ylmethyl, R⁷ represents hydrogen, methyl or ethyl, R⁶ andR⁷ together with the nitrogen atom to which they are attached form apyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring, amorpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a4-hydroxypiperidin-1-yl ring, or one of its salts.
 3. A compoundaccording to claim 1, wherein R¹ represents methyl, ethyl, n-propyl,methoxy or methoxymethyl, R² represents hydrogen or methyl, and R³represents a group of the formula

where * is the point of attachment to the oxopyridine ring, n is thenumber 1, 2 or 3, m represents the number 1 or 2, R⁴ represents, methyl,ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl,2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl,tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl, R⁵ representshydrogen, methyl or ethyl, R⁶ represents hydrogen, methyl, ethyl,cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl,2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl,tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl, R⁷ representshydrogen, methyl or ethyl, or one of its salts.
 4. A compound accordingto claim 1, wherein R¹ represents methyl or methoxy, R² representshydrogen, or R¹ represents methyl, R² represents methyl, and R³represents a group of the formula

where * is the point of attachment to the oxopyridine ring, n representsthe number 2, m represents the number 1, R⁴ represents 2-hydroxyeth-1-ylor 4-hydroxycyclohex-1-yl, R⁵ represents hydrogen, R⁶ represents2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl, R⁷ represents hydrogen, orone of its salts.
 5. A compound according to claim 1, wherein R¹represents methoxymethyl, R² represents hydrogen, or R¹ representsmethyl, R² represents methyl, and R³ represents a group of the formula

where * is the point of attachment to the oxopyridine ring, n representsthe number 2, R⁴ represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,R⁵ represents hydrogen, or one of its salts.
 6. A compound according toclaim 1, wherein R¹ represents methyl, R² represents hydrogen, or R¹represents methyl, R² represents methyl, and R³ represents a group ofthe formula

where * is the point of attachment to the oxopyridine ring, m representsthe number 1, R⁶ represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,R⁷ represents hydrogen, or one of its salts.
 7. A process for preparinga compound of the formula (I) or one or its salts according to claim 1,comprising: [A] reacting a compound of the formula

in which n, R¹ and R² have the meaning given in claim 1, and Xrepresents hydroxyl or bromine, with a compound of the formula

in which R⁴ and R⁵ have the meaning given in claim 1, to give a compoundof the formula

in which n, R¹, R², R⁴ and R⁵ have the meaning given in claim 1, or [B]reacting a compound of the formula

in which m, R¹ and R² have the meaning given in claim 1, and Yrepresents hydroxyl or chlorine, with a compound of the formula

in which R⁶ and R⁷ have the meaning given in claim 1, to give a compoundof the formula

in which m, R¹, R², R⁶ and R⁷ have the meaning given in claim
 1. 8. Apharmaceutical composition comprising a compound according to claim 1and an inert nontoxic pharmaceutically acceptable auxiliary.
 9. Apharmaceutical composition comprising a compound according to claim 1 incombination with a further active compound.
 10. A method for thetreatment and/or prophylaxis of thromboembolic disorders comprisingadministering to a human or animal in need thereof an anticoagulatoryeffective amount of at least one compound according to claim
 1. 11. Amethod for preventing blood coagulation in vitro, wherein ananticoagulatory effective amount of a compound according to claim 1 isadded.